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Abstract
This work is primarily on ADP-ribosylating toxins. ADP-ribosylating toxins 
(ADPRTs) are a family of toxins that catalyse the hydrolysis of NAD and the transfer 
of the ADP-ribose moiety onto a target. This family includes m an y notorious killers, 
responsible for thousands of deaths annually including: cholera, enterotoxic 
Escherichia coli, whooping cough, diphtheria and a plethora of Clostridial binary 
toxins. One of their members, the C3bot exoenzyme from Clostridium botulinum, has 
been extensively used as a cellular tool to study and elucidate the functions of small 
GTPases that it targets. These studies have focused on the well documented specificity 
of C3bot for the mammalian GTPase Rho. Recent work, however, has highlighted a 
novel interaction between C3bot and another small mammalian GTPase, RalA. It is 
this novel interaction between C3bot and RalA and the biochemical consequences of 
this interaction that have been investigated.
In this work, we present an overview of structural motifs that differentiate the different 
classes of bacterial ADPRTs in relation to their function. We also present the structure 
of the C3bot with the small GTPase RalA in two different forms, and in the case o f one 
form, with C3bot in its active (NAD bound) and inactive form. Attempts to determine 
the structure of C3bot with its primary target RhoA and the purification of a related 
ADPRT from Streptococus pyogenes, SpyA, are also described. This also includes an 
analysis of the differing forms of the complex for an insight into the biologically 
relevant form.
A brief overview of X-ray crystallography and experimental work performed on a 
family of cysteine proteases that are produced by pathogenic bacteria such as Yersinia 
pestis, E. coli 0157:H7, Haemophilus somnus and the plant pathogen Psuedomonas 
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1.1 Introduction to ADP-ribosylating toxins
Pathogenic bacteria are known to possess an arsenal of toxins and effectors that assist 
them in targeting and killing their host cells. The ADP-ribosylating toxins (ADPRTs) 
are a large family of dangerous and potentially lethal toxins. Examples of these toxins 
can be found in a diverse range of bacterial pathogens and they are the principal 
causative agents in many serious diseases including cholera, whooping cough and 
diphtheria. ADPRTs, as the name would suggest, break NAD into its component 
parts (nicotinamide and ADP-ribose) before selectively linking the ADP-ribose 
moiety to their protein target, as simple schematic of this is shown in figure 1.1.
Figure 1.1 Schematic of the ADP ribosylation reaction
glutamate forms a hydrogen bond with the 2’-OH of the ribose. This hydrogen bond stabilises the 
active intermediate and leaves the TV-glycosidic bond vulnerable to nucleophilic attack from the target. 





Figure 1.1 A generalised mechanism of ADP-ribosylation: NAD is bound to the toxin and the catalytic
1
In the majority of these toxins the targets are key regulators of cellular function and 
interference in their activity, caused by ADP-ribosylation, leads to serious 
deregulation of key cellular processes and in most cases, eventual cell death.
This large family of toxins has been extensively studied with many structures of 
individual members determined. These include: diphtheria toxin (1TOX) (Bell & 
Eisenberg, 1996), pseudomonas exotoxin A (1AER) (Li et al, 1996), pertussis toxin 
(1PRT) (Stein et al, 1994), cholera toxin (1XTC) (Zhang et al, 1995), E.coli heat 
labile enterotoxin (1LTS) (Sixma et al, 1993), iota toxin (1GIQ) (Tsuge et al, 2003), 
vegetative insecticidal protein (1QS1) (Han et al, 1999) and the C3-like toxins, C3bot 
(1G24) (Han et al, 2001) and C3stau (10JZ) (Evans et al, 2003). These structures and 
extensive cellular and functional research performed over the last 20 years have 
provided an enormous insight into the function of these toxins and an understanding 
on their effects on host cells. These data are summarised in table 1.1.
The ADPRT family can be split into four groups on the basis of their domain 
organisation and the nature of their target. The 3D structure of a representative 
member of each group is shown in figure 1.2. The most well known toxins: cholera, 
pertussis and the E.coli enterotoxin are members of the AB5 family which target small 
regulatory G-proteins. The enzymatically active A subunit is situated on a scaffold 
made of a pentamer of B-subunits (Cassel & Pfeuffer, 1978; Gill, 1976; Locht & 
Keith, 1986; Streatfield et al, 1992; Tamura et al, 1982; Zhang et al, 1995). 
Diphtheria and Pseudomonas exotoxin A ribosylate a diphthamide residue on 
elongation factor 2. Both are large multi-domain proteins with receptor binding, 
transmembrane targeting and protease-resistant catalytic domains (Allured et al, 
1986; Collier, 1975; Hwang et al, 1987; Morris et al, 1985; Sandvig & Olsnes, 1980; 
Wilson & Collier, 1992). The third group are the actin-targeting AB binary toxins 
that, unlike the more common AB5 binary toxins, comprise of two domains, an active 
catalytic domain and a cell-binding domain. This group includes a wide range of 
clostridial toxins including C2 toxin from Clostridium botulinum, Clostridium 
perfringens iota toxin, Clostridium spiroforme toxin, Clostridium difficile toxin and
2
the vegetative insecticidal protein (VIP2) from Bacillus cereus (Aepfelbacher et al, 
1999; Aktories et al, 1986; Popoff & Boquet, 1988; Simpson et al, 1989; Stiles & 
Wilkins, 1986).
Table 1.1 Summary of the ADPRTs that have had their 3D structures
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A subunit B subunit pcntamer
Iota toxin










Figure 1.2. Structures of the C3-like (top left) (Han et al, 2001), DT (bottom left) (Bell & Eisenberg, 
1996), Iota-like (bottom right) (Tsuge et al, 2003) and Cholera toxin (top right) (Zhang et al, 1995) 
classes demonstrating the domain organisation and architecture of the different classes of ADPRTs. In 
all frames the catalytic unit bearing the ADPRT activity is highlighted in red. Figures were made using 
Molscript (Esnouf, 1997).
The final group are the small single domain C3 exoenzymes that have an unknown 
role in bacterial pathogenesis, but are widely used as tools in cellular signalling work, 
and are characterised by C3bot from Clostridium botulinum. This group also includes
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similar enzymes from Clostridium limosum, Bacillus cereus and Staphylococcus 
aureus (Aktories et al, 1988; Aktories et al, 1987; Just et al, 1992; Just et al, 1995; 
Wilde et al, 2002b; Yamaguchi et al, 2001).
Several ADPRT structures determined to date have been elucidated in the presence of 
bound NAD molecule or non-hydrolysable NAD analogues and these have allowed a 
detailed understanding of NAD binding. These structures combined with biochemical 
results have also suggested a possible catalytic mechanism. The current 
understanding of the mechanism of catalysis is that NAD is bound by the ADPRT in 
a manner that orients the glycosidic bond to render it amenable to hydrolysis. The 
“catalytic glutamate residue”, that all known ADPRTs possess, forms a hydrogen 
bond with the 2’-OH of the ribose ring and this can be seen for all 3 classes in Figures 
1.3A-C. This interaction stabilises a positively charged oxocarbenium ion 
intermediate which is then attacked by a nucleophile, either an activated water 
molecule in the case of auto-hydrolysis that many ADPRTs can demonstrate, or the 
protein substrate. A simplified version of this mechanism is shown in figure 1.1. 
While the toxin-substrate recognition process has still not been fully understood, 
through biochemical and mutagenic analysis there are some elements of protein- 
recognition that are known. In the case of cholera, pertussis, the E.coli enterotoxin 
and the diphtheria family of toxins, an “active site loop” has been shown to be 
essential for substrate binding (Han & Tainer, 2002). An example of such a detailed 
interaction has been provided by the recently determined crystal structure of 
elongation factor 2 (eEF2) and Pseudomonas aeruginosa exotoxin A (PAETA) 
complex (Jorgensen et al, 2005) in which the active site loop (L4 in PAETA) plays an 
important role. Likewise, the active site loop has been shown to be essential for 
activity in cholera toxin, E.coli enterotoxin and the distantly related ExoS and T 
toxins (Bell & Eisenberg, 1996). The recent structure of the complex between the 
activated form of cholera toxin (CT) and a human ADP-ribosylation activation factor 
6 (ARF6) may suggest the mechanism of this active site loop involvement. In the 
activated ARF6-CT complex, the binding of ARF6 causes an allosteric change on the 
CT toxin that results in the active site loop forming an extended ‘knob’ near the
5
ADP-ribosyl tum-tum (ARTT) loop altering the structure of the CT active site into a 
more suitable one for substrate binding and ADP-ribosylation. In the C3 and Iota-like 
toxins the details of substrate recognition are less clear though all of them possess an 
aromatic residue on the ARTT loop that has been found to be critical for substrate 
binding (Wilde & Aktories, 2001). The conserved Q/E residue that is found two 
residues upstream of the catalytic glutamate in the ADPRTs may also play a role in 
substrate specificity. The Rho binding toxins all possess a Q-x-E motif whilst the 
actin binding toxins possess an E-x-E motif as shown in the sequence alignment in 
figure 2.4A. The change between Q and E has also been demonstrated to have 
substrate altering properties in the eukaryotic Ecto-ART proteins (Ritter et al, 2003). 
However, as only one toxin-substrate complex has been determined so far, the exact 
mechanism and the process of protein-protein recognition still remain much of a 
mystery.
1.2 Cellular properties of ADPRTs
The bacterial ADPRTs are all thought to play important roles in bacterial 
pathogenesis acting as key vimlence factors in many diseases. The dismption caused 
by the ADPRTs varies considerably between the four classes, but all rely on the 
ADP-ribosylation of key regulatory proteins in the host cells to disrupt cell signalling 
and interfere with downstream regulatory and structural processes.
The AB5 proteins (pertussis toxin (PT), E.coli heat labile enterotoxin (LT) and 
cholera toxin (CT)) all ribosylate a small subsection of the G-protein family. In all 
three toxins, the A l catalytic domain sits on top of a doughnut shaped pentamer of 
binding domains that comprise the cell binding and translocation apparatus 
(Finkelstein et al, 1987; Gill et al, 1981; Sixma et al, 1991; Stein et al, 1994; Zhang 
et al, 1995). In the bacterial cell, this hetero-hexamer is assembled in the bacterium 
before being transported across the membrane via the type II secretion apparatus 
(Sandkvist et al, 2000). Once secreted into the lumen of the gut the B-pentamer 
recognises the GM-1 ganglioside on the host cell surfaces inducing endocytosis and
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translocation into the cytosol. Trafficking and processing of the full holotoxin in the 
host cell is a tremendously complex process and the description is outside the scope 
of this review. For the toxin to become active however, the catalytic domain must 
undergo proteolytic cleavage of the disulphide linked A1-A2 domain before 
becoming fully active (Gill, 1976; Kassis et al, 1982). This also results in the now 
separate A l domain being released from the A2-Bs complex. Even then these toxins 
are not fully functional and require activation by host cell proteins to become fully 
active. In the case of cholera toxin, these ADP-ribosylation activation factors (ARFs) 
come from the host and are small GTPases that bind the cholera toxin in their GTP- 
bound state. Both CT and LT target the Gsa, the stimulatory G-protein of the 
adenylate cyclase system. ADP-ribosylation of this causes the G-protein to be 
maintained in its activated GTP bound state (Galloway et al, 1987) and leads to a 
massive upregulation of adenylate cyclase and subsequent increase in the amount of 
cystolic cyclic AMP (Gill, 1976; Gill & Richardson, 1980). This eventually leads to a 
major loss of fluids and ions from the affected intestinal cells and gives rise to the 
severe diarrhoea and fluid loss associated with both cholera and enterotoxigenic 
E.coli pathogenesis (Field et al, 1989; Peterson & Ochoa, 1989).
Pertussis toxin (PT) is one of the primary virulence agents produced by Bordetella 
pertussis, the major causative agent of whooping cough. Pertussis toxin ADP- 
ribosylates an exposed cysteine residue on several small heteromeric G-proteins. The 
most prominent examples being Gja, G oa, andGta (Katada & Ui, 1982). This results in 
uncoupling of the G-proteins from their effectors and an unregulated increase in 
adenylate cyclase activity and an increase in cyclic AMP (West et al, 1985). As many 
cells possess PT receptors the physiological effects of PT pathogenesis vary greatly 
from one cell type to another.
Diphtheria toxin (DT) and Pseudomanas aeruginosa exotoxin A (PAETA) are both 
examples of elongation factor 2 (eEF2) ribosylating toxins (Wilson & Collier, 1992). 
Upon cell entry they both specifically ribosylate an exposed histidine that has been 
modified by the addition of a diphthamide side-group (Van Ness et al, 1980). The
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ADP-ribosylation interrupts the function of eEF2 in the host cell interfering with 
protein synthesis which results in profound physiological changes and ultimately cell 
death (Collier, 1975; Iglewski et al, 1977). The events leading up to this point are 
well understood; and appear to rely on the action of the receptor binding and 
transmembrane targeting domains. PAETA binds to the a2-macroglobulin receptor on 
the cell surface and induces receptor-mediated endocytosis becoming internalised into 
endosomes where the low pH creates a conformational change in the toxin leaving it 
open to furin protease cleavage that removes the binding domain. The catalytic 
domain then undergoes retrograde transport to the endoplasmic reticulum, 
translocates into the cytoplasm and can enzymatically ribosylate eEF2. DT by 
contrast binds to the epidermal growth factor like growth factor precursor (HB-EGF) 
and is cleaved on the cell surface before uptake through receptor mediated 
endocytosis. Once in the early endosome the DT catalytic fragment is not processed 
and penetrates the membrane of the endosome to pass directly into the host cell 
cytoplasm where it can ribosylate eEF2.
Iota toxin, from Clostridium perfringens (Stiles & Wilkins, 1986), and Vip2 from 
Bacillus cereus (Han et al, 1999) are both actin ADPRTs, each ribosylating actin at 
an exposed arginine, Argl77 (Aktories, 1990). The ADP-ribosylation prevents actin 
polymerisation by capping the exposed ends of the actin filaments which leads to cell 
rounding and eventual cell death as the actin cytoskeleton breaks down (Aktories & 
Hall, 1989). This class of actin modifying binary toxins also includes Clostridium 
botulinum C2 toxin (Aktories et al, 1986), Clostridium spiroforme toxin (Simpson et 
al, 1989) and Clostridium difficile toxin components cdtA and cdtB (Popoff & 
Boquet, 1988). The domain structure of Iota and Vip2 is also of interest as the 2 
domains resemble one another closely. The second domain is responsible for cell 
binding and lacks catalytic activity suggesting that the binary toxins may have arisen 
from gene duplication of an original ADPRT ancestor (Han et al, 1999). The toxins 
do not bind cells as complete A-B units. Instead proteolytically activated B 
monomers bind to cell surface receptors as homo-heptamers. These homo-heptamers 
then bind the A domains and are taken into cells via endocytosis. Once inside acidic
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endosomes the low pH activates the translocation function of the B domain heptamers 
and they translocate the catalytic A domains across the endosomal membrane into the 
cytoplasm where they can act to ribosylate actin and bring about cell death (Barth et 
al, 2004).
The C3 exoenzymes are characterised by C3bot first identified from Clostridium 
botulinum (Aktories et al, 1987) but also include representatives from Clostridium 
limosum (C31im) (Just et al, 1992), Bacillus cereus (C3cer) (Bohmer et al, 1996) and 
Staphylococcus aureus (C3EDIN, C3Stau2) (Wilde et al, 2002c; Yamaguchi et al, 
2001). This family of ADPRTs selectively ribosylates the small GTPases, Rho A, B 
and C (Chardin et al, 1989) at an exposed Arg 41 (Sekine et al, 1989). This reaction 
is highly specific to only those substrates, except in the case of C3stau2 which has a 
slightly broader specificity that includes RhoE and Rnd3 (Etienne-Manneville & 
Hall, 2002; Wilde et al, 2002b). The ADP-ribosylation prevents Rho moving into its 
active GTP bound state and leads to a loss of control in the downstream pathways 
controlled by the Rho GTPases and resulting in loss of control of the cell 
cytoskeleton and eventual cell death (Wilde & Aktories, 2001). Although these 
affects are in seen in vitro, the role of C3bot and its related ADPRTs in pathogenesis 
is not yet known as they lack any cell translocation or binding domains. C3stau, 
however, has been found in some clinical isolates and both C3bot and C3stau2 have 
been shown to prevent wound healing in vivo (Aepfelbacher et al, 1997; Czech et al, 
2001) suggesting that they may have some role in pathogenesis.
In addition to the selection of bacterial ADPRTs there are ADP-ribosyltransferases 
(ART) present in eukaryotic organisms. Eukaryotic ADP-ribosylation can be of two 
forms: (1) poly-ADP ribosylation that is mediated by poly ADP-ribose polymerases 
(PARPs) and catalyses the transfer of multiple ADP-ribose moieties onto a substrate; 
and (2) mono-ADP ribosylation that catalyses the transfer of a single ADP-ribose 
moiety onto a target and is mediated by Ecto-ADP ribosyltransferases (Ecto-ARTs) 
(Schreiber et al, 2006). The PARP superfamily plays a role in the repair of DNA 
strand breaks and modulation of chromatin (Schreiber et al, 2006). The structure of
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the catalytic domains of chicken PARP-1 and mouse PARP-2 however did 
demonstrate structural homolgy to the active site of diphtheria toxin (Ruf et al, 1996). 
The 5 Ecto-ARTs found in mammalian systems, named Ecto-ARTl-5, are located in 
the extracellular space of mammalian tissues and play a role in cell adhesion and the 
immune system. They are closer in structure to the C3-like ADPRTs than to the 
PARP family (Mueller-Dieckmann et al, 2002).
1.3 Structural analysis of the NAD binding site between ADPRTs
It has previously been demonstrated that all the ADPRTs, both bacterial and the 
eukaryotic Ecto-ARTs, share a common active site and NAD binding motif 
(Domenighini & Rappuoli, 1996; Han & Tainer, 2002). With the determination of 
several ADPRT structures an examination of the active sites and interactions that are 
necessary for NAD binding and ribosyl transfer is possible. The structural analysis of 
several ADPRTs has led to them being classified into two groups that share a similar 
active site architecture but lack sequence homology. The D T ’ group is based on the 
active site and NAD binding features of Diphtheria toxin (Bell & Eisenberg, 1996) 
and also includes Pseudomonas exotoxin A (Allured et al, 1986) and the mammalian 
poly-ADP ribosylating proteins (PARP’s) (Marsischky et al, 1995). The ‘CT’ group 
is based upon the NAD binding observed in cholera toxin (Zhang et al, 1995) and 
includes: the E.coli heat labile toxin (Sixma et al, 1991); pertussis toxin (Stein et al, 
1994); C3bot (Han et al, 2001); VIP2 (Han et al, 1999); iota toxin (Tsuge et al, 2003) 
and the Ecto-ART (Ritter et al, 2003) family from eukaryotes (Domenighini & 
Rappuoli, 1996). With the determination of more ADPRT structures it is now clear 
that the CT group should be divided further into those toxins that possess an active 
site loop involved in substrate binding (Bell & Eisenberg, 1996) and those that 
instead have an a-helix forming part of the NAD binding cleft (Han et al, 2001).
There are five key structural features that have been identified in the ADPRTs 
(Domenighini & Rappuoli, 1996). These are: (a) the Q/E-X-E motif centred on the 
catalytic glutamate and the glutamate/glutamine responsible for the ribosyltransferase
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activity; (b) The Arom-H/R motif that contains either a histidine or an arginine that 
contributes to the NAD binding and maintains the structure of the active site cleft; (c) 
The Aromatic-Hydrophobic-S-T-S motif on a (3-strand that stabilises the NAD 
binding; (d) the Y-Xio-Y motif in DT and PAETA that fulfils the role of the STS motif 
in the bacterial ADPRT; and (e) the phosphate nicotinamide (PN) loop that contains 
A/G-x-R-x-I motif and is found in the Iota-like binary toxins and C3bot type 
ADPRTs. The PN loop is a flexible loop above the NAD binding site that creates a 
more compact binding site. It also brings into play an essential arginine residue which 
positions the NAD in a conformation more suitable for the cleavage of the 
nicotinamide N-glycosidic bond in these toxins (Menetrey et al, 2002). The 
conserved sequences and physical position of these features are shown in Figures
1.4 A and B.
1.3.1 The ADPRT core fold
All the ADPRTs, both in the DT and the CT family possess a near identical mixed 
a/p core structure of approximately 100 residues even though there is little sequence 
homology among many of them. This core structure has the approximate dimensions 
o f 35A x 40A x 55A and possesses the NAD binding site which supports both NAD 
glycohydrolytic and ribosyltransferase activities. The core is constructed from 2 
perpendicular p-sheets with a variable number of a-helices attached to it both above 
and below the frame of P-sheets. The NAD binding site is positioned in a cleft made 
between the p-ffamework and either an a-helix in the case of C3bot, C3stau, Vip2, 
iota and mammalian Ecto-ART or a variable length active site loop in pertussis, 
cholera, E.coli heat labile toxin, diphtheria and exotoxin A. The latter is thought to be 
involved in EF2 or G-protein recognition (Bell & Eisenberg, 1996).
11
Figure 1.3 The NAD binding site of ADPRTs
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Figure 1.3A. Schematic view of the active site cleft of the DT class of toxins highlighting the key 
catalytic residues and mode of NAD binding (Bell & Eisenberg, 1996). This illustrates the stacking of 
the nicotinamide ring between the conserved tyrosines, the binding of the conserved His to the 0 2  of 
the adenine ribose and the carbonyl oxygen of Y54 and the binding of the conserved catalytic 
glutamate to the 0 2  of the nicotinamide ribose. 1.3B: Schematic view of the NAD binding cleft of the 
cholera-like class of toxins showing the intramolecular interactions around the active site and the key 
features (Zhang et al, 1995). The binding of R7 to the oxygens of the NAD when in the active state 
instead of the carbonyls of R54 and S61 in the inactive form can clearly be seen. An arginine from the 
active site loop, in its active form, is also involved in binding the phosphate-oxygens and the ribose 
ring of the adenine.; 1.3C: The important residues and bonds formed around the NAD binding site by 
the 4 motifs found in the a-3 type Toxins (Han et al, 2001). The a-3 asparagine and arginine bind the 
phosphate oxygen holding the NAD in a compact state. This is the role also undertaken by the 
conserved arginines of the PN-loop and Arg/His motif. The catalytic glutamate and its stabilising bond 
from the tyrosine of the a-3 motif are also shown.
1.3.2 The ARTT motif
The ARTT loop contains the key catalytic glutamate responsible for the catalysis and 
transfer of the ribose moiety and the Q/E-X-E motif that is found in all members of 
the CT group (Domenighini & Rappuoli, 1996). The ARTT loop is of variable length 
comprised of two sharp turns (turn 1 and turn 2) connecting either two P-sheets as in 
the ARTT loop of iota toxin (Tsuge et al, 2003) and C3bot (Han et al, 2001) that 
connects p5 and P6. Or a longer loop connecting an a-helix to a p-sheet as in cholera 
toxin, pertussis toxin and E.coli heat labile toxin. The ARTT loop in the different 
types of ADPRT can be seen in figure 1.4B. In all the ADPRTs that are members of 
the CT group there is also a Glu or Gin residue two residues from the catalytic 
glutamate residue (Han & Tainer, 2002). This second residue is vital for the 
ribosyltransferase activity of the ADPRT but not necessarily the NAD 
glycohydrolysis activity (Nagahama et al, 2000; Wilde et al, 2002c). In Ecto-ART 
the equivalent residue, Gin 187, has been implicated in changing the substrate from 
cell surface to cytoplasmic substrates (Ritter et al, 2003). This substrate selectivity 
has also been observed through mutational analysis of C31im where mutation from 
Gin to Glu altered the ADP-ribosylation target from asparagine to arginine 
(Vogelsgesang & Aktories, 2006). This Gln/Glu residue may play a role in substrate
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selection. As can be seen from the sequence alignment in figure 1.4A the actin and G- 
protein modifying proteins that ribosylate an exposed arginine possess a glutamate 
residue. In the Rho GTPase ribosylating proteins that ribosylate an exposed 
asparagine it is a conserved glutamine residue.
Another important residue on the ARTT loop is the aromatic group situated on the 
centre of the loop between turn 1 and turn 2 that is found in C3bot, C3stau, Iota, Vip2 
and Ecto-ART. In C3bot this has been shown to be essential for Rho substrate 
binding (Wilde et al, 2002c) and in the proposed model of C3bot-RhoA recognition 
(Han et al, 2001) it is a vital determinant of substrate recognition and binding. This 
mode of action could apply to the other closely related ADPRTs. This aromatic 
group, proposed to be important in substrate binding, is only present in the actin and 
Rho GTPase-modifying toxins and Ecto-ART family. The C3, Iota-like and Ecto- 
ART enzymes have also substituted the active site loop with an a-helix at the NAD 
binding cleft. In CT and DT the active site loop is involved with substrate selectivity 
and binding and has been seen to become disordered and undergo conformational 
change upon binding of NAD in both DT and PAETA (Bell & Eisenberg, 1996; Li et 
al, 1996).
1.3.3 The STS motif
The STS motif forms part of the p-sheet that comprises part of the NAD binding 
cavity and follows the pattern: Aromatic-Hydrophobic-S-T-S (Domenighini & 
Rappuoli, 1996). The STS motif acts as an anchor to hold the NAD binding site 
together. In C3bot the contribution of the STS motif (Ser 174, Thr 175, Ser 176) is 
well understood (Han & Tainer). Ser 174, the first ‘S’ of the motif forms hydrogen 
bond with the catalytic glutamate and a tyrosine residue (Tyr 79) beneath the cleft to 
hold the glutamate in the correct position to catalyse the cleavage of NAD. This is 
also seen in the Ecto-ART2 structure with the STS (Ser 147) forming a hydrogen 
bond with the catalytic glutamate (Glu 189) (Mueller-Dieckmann et al, 2002). 
Similar interactions are also observed in C3stau2 (Evans et al, 2003) and Vip2 (Han
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et al, 1999). Mutation of this serine residue in the C.botulinum C2 toxin (Barth et al, 
1998b) eliminates the transferase activity. However, in diphtheria and iota toxins 
mutation of this serine residue reduces activity but does not entirely abolish the 
glycohydrolytic activity (Bell & Eisenberg, 1996; Nagahama et al, 2000) suggesting 
that while the serine of this motif plays an important role in stabilising the catalytic 
glutamate it is not essential in all ADPRTs. The threonine residue forms additional 
hydrogen bonds with perpendicular p-strands to stiffen the active site. Ser 176 in 
C3bot, the second ‘S’ of the motif, forms hydrogen bonds with the loop immediately 
following the STS p-sheet and also with the glutamine residue of the Gln/Glu-x-Glu 
motif keeping the ARTT loop and the glutamine in the correct orientation for the 
transferase reaction (Han et al, 2001). In C3stau2, the second serine is replaced with a 
glutamine residue that binds to the nicotinamide of NAD directly. This is different to 
other ADPRTs that possess serine where the ‘S’ has a role in forming intramolecular 
bonds with the catalytic glutamatic acid. Because of this, the STS motif is thought to 
have a less important role in C3stau than in other related C3-like enzymes (Evans et 
al, 2003).
In the DT group, the STS motif is partially lost (diphtheria) or entirely lost (exotoxin 
A). In diphtheria toxin the STS motif is replaced by an YTS motif, but both the T and 
S residues are in similar positions as they are in the other CT toxins and are likely to 
play a similar role. The tyrosine residue (Tyr 54) is crucial to the diphtheria activity 
and is one of the two conserved tyrosines essential for NAD binding through 
aromatic ring rc-orbital stacking (Carroll & Collier, 1984; Carroll & Collier, 1987; 
Carroll & Collier, 1988). This is also the case in exotoxin A, with Tyr470, though it 
lacks the serine or threonine residue of the YST motif. This ring stacking stabilises 
the bound NAD and plays a similar role to that of the STS motif in other toxins; that 
of stabilising and maintaining the structure of the active site (Bell & Eisenberg, 1996; 
Li et al, 1996).
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1.3.4 The key Arg/His residue
The conserved Arg/His residue (Domenighini & Rappuoli, 1996) is comprised of an 
aromatic residue followed by the Arg/His and has been found in all the ADPRTs to 
date. In the DT family, the motif is Tyr-His while the members of the CT family also 
include a Val/Leu before the aromatic residue and all have arginine not histidine. In 
the ADPRTs, the purpose of the Arg/His motif is NAD binding and maintaining the 
structure of the active site rather than actual involvement in either glycohydrolase or 
the transferase reaction. Though not directly involved in the catalysis, the presence of 
the Arg/His motif has been shown to be vital from mutagenesis studies on C3stau2 
(Wilde et al, 2002c), LT (Lobet et al, 1991), PT (Burnette et al, 1988; Cieplak et al, 
1988), CT (Burnette et al, 1991) and iota toxin (Tsuge et al, 2003) and it has been 
shown that loss of this arginine abolishes transferase activity either severely 
(C3stau2) or completely (Iota, LT, CT, and PT) reduces the hydrolase activity as 
well. The exact role that this Arg/His residue plays in NAD binding varies between 
the toxins depending on whether they contain an active site loop (e.g. DT, PAETA, 
CT, LT and PT) or an a-3 helix (e.g. C3-like and Iota like binary toxins). In the 
“active site loop group” the residue, His21/440 in diphtheria/PAETA, Arg 7 in LT 
and CT and Arg 9 in PT, does not play an important part of binding NAD but instead 
supports key parts of the active site to position them in the correct orientation to 
hydrolyse the NAD. In DT, the histidine forms a hydrogen bond (Bell & Eisenberg,
1996) with one of the hydroxyl groups on the adenenine ribose ring and more 
importantly forms a bond with the backbone carbonyl of one of the tyrosine pair in 
DT (Tyr 54). Through this bond the tyrosine is orientated into the correct orientation 
to bind the NAD, and can be seen in Figure 1.3A. Until the recent structure of the 
NAD-bound cholera toxin (O'Neal et al, 2005) a similar active site stabilisation was 
thought to occur in LT and the related CT and PT toxins (Sixma et al, 1993). In the 
absence of NAD the catalytic Arg 7 forms hydrogen bonds with Ser 61 of the STS 
motif and the main chain carbonyl of Arg 54, an arginine that forms electrostatic 
bonds with both Glu 110 and Glu 112. This network of bonds plays an important role 
in stabilising the active site. However when the cholera toxin is activated by an ARE
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protein the active site loop undergoes a large conformational shift. This results in Arg 
54 being unavailable to interact with Arg 7 and has a slight effect on the position Arg 
7 enabling it to bind an oxygen from each of the NAD phosphates rather than 
stabilising Ser 61 as shown in Figure 1.3B. Thus, Arg 54 acts in a manner similar to 
that seen in the a-3 toxins by binding directly to the NAD phosphates and positioning 
the NAD in a suitable conformation for hydrolysis. In DT and LT the conserved 
His/Arg occupy the same spatial position and interact with the backbone carbonyls of 
analogous residues, Tyr 54 in DT and Ser 61 of LT, that are the first residues of the 
YST/STS motifs. They also support a network of interactions that maintain the 
structure of the active site. Upon activation however, the role of the catalytic arginine 
in CT reverts to the manner seen in the a-3 toxins by binding directly to the NAD. In 
the a-3 toxins the arginine forms hydrogen bonds with the phosphates of the NAD 
positioning them in a more compact manner than is found in the “active site loop” 
ADPRTs. These hydrogen bonds serve two purposes: firstly to improve the binding 
of NAD to the toxin and secondly to hold the phosphates in a position where they can 
interact with the nicotinamide amide group NN7 of the nicotinamide mononucleotide 
moiety (NMN) (Tsuge et al, 2003). This can then assume a ring like conformation 
that is prevented from moving due to stacking interactions with the aromatic residue 
on the PN loop (Phe 349 in Iota toxin, Phe 183 in C3bot) and withdraws electrons 
from the nicotinamide ring amide increasing the susceptibility of the TZ-glycosidic 
bond to cleavage (Ritter et al, 2003). Thus the role of the Arg/His in the a3-helix 
toxins is very different to their structural role in the DT toxins and the NAD-free CT 
toxins where the Arg/His holds the active site in the correct manner to facilitate NAD 
binding.
1.3.5 The Tyr-Xio-Tyr motif
The toxins of the DT group (diphtheria and exotoxin A) are different from those in 
CT group in several respects. The first difference is the absence of the Gln/Glu-x-Glu 
motif (both diphtheria and exotoxin A possess only the catalytic glutamate) and the 
second is the lack of the STS motif that the toxins of the CT group possess. Instead
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the DT group possess a pair of tyrosines that stack above and below the plane of the 
NAD moiety and contribute to binding via 7c-orbital interactions as shown in figure
1.3 A. The orbital stacking is of vital importance here and has been shown by 
mutagenesis studies of PAETA with Tyr 470 Phe/Tyr 481 Phe mutants still 
possessing enzymatic activity (Lukac & Collier, 1988). Aromatic ring stacking may 
explain the slightly different conformation that NAD possesses in the PAETA and 
diphtheria toxin structures compared to the structures of ADPRTs from the CT group 
(Bell & Eisenberg, 1996; Dolan et al, 2000). The aromatic stacking also places the 
NAD molecule in a position suitable to interact with the catalytic glutamate with the 
anomeric carbon of ribose exposed to solvent available for nucleophilic attack. Many 
of the CT group from the binary and C3-like families that possess the PN-loop have 
an aromatic residue that stack against the nicotinamide ring in a similar manner to the 
first tyrosine of the Tyr-Xio-Tyr pair.
1.3.6 The PN loop
The PN loop was first identified in the C3bot-NAD structure (Menetrey et al, 2002) 
and forms an essential part of the NAD binding site apparatus. The PN loop is a 
flexible loop that occurs ten residues after the STS motif connecting strands 03- 04 
and which undergoes a large movement upon NAD binding becoming more ordered 
in the process. In C3bot the PN loop has two residues that contributes to the binding 
of NAD; Arg 186 which forms a hydrogen bond with one of the phosphate groups of 
NAD and Phe 183 which stacks against the nicotinamide ring of NAD as can be seen 
in figure 1.3C. Mutational analysis of Arg 186 has revealed that it is essential to NAD 
binding (Menetrey et al, 2002). In the case of Phe 183, the stacking is similar to that 
of Tyr 65 from diphtheria toxin, Phe 160 from Ecto-ART and Tyr 481 from exotoxin 
A. In C3stau, the PN loop is present and retains the critical Arg residue (Arg 150) but 
the aromatic residue is replaced by a leucine. In both iota and Vip2, the PN loop is 
intact with an Arg residue (Arg 352 and Arg 400 respectively) that forms bonds with 
an NAD phosphate molecule and an aromatic residue (Phe 349 and Phe 397 
respectively) that stacks directly above the nicotinamide ring. In a similar manner to
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C3bot, the important nature of the PN loop has been confirmed in iota toxin with 
mutants of Arg 352 and Phe 349 showing no activity or strongly diminished activity 
(Tsuge et al, 2003). The PN-loop is found in the a-3 toxins, both the C3-like and 
Iota-like, and there are no analogous arginines or aromatic residues present among the 
members of the CT group that possess active site loops. The DT group possesses a 
conserved tyrosine in a similar position to the aromatic residue of the PN loop’s 
Arom-X2 -R motif, but lacks the conserved arginine that is involved in NAD binding.
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Figure 1.4 The conserved ADPRT binding motifs
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Figure 1.4A. Sequence alignment of the three classes of ADPRT highlighting the conserved residues 
that make up each of the motifs. The conserved residues in each motif are shaded in the same colours 
used in figure 1.4B. Ribbon diagrams of a diphtheria-like (Bell & Eisenberg 1996), cholera-like 
(Zhang et al 1995) and a-3 (Han et al, 2001) toxins highlighting the important motifs in each 
molecule. The glutamate containing ARTT loop is highlighted blue with the STS and Arg/His motif in 
purple and yellow respectively. The active site-loops are shown in red as is the a-3 helix. In green is 
the PN-loop from the a-3 toxins and the Ty-Xio-Tyr motif for the DT toxins. In all cases figures were 
generated using Molscript (Esnouf, 1997).
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1.3.7 The a-3 motif
Within the ADPRT family, the actin-binding enzymes and C3-like exoenzymes all 
lack a 15-residue active site loop that is found in the cholera and diphtheria-like 
toxins (Bell & Eisenberg, 1996; Sixma et al, 1991). In CT and LT this loop is 
implicated in G protein binding and occurs around residues 45-58. (O'Neal et al,
2005). In DT and PAETA this active site loop is called L4 and comprises residues 39- 
48 and 483-490 respectively. In its place the iota and C3-toxins (Evans et al, 2003; 
Han et al, 2001; Han et al, 1999; Tsuge et al, 2003) have an a-helix that packs tightly 
against the NAD cleft forming a more compact binding site. Amongst these ADPRTs 
there are three important residues that appear on this a-helix and are conserved 
amongst nearly all of the C3-like and iota-like ADPRTs. These are: (a) a tyrosine 
residue that interacts with the ‘S’ of the STS motif and the catalytic glutamate 
through hydrogen bonds (b) an asparagine residue and (c) an arginine residue that 
form part of the adenine ring binding pocket. These three residues form another motif 
specific to the C3bot-like ADPRTs that possess the a-3 helix instead of the active site 
loop including the EctoART-2 (Ritter et al, 2003). From sequence alignment the 
related C3cer and C31im also seem to have the signature sequence Y-X6/7-N-X2 -L-R 
except in the case of iota and Clostridium difficile toxin where the arginine residue is 
replaced with an isoleucine. Tyr 79 in C3bot (Han et al, 2001) and Tyr 78 in Ecto- 
ART (Mueller-Dieckmann et al, 2002) can be seen to form' charge interactions with 
the serine of the STS motif (Ser 174 and Ser 146 respectively) and the catalytic 
glutamate (Glu 214 and Glu 189 respectively). Mutational analysis on the equivalent 
tyrosine (Tyr 246) in iota toxin (Tsuge et al, 2003) showed that loss of the tyrosine 
resulted in reduced glycohydrolytic and transferase activities. This Y-S-E network of 
interactions may act as a stabilising influence on the catalytic glutamate residue to 
ensure that it is positioned correctly to bind the NAD molecule and in a suitable 
charge state to stabilise the positively charged oxocarbenium transition state 
intermediate. The arginine and aspargine residues are involved in binding to the 
adenine end of NAD with binding observed in C3bot (Arg 91- hydrophobic packing 
with the adenine ring and Asn 87 binding to one of the phosphates), C3stau (Arg 48 -
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binding to the adenine ring), Vip2 (Arg 315) and Ecto-ART2 (Asn 87 and Arg 91). In 
iota toxin although the arginine at position 259 is replaced with an lie, a downstream 
asparagine residue (Asn 255) has been shown to bind to the phosphates at the adenine 
end of the molecule. This bond contributed by the a-3 helix can be observed in figure 
1.3C. Mutation of this asparagine to alanine caused a significant drop in enzymatic 
activity (Tsuge et al, 2003). This binding to the adenine moiety may help NAD 
binding and assist in holding the ADP-ribose+ after cleavage of the N-glycosidic bond 
until the transferase reaction can take place. The interactions between the Asn and the 
phosphates may contribute to positioning the phosphates closer to the NMN ring in a 
similar manner to the arginines of the Arg/His motif and PN-loop.
1.4 Catalytic model and mechanism
The conserved nature o f the NAD binding site and key catalytic residues would 
suggest a common catalytic mechanism shared between all members of the ADPRT 
family. The nucleophillic attack occurs at the anomeric carbon of the nicotinamide 
ribose and results in the cleavage of N-glycosidic bond separating the ADP-ribose 
moiety from the nicotinamide ring. The manner in which this occurs is still not 
precisely understood. Mechanisms have been put forward for SnI and Sn2 type 
reactions though recent biochemical data would indicate that the reaction is of an SnI 
type.
The Sn2 reaction was first suggested for diphtheria toxin (Bell & Eisenberg, 1996) 
and has also been put forward for Vip2 (Han et al, 1999), C3bot (Han et al, 2001), 
pertussis toxin (Locht & Antoine, 1995) and Ecto-ART2 (Ritter et al, 2003). In the 
Sn2 reaction the attacking nucleophile that may be the substrate arginine, 
diphthamide or asparagine depending on the toxin involved or even water in auto­
hydrolysis. This nucleophile is then deprotonated by either the conserved glutamate 
in diphtheria toxin (Bell & Eisenberg, 1996; Wilson et al, 1990), or the downstream 
Gln/Glu-X-Ghi in the suggested mechanisms for Iota, C3bot and Vip2 or in pertussis 
toxin by a catalytic His 35 (Locht & Antoine, 1995). This activated nucleophile then
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attacks the anomeric carbon of the ribose ring which due to the conformation of the 
NAD, has been exposed to the solvent forming a pentacoordinate oxocarbenium 
transition state intermediate. In the CT group this intermediate is partially stabilised 
by the catalytic glutamate forming a hydrogen bond with the 0 2  atom on the 
nicotinamide ribose. This makes the ring more electronegative which stabilises the 
positively charged oxocarbenium ion before the vV-glycosidic bond is cleaved 
completing the transfer of the ADP-ribose+ moiety on to the substrate. In the “a3- 
helix” toxins, the nucleophilic attack may also be aided by the interactions between 
the nicotinamide amide group and phosphate oxygens that withdraw electrons from 
the nicotinamide ring making the A-glycosidic bond even more attractive to the 
attacking nucleophile.
An SnI reaction has also been proposed for ADPRT catalysis (Parikh & Schramm, 
2004), that has an isolated positively charged oxocarbenium intermediate stabilised in 
a pentacoordinate state with direct stabilising electrostatic interactions from the 
catalytic glutamate and serine hydroxyl group. This oxocarbenium intermediate 
comes about after the breaking of the glycohydrolytic bond. The serine residue in this 
case is conserved and found in the STS motif. In the SnI reaction mechanism the 
ADP-ribose+ stays bound to the protein until attack from the nucleophilic substrate. 
Of the two mechanisms the SnI reaction seems to be favoured by the available 
biochemical data, especially the uncoupling of glycohydrolytic and transferase 
reactions. This was achieved through mutagenesis of the Glu/Gln residue (Glu 338 in 
iota or Gin 212 in C3bot). The DT group only possesses the catalytic glutamate that 
in the SnI reaction is required to stabilise the oxocarbenium intermediate. However, 
members of his group possess the active site loop that is thought to be involved in 
substrate binding and could position and activate the diphthamide group for 
nucleophilic attack on the stabilised oxocarbenium intermediate. Recently, the idea of 
a compulsory order SnI reaction with the NAD binding being required for substrate 
binding has been challenged by new findings that demonstrate the interaction 
between PAETA and eEF2 follows a random order reaction mechanism and that 
either NAD or eEF2 can bind and the reaction takes place via a random third order
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SnI reaction (Armstrong et al, 2002). This has also been observed through kinetic 
isotope exchange studies (Parikh & Schramm, 2004) which supports a random order 
SnI type reaction. A more recent development supporting the available biochemical 
data is the determination of the structure of the eEF2-TAD-PAETA complex that 
captures the ADPRT reaction at an intermediate stage (Jorgensen et al, 2005). 
Though this complex supports eEF2 and PAETA react via an SnI mechanism, the 
exact nature of the reaction is still unknown. In the complex structure the distance 
between the diphthamide N3 and the anomeric carbon was much larger than 2.8A as 
suggested by the kinetic isotope exchange work inferring that a crucial step in the 
mechanism has still not been captured.
1.5 Summary
The conserved ADPRT core structure with a network of perpendicular p-strands is 
present in all of the ADPRTs that have had their structure determined to date. This is 
also true of the catalytic glutamate that is found in both the DT and the CT families. 
This residue occurs in an equivalent position in all the structures determined to date 
where it is required to stabilise the positively charged oxocarbenium ion transition 
state. The conserved structural features and conserved areas of sequence are 
highlighted in figure 1.4A and 1.4B.
The division between the CT group and DT group is not as clear as once thought. 
Although members of the DT group lack the Q/E-x-E motif, and in the case of 
PAETA the STS motif, they possess a unique Y - X jo- Y  motif and, importantly, 
contain an active site loop that is responsible for substrate recognition and binding. 
This “active site loop” makes them similar in both structure and function to the 
members of the CT group that have active site loops. The CT group should be split 
into two groups; (a) the ‘active site loop’ toxins including cholera toxin, pertussis 
toxin, E.coli heat labile toxin and (b) the ‘a -3 ’ toxins that possess an a-helix beside 
the active site rather than a loop. These include the Iota-like binary toxins, the C3-like 
toxins and the eukaryotic Ecto-ART family. The a3-toxins differentiate themselves
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from the ‘active site loop’ toxins in the PN-loop and the a-3 helix as well as the 
behaviour of the Arg/His motif.
The recent kinetic and biochemical studies and eEF2-PAETA complex, (Jorgensen et 
al, 2005) have confirmed that for the DT group, the reaction is a third order SnI 
reaction. It seems likely that with the similarity in the mode of transferase action that 
the other ADPRTs will follow a similar reaction mechanism relying on the “active 
site loop” or the Gln/Glu-X-E motif to differentiate between their substrates. The 
“active site loop” or the Gln/Glu-X-E motif can also select the nature of the activated 
nucleophile that attacks the ADP-ribose+ moiety from toxin to toxin. This is 
supported by the findings that actin, eEF2, Gaj, Gas and the Rho GTPases all have 
target residues that are analogous to diphthamide and a nearby aspartate/glutamate 
residue similar to one of the key ADPRT binding residues seen in the eEF2-PAETA 
complex (Asp 696 of EF2). This aspartate interacts with the 2-OH of ADP-ribose in a 
manner similar to that of the catalytic glutamate of the ADPRT and this could be 
essential to the mechanism and form part of the mechanism that has not yet been 
captured in a crystallographic structure. This could be part of a conserved recognition 
site for all the ADPRT substrates. But to confirm that the CT and a-3 toxins do have 
similar mechanisms further structural studies with their substrates must be performed.
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2. The structure of the C3bot-RalA complex at 2.66A
2.1. Aims of structural studies on the C3bot-RalA complex
The C3bot ADPRT from Clostridium botulinum has high specificity to the RhoA-C 
small low molecular weight GTPases. It has been shown recently however that 
C3bot, along with the related C31im and C3cer also interact with the small low 
molecular weight GTPase RalA. This interaction does not result in the ribosylation of 
RalA and displays several other unusual properties. We aim to determine the structure 
of a complex between C3bot and RalA to allow us to understand how this interaction 
comes about and how this gives rise to the observed biochemical results.
2.2.1 The C3bot exoenzyme from Clostridium botulinum
Clostridium botulinum produces a large number of toxins including the binary 
ADPRT C2 toxin (Aktories et al, 1986) and the seven neurotoxic botulinum toxins A- 
G. Early research indicated that the Clostridium botulinum neurotoxins Cl and D also 
possessed cytotoxic ADPRT activity (Ohashi & Narumiya, 1987) targeting small 21- 
26kDa GTPases. However this was proved to be incorrect as a low molecular weight 
ADP-ribosyltransferase distinct from the Cl and D neurotoxins (Rosener et al, 1987) 
or the binary C2 toxin (Aktories et al, 1987) was identified and titled C3bot. Studies 
on C3bot identified a group of small 21-24 kDa GTPases as targets for the 
ribosyltransferase activity (Rosener et al, 1987; Aktories & Frevert, 1987) and this 
GTPase was confirmed as the Rho GTPase (Narumiya et al, 1988; Kikuchi et al,
1988). Like the binary C2 toxin (Aktories et al, 1986) and Iota toxin (Stiles & 
Wilkins, 1986) the C3bot ADPRT had NAD glycohydrolytic activity as well as a 
ribosyltransferase activity. The KM of these interactions was determined as a 2pM for 
the ADP-ribosylation (Aktories et al, 1988) and 60pM for the glycohydrolase activity 
(Aktories et al, 1989).
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Substrate studies of C3bot confirmed that RhoA-C are the substrates of C3bot and not 
the closely related GTPases Rac, Ras or Cdc42 (Aktories & Hall, 1989; Sekine et al,
1989). The ribosylation on Rho was also identified as an asparagine residue (Asn 41) 
lying in the important switch I region of the GTPase as the residue that is targeted by 
the transferase reaction (Sekine et al, 1989).
2.2.2 Related C3-like exoenzymes
There are now 5 other C3-like ADPRTs identified from other bacterial species. These 
are C3cer from Bacillus cereus (Just et al, 1995), C31im from Clostridium limosum 
(Just et al, 1992) and the 3 isoforms isolated from Staphylococcus aureus, C3staul-3. 
The C3stau exoenzymes may also be referred to as C3EDIN (Epidermal 
differentiation inhibitor) (Czech et al, 2001; Wilde et al, 2001). C31im is about 63% 
identical to C3bot while C3cer and C3staul-3 share -30%  identity with C3bot.
In the case of C3cer and C31im it is apparent that they function in a similar manner to 
C3bot and ADP-ribosylate the same residue as C3bot on Rho (Just et al, 1992). 
C3stau has demonstrated the same effects on RhoA-C but also extends its substarte 
specificity to the related GTPases RhoE and Rnd3 (Wilde et al, 2002c)
2.2.3 Biological role of C3bot
The biological targets o f the C3 family of ADPRTs are the small low molecular 
weight Rho GTPases. The Rho GTPase family is a large family comprising of more 
than twenty related proteins. This includes the Rho proteins (Rho A, B, C, D, E, G, F, 
G and H), Rac proteins (Rac 1, lb, 2, 3), Rnd 1-3 and Cdc42 (Wilde & Aktories, 
2001; Wennerberg & Der, 2004). These GTPases function as molecular switches in 
eukarayotic cells cycling between their inactive GDP bound state and their active 
GTP bound state (Wilde & Aktories, 2001). Cycling between the inactive and active 
forms is tightly controlled by 3 main classes of regulating proteins: (1) guanine
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nucleotide dissociation inhibitors (GDIs) that sequester inactive GTPase in the 
cytosol away from the plasma membrane; (2) guanine nucleotide exchange factors 
(GEFs) that initiate the exchange of GDP to GTP; and (3) GTPase activating proteins 
(GAPs) that stimulate the catalytic activity of the GTPases and hydrolyse GTP back 
to GDP. While there have been only been 3 different GDIs identified, a large number 
of GAPs (over 70) and GEFs (over 60) have been identified due to the broad range of 
cellular processes that the Rho GTPases are implicated in. A simplified view of the 
cell cycle is shown below in figure 2.1. In their active GTP bound state the Rho 
GTPases interact with effector molecules to pass on their downstream function. There 
have been over 50 of these effector molecules identified for Rho proteins and these 
can be scaffold proteins, serine/threonine kinases, tyrosine kinases, lipid kinases, 
lipases or oxidases (Jaffe & Hall, 2005). The interaction with these efffector 
molecules centres around 2 switch regions that are involved in the nucleotide binding. 
Both switch regions undergo dramatic conformational shifts upon GDP/GTP transfer. 
These switch regions are common to all the small-GTPases and are involved in the 
binding of nucleotides and the co-ordination of Mg2+ that has been found to be 
essential for GTPase activity. GEFs are also thought to bind to the switch I region 
during GDP/GTP exchange and are involved in stabilising the switch region during 
nucleotide transfer (Shimizu et al, 2000). Asparagine 41, the target for the C3 family 
of ADPRTs lies on switch I and ribosylation of this asparagines residue results in 
GEFs unable to bind to RhoA and permanent inactivation of RhoA as it is unable to 
facilitate the transfer of GDP to GTP. Ribosylation however does have a minimal 
effect on nucleotide binding or GTPase activity, either intrinsic or GAP stimulated. It 
also does not prevent the Rho protein interaction with effectors although this requires 
the Rho to be in the activated state prior to ribosylation (Genth et al, 2003a; Genth et 
al, 2003b).
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Figure 2.1 The Rho GTPase cycle
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Figure 2.1. The Rho GTPase cycle. Rho starts off (1) sequestered in the cytsosol bound to the Rho 
guanidine dissociation inhibitor (Rho-GDI). It is then bound still in its inactive, GDP, form to the 
membrane (2) and then with assistance from a guanidine exchange factor (GEF) the GDP is exchanged 
for GTP and Rho is active (3) and able to interact with effectors. It then interacts with a GTPase 
activating protein that stimulates the GTPase activity of Rho and hydrolyses GTP to GDP inactivating 
Rho (4). C3bot ribosylates asparagines 41 on switch I of Rho preventing GEFs binding and trapping 
Rho in its GDP bound inactive state.
This interrupts the essential functions of Rho proteins within the cell. These functions 
include: regulation of actin cytoskeleton and stress fibres, regulation of NADPH 
oxidase, cell cycle control, secretion, apoptosis, transcriptional activation, cell 
adhesion, cell transformation and transcriptional activation (Wilde & Aktories, 2001; 
Etienne-Manneville & Hall, 2002; Aktories etal, 2004; Jaffe & Hall, 2005).
The most prominent and well studied effect of this is to disrupt the ability of Rho 
proteins to maintain the cellular cytoskeleton. This results in well characterised cell 
rounding, redistribution of actin filaments and the breakdown of stress fibres 
(Chardin etal, 1989). Other well studied processes that are inhibited by ribosylation
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by C3bot are related to the immune system and immune response and may represent a 
pathogenic purpose to C3 activity. Areas of the immune system affected include: cell 
adhesion (Nemoto et al, 1996); lymphocyte cytotoxicity (Lang et al, 1992); and the 
migration and invasion of both leukocytes and lymphocytes (Stam et al, 1998; 
Laudanna et al, 1996).
The great specificity of C3bot and the related C3s has been used as a pharmacological 
tool in many experiments studying the various effects of the Rho proteins on the cell 
cycle, skeleton and gene transcription. However in these studies the lack of any 
translocation or receptor binding domains on C3bot results in these experiments 
relying on either micro injection (Paterson et al, 1990) or the construction of chimeric 
toxins. The approach with chimeric toxins has proved successful and in all cases 
improved the potency of the C3 exoenzyme involved by several hundredfold. The 
reported chimeric toxins have involved fusing a C3 toxin to the binding and 
translocation domain of either diphtheria toxin (Aullo et al, 1993) or to the binding 
and translocation domain of Clostridial C2 binary toxin (Barth et al, 1998a). More 
recently new techniques have been used that rely on attaching a short peptide chain to 
the C-terminus of C3bot to encourage uptake into target cells. A short sequence of the 
HIV Tat gene (Park et al, 2003) or a short proline or arginine rich sequence (Winton 
et al, 2002) have both been used in this way.
The lack of a translocation or binding domain has left the exact role of C3bot in 
pathogenicity largely unknown. As despite the wide ranging effects that C3bot action 
has on cells there is no obvious method for C3bot to gain entry into its host cells. By 
examining the behaviour of other pathogens there are two possibilities that may 
explain the single domain nature of C3bot: (1) More pathogenic bacteria than first 
though have now been observed to invade host cells. If this is the case for Clostridial 
species then C3bot could be secreted directly into the cell cytosol (Wilde & Aktories,
2001). (2) It has been observed in Streptococcus pyogenes that the cholesterol 
dependant streptolysin O can form a pore to translocate S. pyogenes NAD- 
glycohydrolase (SPN) into host cells (Madden et al, 2001). Pore forming proteins are
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common to many C3 producing bacteria that may exhibit a similar mechanism. This 
method of entry is also fairly reminiscent of the type III secretion system used by 
many species of pathogens.
2.2.4 The structure of C3bot
C3bot is a 251 amino acid protein though the first 40 residues have been identified as 
a general secretory protein signal peptide. This signal sequence possesses a series of 
positively charged amino acids at the extreme N-terminus (Lys2, Arg5 and Arg6), a 
hydrophobic central region (Ile8 to He26) and a proteolytic cleavage site between 
Lys40 and Ala41 in keeping with the general features of a general secretory protein 
(Popoff et al, 1991; von Heijne, 1985).
Figure 2.2 The structure of C3bot
Figure 2.2. The structure of C3bot [PDB code 1G24] (Han et al, 2001) showing the mixed a/p core 
and highlighting the active site and the 2 important loop regions.
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C3bot also shares an active site with the other members of the C3 family and a 
common 3-dimensional structure. The structure of C3bot showed a central mixed a/p 
core with a 5 stranded anti-parallel p-sheet stacking perpendicular against a 3 
stranded anti-parallel P-sheet and is shown above in figure 3.2. The 3 stranded sheet 
is flanked by four consecutive a-helices below the active site and a fifth a-helix 
stacks against the 5 stranded sheet above the active site. The active site of C3bot is 
similar to that of the other bacterial ADPRTs (Holboum et al, 2006) and it possesses 
the 5 motifs common to the family of a-3 ADPRTs: (1) an ARTT loop containing the 
catalytic glutamate (Glu 214) and substrate determining glutamine (Gin 212) two 
residues upstream. In C31im mutation of this glutamine to glutamate has been shown 
to change the specificity from asparagine to arginine (Vogelsgesang & Aktories,
2006). (2) An STS (Ser 174-Thrl75-Serl76) motif to stabilise the active site and 
form a network of hydrogen bonds between the catalytic glutamate and Tyr79 of the 
a-3 helix. (3) The PN loop (residues 182-186) that moves in a “crab-claw” motion to 
close the active site around the bound NAD. The PN loop contains a phenylalanine 
(Phel83) that stabilise the nicotinamide with stacking interactions and an arginine 
(Arg 186) that binds to the phosphate oxygen (Evans et al, 2003) (Menetrey et al,
2002). (4) The conserved arginine (Argl28) from the conserved Arg/His motif found 
in all of the ADPRT family forms another stabilising interaction with one of the 
phosphate oxygens. A third arginine (Arg91) on the (5) a-3 helix stacks against the 
adenine ring. Helix a-3 also possesses tyrosine (Tyr79) and an aspargine (Asn87) that 
forms another bond with another of the phosphate oxygens.
2.3 Interactions between C3bot and RalA
While C3bot specifically binds to and ADP-ribosylates Rho -A,-B,-C GTPases it has 
recently been demonstrated that it also binds Ras-like GTPase RalA. This occurs 
without ribosylation of RalA and inhibits the ADP-ribosylation of Rho by C3bot 
(Wilde et al, 2002a). C31im and C3cer were also found to bind to RalA in a manner 
that does not result in the ribosylation of RalA and inhibits the activity of the C3 
exoenzyme involved, though to a lesser extent than the inhibition observed with
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C3bot. C3stau2 although sharing 35% identity with C3bot does not bind, and is not 
inhibited by, RalA.
Ral (Ras-like) GTPases were originally identified in simian B-cell line cDNA library 
due to their similarity to Ras and others in the GTPase family (Chardin et al, 1989). 
Ral occurs in two isoforms, A and B, that have a high sequence identity of -80%. 
Related proteins in the Ras superfamily include several of the Ras proto-oncogenes 
including H-, N-, and K-Ras that share -58%  identify to Ral (Feig, 2003) and 33% 
identity to RhoA (Wilde et al, 2002a).
RalA like the other GTPases functions as a molecular switch by cycling between a 
GTP and GDP bound form. RalA is inactive in the GDP bound form and active in the 
GTP bound form and the binding and exchange of GTP is regulated by guanine 
nucleotide exchange factors (GEFs), guanine nucleotide dissociation inhibitors 
(GDI’s) and GTPase activating proteins (GAPs). In the case of RalA these include a 
subset of specific GEFs and GAPs specific to Ral alone (Feig, 2003). RalA binds to 
GDP very strongly and requires the assistance of GEFs to remove GDP and to allow 
GTP to bind in its place. The GTP-bound RalA is then active and through post- 
translationally modified residues with palmitoyl, famesyl or geranylgeranyl groups 
interacts with downstream effectors. The GDIs prevent the dissociation of GDP and 
act as a negative control on the activation of RalA. GAPs are required as the GTPase 
activity of the small GTPases is quite slow and the GAPs speed up the process in 
returning the active GTP-bound form to the inactive GDP-bound form (Takai et al, 
2001). RalA, like the related Ras, Rho and Rac GTPases are regulated by GTP/GDP 
transfer. This exchange occurs around the nucleotide-binding region that is made up 
of two sequences defined as switch I and switch II. These switches have been 
identified in RalA; switch I residues 40-48 and switch II 70-78 (Fukai et al, 2003). 
Both switch regions undergo dramatic conformational shifts upon GDP/GTP transfer. 
These switch regions are common to all the small-GTPases and are involved in the 
binding of nucleotides and the co-ordination of Mg and are shown below in figure 
2.3. GEFs are also thought to bind to the switch I region during GDP/GTP exchange
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and are involved in stabilising the switch region during nucleotide transfer (Shimizu 
et al, 2000).




Figure 23 . The structure of RalA highlighting the important switch I and switch II regions and the 
GDP binding site [PDB code 2BOV] (Holboum et al, 2005).
RalA like all GTPases has many functions in the cell and can mediate a plethora of 
different cellular processes. RalA is primarily activated by Ras. Ras binds to and 
activates a family of Ral specific GEFs including the Ral-GDP disassociation 
stimulator (Ral-GDS) and transfers them to where they may interact with Ral at the 
plasma membrane (Feig, 2003). Ras may also act on another protein, PI3K, which 
enhances the Ral GEFs intrinsic GEF activity to switch on Ral ( Tian et al, 2002; 
Feig, 2003). Additionally Ral may be activated directly by intracellular secondary 
messengers such as Ca2+ (Hofer et al, 1998). Ral plays a role in many important 
pathways, Some of these diverse signal processes are illustrated below in figure 2.4.
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Figure 2A. The role of Ral in the cell. Ral is implicated in many cellular processes. This includes 
modulation of the actin cytsoskeleton either through interactions with filamin or through the exocyst 
complex. It is involved in secretion through regulation o f the exocyst complex. It mediates endocytosis 
through phospholipase D1 or through an intermediary RalBLPl. It also activates several transcription 
factors including NF-kB, Jun kinase and SRC through an unknown effector.
One of the most well studied roles of Ral is in vesicle trafficking in the plasma 
membrane (Nakashima et al, 1999; Brymora et al, 2001). This involves cycling 
between the control of both secretion through the exocyst complex and indirect 
control of receptor mediated endocytosis through regulation of RalBPl and through 
stimulation of phospolipase D1 (PLD1) ( Jiang et al, 1995; Feig, 2003). This includes 
a regulatory role in neurotransmitter release through the control of vesicle secretion 
(Polzin et al, 2002).
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It also plays a substantial role through several pathways in control of the cytoskeleton 
and alterations in cell morphology such as the formation of filopodia and the 
cytoskeletal changes associated with cell migration (Ohta et al, 1999; Takai et al, 
2001). These are controlled by either direct interaction of Ral with filamin or the 
exocyst complex (Feig, 2003) or via RalBLPls GAP activity on Cdc42 and Rac 
GTPases (Jullien-Flores et al, 1995).
A still not fully understood role of Ral is the control of gene transcription. It has been 
shown to activate a host of transcription factors via interaction with an unknown 
effector. These transcription factors include nuclear factor-KB (Henry et al, 2000), a 
tyrosine kinase (Src) (Feig, 2003), the ternary complex factor (TCF) (Wolthuis et al,
1997) and the forkhead transcription factor (AFX) (Kops et al, 1999).
Finally it has been seen to play a role in cell proliferation, promotion of oncogenesis 
and Ras-mediated cell transformation (Urano et al, 1996; Feig et al, 1996). Its 
contribution to cell proliferation occurs partly through the activation of PLD1. (Lu et 
al, 2000) Its role in cell proliferation has now been widened to include cell 
differentiation as well. (Verheijen et al, 1999).
The interaction between C3bot and RalA is surprising given the well documented 
specificity of C3bot for RhoA-C and its use as a pharmacological tool in studying the 
Rho GTPases and their role in the cell. There are several major questions raised by 
the observed interaction. The interaction although resulting in inhibition of 
ribosylation of RhoA, increases the rate of NAD-glycohydrolysis five fold (Wilde et 
al, 2002a) and does not result in the ribosylation of RalA. Another ADP-ribosylating 
enzyme, ExoS, the Pseudomonas auruginosa exoenzyme, is known to ribosylates 
RalA at Arg52- the equivalent residue to Asn41 on RhoA (Fraylick et al, 2002). 
Further initial studies demonstrated that a mutation of the aromatic residue on the 
ARTT loop of C3bot (Phe209) had no effect on the interaction with RalA suggesting 
that this binding occurred in a novel manner. This binding is not unique to C3bot as 
both the related C3 exoenzymes C31im and C3cer interact with RalA and suffer
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inhibition of their ribosylation activity though less than the inhibition shown for the 
C3bot-RalA interactions, though in the case of C31im the interaction has been shown 
to be stronger (Kd ~12nM) (Wilde et al, 2002a) than that of the C3bot-RalA 
interaction. ( K d  ~60nM) (Pautsch et al, 2005). This inhibition is also specific to the 
RalA GTPase as there is no similar inhibition reported for the related Rac, Ras or 
CD42 small GTPases and has several potentially important functional consequences 
for RalA. The first of these is that the interaction between C3bot and RalA seems to 
prevent the activation of PLD1 by RalA which would have serious affect on the 
ability of RalA to maintain its normal cellular function (Wilde et al, 2002a). 
Secondly, RalA, like many small GTPases, is glucosylated by Clostridium sordelli 
lethal toxin at Thr46 on the switch I region (Genth et al, 1996) and interaction with 
C3bot prevents this interaction giving a clue as to where the interaction between 
C3bot and RalA may take place. There are also conflicting reports of the nucleotide 
dependant state of the interaction with it being reported as GDP/GTP independent 
(Wilde et al, 2002a) and GDP dependant (Pautsch et al, 2005).
We have determined the strucuture of complex between C3bot-RalA at 2.66A 
(Holboum et al, 2005). This complex answers many of the questions raised by the 
biochemical studies and accounts for the broad C3 specificity (all C3 exoenzymes 
apart from C3stau) but narrow GTPase specificity (only RalA).
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2.4 Methods
The expression and purification was based on methods previously described by Evans 
et al (Evans et al, 2004) and myself (Holboum et al, 2005).
2.4.1 Expression of C3bot
A C3bot-MBP fusion construct in BL21(DE3) cells was kindly provided by Dr. J.M. 
Sutton (Health Protection Agency UK). A 10ml starter culture of the C3bot-MBP 
construct was grown overnight at 37°C in Terrific Broth supplemented with 35mg/l 
chloramphenicol and 0.5% (w/v) glucose. The overnight culture was diluted 1:50 in 
fresh media and grown for four hours until an OD600 of ~0.8 was reached. Protein 
expression was induced with a final concentration of 500pM isopropyl-p-D- 
thiogalactopyranoside (IPTG) for four hours at 25°C. Cells were harvested by 
centrifugation (Beckman Avanti J-25).
2.4.2 Purification of C3bot
Cell pellet was resuspended in 20mM Hepes pH 7.3, 20mM NaCl, ImM 
Ethylenediaminetetraacetic acid (EDTA), ImM PMSF, 1 mg/ml lysosyme and stirred 
on ice for 45 minutes. The cells were lysed by sonication (Soniprep 150) and the cell 
lysate was clarified by centrifugation (Beckman Avanti J-25).
The clarified cell lysate was applied to an SP-sepharose column (GE Healthcare) 
equilibrated with 20mM Hepes pH 7.3 and was eluted on an ascending NaCl gradient 
as a single peak. Peak fractions were pooled with 1U Factor Xa (New England 
Biolabs) /100ug protein overnight at room temperature. The cleaved C3bot was 
reapplied to an SP-sepharose column (GE Healthcare) equilibrated with 20mM Hepes 
pH 7.3 and was eluted with an ascending NaCl gradient. The protein was 
concentrated in a lOkDa centrifugal concentrator (Amicon) and applied to a Superdex 
200 gel filtration column (GE Healthcare) equilibrated in 20mM Hepes pH 7.3,
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120mM NaCl. The purified protein was concentrated down to lOmg/ml in a lOkDa
centrifugal concentrator (Amicon) and stored for crystallisation.
2.4.3 Expression of RalA
The human RalA gene clone (as a pGEX-2T fusion) was a kind gift of Dr Hiroshi 
Koide, Department of Stem Cell Biology, Graduate School of Medical Science, 
Kanazawa University, Japan. The plasmid was then transferred to the host strain 
JM109 for expression. The clone was inoculated into 100ml of Terrific Broth 
supplemented with 0.5% glucose and lOOpg/ml ampicillin and grown overnight at 
37°C. The culture was diluted 1:50 into 11 of fresh medium and grown for 4 hours at 
37°C until an OD600 of ~0.8 was reached. Expression was induced by addition of 
IPTG to a final concentration of ImM and grown for a further 4 hours at 25°C. Cells 
were harvested by centrifugation (Beckman Avanti J-25).
2.4.4 Purification of RalA
Cell pellets were resuspended in 50mM BisTris, 0.5M NaCl pH7.0 lmg/ml lysozyme 
and left on ice for 45 minutes. The cells were lysed by sonication (Soniprep 150) and 
the cell debris removed by centrifugation (Beckman Avanti J-25).
The clarified cell lysate was applied to a GST-trap column (GE Healthcare) 
equilibrated with 50mM BisTris pH 7.0, 0.5M NaCl, and was eluted with 20mM Tris 
pH 8.0, 0.2M NaCl, lOmM reduced glutathione as a single peak. The peak was 
dialysed into 20mM Hepes pH 7.3, 150mM NaCl, 5mM MgCh, 2.5mM CaCh 
overnight at 4°C. It was then treated with 1U thrombin (New England Biolabs) 
/100pg protein overnight at 4°C. RalA was separated from the GST fusion tag by 
reapplication to the GST-trap column. The RalA protein was concentrated in a lOkDa 
centrifugal concentrator (Amicon) and applied to a Superdex 200 gel filtration 
column (GE Healthcare) equilibrated with 20mM Hepes pH 7.3, 20mM NaCl, 5mM
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MgCl2, ImM EDTA. The purified sample was further concentrated to lOmg/ml in a
1 OkDa centrifugal concentrator (Amicon) and stored for crystallisation.
2.4.5 Formation of the C3bot-RalA complex
Pure C3bot and RalA were incubated together at 4°C overnight in a range of ratios 
ranging from 2:1 to 1:2. The formation of a complex after incubation was observed 
on a continuous 15% acrylamide, 30mM histidine-3OmM Mes pH 5.9 native gel. In 
all cases the gel was pre-electrolysed for 45 minutes at 120V. Samples were loaded as 
a mixture of 2ul methyl green and 2ul of the C3bot-RalA.
2.4.6 Crystallisation of the C3bot-RalA complex
For crystallisation RalA and C3bot were incubated together overnight in a ratio of 2:1 
giving a working concentration of 6.67mg/ml RalA and 3.33mg/ml C3bot. 
Crystallisation trials were performed as hanging drops using 2pl o f protein with 2pi 
of reservoir solution in the drop, giving a final protein concentration of 3.3mg/ml 
RalA and 1.67mg/ml C3bot in the crystallisation drops. Structure screens I and II 
(Hamptons Research) were used to generate initial crystallisation conditions. 
“Whisker-like” crystals were observed in condition 19 of structure screen II 
(Hamptons Research) (0.1M Hepes pH 7.5,10% PEG8000 and 8% ethylene glycol).
Fine screening around this condition led to narrow crystals appearing over the course 
of ~3 days in 0.1M Hepes pH 7.3, 12-15% ethylene glycol, 14-18% PEG8000 at 
16°C.
2.4.7 Data collection and refinement
Diffraction data to 2.66A were collected from a single cryo-cooled (100K) crystal 
with 25% ethylene glycol on station PX9.6 of the synchrotron radiation source at 
Daresbury (UK) using an ADSC Quantum 4 CCD detector and one of the diffraction
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images is shown below in figure 2.5. The data were processed and scaled using the 
HKL2000 package (Otwinowski, 1993a; Otwinowski, 1993b) (Otwinowski, 1993a). 
The symmetry and systematic absences were consistent with the P2i2i2i space group 
(unit cell dimensions <2=56.63A, 6=90.84A and c=100.40A) with one C3botl-RalA 
complex per asymmetric unit and the crystals containing -54%  solvent. Data 
reduction was carried out using the program TRUNCATE (CCP4, 1994).
The structure of the C3botl-RalA complex was determined by molecular 
replacement method with MOLREP (Vagin & Teplyakov, 2000) using PDB entries 
1G24 for native C3botl (Han et al, 2001) and 1UAD for RalA from the RalA-Sec5 
complex (Fukai et al, 2003) as search models. Initial refinement of the structure was 
carried out using REFMAC5 (Murshudov, 1997) which improved the model and 
subsequent rounds of refinement was carried out using the CNS suite (Briinger et al,
1998) and the model building program O (Jones et al, 1991). In each data set 5% of 
reflections were kept aside for Rfree calculation (Briinger, 1992). Water molecules 
were added using the WATERPICK module of CNS. The clear continuous density 
observed (in both the 2mFo-nFc and mFo-nFc SIGMA-A weighted maps) in the GTP 
binding pocket of RalA during the final stages of the refinement was interpreted as 
GDP. The final model contains 3010 protein atoms, 214 water molecules and 24 
ligand atoms, has an R-factor of 21.8 and an R-ffee value of 27.9%. The details of the 
data processing and refinement statistics are presented in table 2.1. The 
stereochemical quality of the finished model was checked using PROCHECK 
(Laskowski et al, 1993).
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Figure 2.5 A diffraction pattern from the C3bot-RaIA complex
Figure 2.5. Diffraction pattern from a cryo-cooled crystal o f  the complex between C3bot-RalA at 
station 9.6 at the SRS Daresbury. The resolution range is shown by a series o f  concentric circles.
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Table 2.1 Details of crystallographic data
Resolution range (A) 50-2.66
Wavelength (A ) 0.87
Exposure time (s) 20
Number of images 150
Rotation per image (°) 1
Number of reflections measured 242,860
Unique reflections 15,556
I/o(I) (outer shell3) 14.6 (5.8)
Completeness (outer shell3) % 99.8 (99.9)
R symmb (outer shell3) (%) 11.1 (26.0)
^cryst" (% ) 20.6
27.4
Average temperature factor (A  ):
RalA main-chain (side-chain) 20.4 (21.9)




RMSD from ideal values:
Bond lengths (A) 0.006
Bond angles (°) 1.1
“Outer shell is 2.16k -  2.66k
bRsymm='LhLi |/(h)-/j(h)|/ZhZi/(h), where /j(h) and 1(h) are the /th and the mean measurements 
of the intensity of reflection h, respectively.
°̂ cryst = ĥ |F0-  Fc|/IhF0, where F0 and Fc are the observed and calculated 
structure factor amplitudes of reflection h, respectively.
di?free is equal to RCIyst for a randomly selected 917 (5.9%) reflections not used in the 
refinement
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2.5 Results and discussion
2.5.1 Experimental results
The expression and purification of C3bot and RalA was fairly straightforward as a 
protocol was already available and needed little modification to yield reasonable 
amounts of pure homogenous protein, ~12mg/l C3bot and ~3mg/l RalA. SDS-page 
gels illustrating the various stages of purification are shown below in figures 2.6A 
and 2.6B.
Figure 2.6 Purification of C3bot and RalA 
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Figure 2.6. A The purification of RalA showing the purification of the initial 45kDa RalA-GST fusion 
protein and the post cleavage the purification of the 24kDa RalA.B Dlustrates the purity of C3bot at the 
various stages throughout purification. The initial 60kDa band is the C3bot-MBP fusion construct The 
MBP is then cleaved off and the C3bot isolated with a second ion exchange step and further purified 
with gel filtration.
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To assess the formation of the complex a native gels were used rather than gel 
filtration as there was a limited amount of material available. On the native gels the 
C3bot band appears as a clear band while the RalA band is never present. The 
complex is seen as a third band near the top of the gel and can be seen in figure 2.7.
Figure 2.7 Native gel of the 2 competing crystal forms
C3bot Mixture Ciystal 1 Crystal 2 
RalA
Figure 2.7.. A native gel illustrating the formation o f  the C3bot-RalA complex and the composition o f  
two possible crystal conditions. Sample o f  pure C3bot and RalA were run but due to the nature o f  the 
native gel RalA does not move from the top o f  the gel. The complex can be seen as a band at the top o f  
the gel in the lane marked ‘mixture’. The possible crystals were removed from the drops with a crystal 
loop before being mixed resuspended in gel loading buffer and mixed vigorously. Crystal form 1 is a 
C3bot crystal; crystal from 2 is the C3bot-Ral A complex.
In the course of crystallisation trials the initial structure screens gave two possible 
conditions: Condition 6 from Hamptons structure screen 1 (0.1M Na acetate 
trihydrate, 8% PEG 4000); and condition 19 from structure screen I (0.1M Hepes pH 
7.5, 10% PEG8000 and 8% ethylene glycol). Prior to data collection samples of both 
crystals were taken, crushed and applied to a native gel as shown below in figure 2.7. 
The results of this gel suggested that the first crystal form in 0.1M Na acetate
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trihydrate, 8% PEG 4000 was a new crystallisation condition for C3bot. The second 
condition was that of the C3bot-RalA complex. Optimisation screens around this 
gave final crystallisation conditions of 0.1M Hepes pH 7.3, 12-15% ethylene glycol, 
14-18% PEG8000. These crystals appeared as long thin hollow needles as shown in 
figure 2 .8 .
Figure 2.8 Crystals of the C3bot-RalA complex
Figure 2.8. Crystals of the C3bot-RalA complex grown by hanging drop vapour diffusion at 16°C in 
0.1M Hepes pH 7.3, 12-15% ethylene glycol, 14-18% PEG8000.
Data to 2.66A were collected from a single cryo-cooled (100K) crystal on an ADSC- 
CCD detector on station PX9.6 at the Synchrotron radiation source at Daresbury, UK. 
The data were processed & scaled using the HKL2000 package (Aepfelbacher et al,
1997). Initial determination of cryo-conditions using 25% ethylene glycol proved 
satisfactory and 25% ethylene glycol was used as the cryo-protectant in all diffraction 
studies. The structure of the NAD-free wild type C3bot (PDB code 1G24) (Han et al, 
2001) and RalA from the complex with the Sec5 (PDB code 1UAD) (Fukai et al, 
2003) were used as search models for molecular replacement using MOLREP (Vagin
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& Teplyakov, 1997). MOLREP gave many possible solutions; the final molecular 
replacement solution had an R-factor of 44.7% and a correlation coefficient of 54.1%. 
The MOLREP solution chosen was the top solution as the second solution found had 
an R-factor of 54.6% and a correlation coefficient of 26.5%. Initial refinement using 
REFMAC (CCP4, 1994) dramatically improved the model (Rcrys 29.7, R^e 38.1, 
FOM 81.3). Subsequent rounds of refinement and model building were performed 
using CNS (Briinger et al, 1998) and O (.Jones et al, 1991). During the course of 
refinement a large stretch of contiguous difference density was observed in the 
nucleotide binding site of the RalA molecule and this was modelled as GDP and a 
single magnesium ion as shown below in figure 2.9.
Figure 2.9 Electron density surrounding the GDP molecule
Figure 2.9. Stereo view of the contigious 2Fo-Fc density at 3 sigma in the nucleotide binding site with 
a molecule of GDP modelled into it. The Mg2+ ion is shown as a green sphere. The PDB file for GDP 
and the torsion and parameter files were supplied by the Hicup Webserver (Kleywegt & Jones, 1998)
The N and C termini of the RalA molecule were visible but residues 41-44 of the 
C3bot N-termini were removed due to insufficient density, residues 181-184 on 
C3bot were disordered and modelled on the basis of weak density with the side 
chains of residues 181 and 182 and 54 modelled with 0 occupancy due to weak 
density, residue 210 on C3bot was also modelled with 0 occupancy due to insufficient 
density. Analysis of the Ramachandran plot (¥-<£), shown below in figure 2.10, 
showed 86.5% of residues lie within the most favourable region with 0.3% in 
disallowed regions (Alai 84 on C3bot). The details of the data processing and
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refinement statistics are presented in table 2.1. The stereochemical quality of the 
finished model was checked using PROCHECK (Laskowski et al, 1993). The final 
refined structure of C3botl-RalA complex at 2.66A resolution has a conventional R- 
factor (Rcryst) of 20.64% and a free R-factor (Rfree) of 27.36% and is shown below in 
figure 2.11. The final model of the complex contains 3010 protein atoms, 260 water 
molecules and one GDP molecule, with an Mg2+ ion, bound to the nucleotide binding 
site of RalA (Holboum et al, 2005).
2.5.2 Overall structure of the C3bot-RalA complex.
The overall topology of C3bot in the complex is identical to that of previously 
determined structures of native C3bot molecule (Evans et al, 2004; Han et al, 2001; 
Menetrey et al, 2002). C3bot consists of a mixed a/p core. A five stranded mixed P- 
sheet (p i, P2, P4, P7, P8) stacks perpendicularly against a three stranded anti-parallel 
p-sheet (p3, p5, p6) with four helices (a l, a2, a3, a4) arrayed around the three 
stranded sheet plus a fifth helix (a5) flanking the five stranded sheet. A least squares 
superposition of the C3bot with uncomplexed C3bot (PDB code 1G24; 24) yields a 
root mean square deviation of 0.79 A for 207 Ca atoms. The largest difference 
between the structures concerns the conformation of the ARTT loop. There is also a 
change in conformation for residues 232-236 between strands P7 and P8 on the 
surface of the molecule.
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Residue* ia uioq favoured rcgnv*  |A.H.I | 2 % 86.551-
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Residues ia d isd lcm ed  regions 1 0391
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flatcd un an  analysis o l 11H structures o l  ncsolotkm of a t least 2.0  Angstroms 
and R -la tte r  no  greater than XWJ.  a pood quality rondel would be exported 
to  have over 90 'S  its the m od favoured regions
Figure 2.10. A Ramachandran plot o f the refined structure of the C3bot-RalA complex. One residue 
lies in the disallowed region (Alai84 of C3bot) and 86.5% of the residues lie within the most 
favourable region. The Ramamchandran plot was calcualted with PROCHECK (Laskowski et al, 
1993).
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Figure 2.11 The structure of the C3bot-RaIA complex
Switch I ARTT loop
Switch II
C
Figure 2.11. The structure of the C3bot-RalA complex shown in cartoon form. RalA is shown with 
yellow helices and green strands and switch I and II are highlighted. The bound GDP molecule is 
shown bound into the active site and the bound Mg2+ ion is shown in purple. C3bot is shown with red 
helices and blue strands and the PN loop and ARTT loop at the active site are highlighted.
RalA is constructed from a six stranded mixed P-sheet sandwiched between five a- 
helices; three helices (a2, a3, a4) below the plane of the p-sheet, two helices (al, a5) 
above. RalA, like the other related low molecular weight GTPases, possesses two 
switch regions that form part of the GDP binding pocket and change conformation on 
GTP or GDP binding. In RalA, the switch regions comprise residues 40-48 (switch I, 
between helix a l and strand p2) and 70-78 (switch H, between helix a2 and strand 
P3). These regions, which display a wide range of conformations among known 
GTPase structures, are well ordered in the C3bot-RalA complex structure. The GDP 
binding site has a total buried surface area of 808.9A2, 9.25% of the RalA-GDP total 
surface area (8743.8A2). The binding of GDP to RalA in the C3botl-RalA complex is
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somewhat different to that of GppNHp (a non-hydrolysable GTP homologue) to RalA 
in the RalA-Sec5 complex (Fukai et al, 2003). It follows the normal mode of GDP 
binding as seen in other small G-proteins (Takai et al, 2001) and is shown below in 
figure 2 .12.
Figure 2.12 The GDP binding site of RalA
K12S
Figure 2.12. A stereo view of the GDP binding site o f RalA highlighting the bonds made between 
RalA and the bound GDP. The magnesium ion is shown in green and water molecules are show in 
turquoise. The Mg2+ ion has a square pyramidal geometry through Ser28 of RalA and water mediated 
hydrogen bonds. The guanine ring is stabilised by the conserved NKXD motif with Asnl27, Lysl28 
and Asp 130 forming the hydrogen bonds.
The guanine base is recognized by residues from the consensus sequence NKXD 
(loop between a4 and p5) with Lysl28 and Aspl30 making direct interaction with 
the nucleotide. In addition, part of the loop located between helix a5 and strand p6 
acts as a recognition site for the guanine base in both structures. The loop (also 
known as P-loop), connecting strand pi and helix a l ,  houses the a- and p- phosphate 
groups. Binding of GDP requires coordination by the Mg2+ ion (square pyramidal 
geometry) that binds the P- phosphate oxygen. The other coordinating atoms for the
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Mg2+ are provided by three water molecules and the OG atom of Ser 28 from the a l  
helix.
Superposition of RalA molecule from the C3bot-RalA complex with the RalA-Sec5 
complex (PDB code 1UAD) (Fukai et al, 2003) shows a root mean square deviation 
of 1.2 A  for 172 Ca atoms, although this value is biased by different conformation of 
the switch I and switch II regions (root mean square deviations of 2 .6A  and 2.2A  
respectively). The striking conformational differences between the RalA switch 
regions between the Sec5 and the C3bot complexes, in particular switch I, can be 
attributed to the different nucleotides bound, the GTP analogue, GppNHp, in the Sec5 
complex, and GDP in our C3bot complex. Exchange of GDP to GTP would be 
unlikely to cause any changes in the RalA-C3bot structure, however, as the switch 
regions are not involved in binding of C3botl and previous studies have shown the 
binding to be nucleotide independent (Wilde et al, 2002a).
2.5.3 The C3bot-RalA interface.
Sixteen residues (9 from C3botl and 7 from RalA which are well ordered and clearly 
defined in the electron density) provide all the interactions at the binding interface as 
shown below in figure 2.13. The contact residues on C3bot are positioned on helices 
a l ,  a2  and the ARTT loop. The contacts on the RalA molecule are distributed on 
helix a4  and strand (36. This orientation of the complex is notable as RalA binds 
C3bot at the same position that RhoA is presumed to bind (at the ARTT loop) but in a 
different orientation. The ribosylation target of C3bot in RhoA (Asn41), and the 
equivalent residue in RalA (Arg52), lies close to switch I. But in the C3bot-RalA 
complex, the switch regions I and II and the GDP binding pocket are on the opposite 
side of RalA to the binding interface. The interaction of RalA with the ARTT loop of 
C3bot implies that RalA inhibits RhoA ribosylation by blocking the RhoA binding 
site.
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Figure 2.13 The interface between RalA and C3bot
Loop Between
p5-a4
Figure 2.13. A stereo view of the interface between RalA (in yellow) and C3bot (in red and blue). The 
base o f the interface is anchored by Lys73 and Lys81 from C3bot and the top of the interface is 
anchored by Lys56 of C3bot. The centre of the interface is between helix a4 of RalA and the ARTT 
loop of C3bot.
There are a total of 22 interactions at the interface between 14 RalA atoms (3 main- 
chain and 11 side-chain atoms) and 14 C3bot atoms (6 main-chain and 8 side-chain 
atoms). All of the residues involved in the interface are detailed in tables 2.2-2.4. 
Some 642.3 A2 of the total accessible surface area is buried at the interface upon 
complex formation (compared to 925 A2 in Sec5-RalA complex, 28), equivalent to 
3.5% of the total surface area of the C3bot-RalA complex.
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D ...A (A )
Angle D- 
H ...A  (°)
Asp204 O 20.65 Lysl43 NZ 21.80 2.57 160.7
Ser207 O 33.10 Lysl43 NZ 21.80 2.56 160.0
Lys56 NZ 32.30 Glul47 OE2 45.03 2.84 156.4
Lys73 NZ 22.40 Glul40 OE1 25.38 2.91 170.3
Tyr63 OH 27.19 Glul40 OE2 24.88 2.73 175.3
Lys81 NZ 22.4 Glul55 OE1 20.05 2.57 163.0
All contacts shorter than 3.6A with D-H...A angle > 120° are shown (D, hydrogen bond donor; A, 
hydrogen bond acceptor). Hydrogen bond parameters were calculated with the program HBPLUS
(McDonald & Thornton, 1994) .
Table 2.3 Water mediated hydrogen bonds between the C3bot and RalA
Water C3bot Distance RalA residue Distance B-factor
residue (A) (A) (A 2)
54 Lys81 NZ 2.88 Seri 29 O 2.57 22.99
Glul 32 OE1 2.96
213 Pro205 O 2.64 G lul40O 2.61 24.70
Hydrogen bond parameters were calculated with the program HBPLUS (McDonald & Thornton,
1994).
2.5.3.1 The role of the ARTT and PN loops
The ARTT loop (residues 207-214) in the C3bot has been established by structural 
and mutational studies to be the key region responsible for ADP-ribose transfer. It 
contains residues Gln212, and Glu214, conserved across all C3 exoenzymes, which 
are essential for the transfer of ADP-ribose onto Asn41 of RhoA (Menetrey et al, 
2002; Sekine et al, 1989). The ARTT loop also contains Phe209 that has been 
implicated in RhoA binding by mutational studies with a P209A C3bot mutant that 
lost the ability to bind to, and ribosylat RhoA (Wilde et al, 2002a). This mutant 
however was found to retain the ability to bind RalA, suggesting that RalA did not 
interact directly with the ARTT loop. In our structure, this loop is well ordered apart 
from residues Ala210 and Gly211 and in agreement with the work performed by 
Wilde (Wilde et al, 2002a), Phe209 does not interact directly with RalA.
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Table 2.4 Contacts in the C3bot-RalA structure
RalA residue C3bot residue Distance (A)
Val 139 CG2 Val 77 CGI 3.61
Glu 140 CA He 206 CG2 3.98
Glu 140 CB lie 206 CG2 3.57
Glu 140 CD Tyr 63 OH 3.47
Lys 73 NZ 3.81
Glu 140 OE2 Tyr 63 CZ 3.40
Lys 143 CD Pro 205 C 3.93
Pro 205 O 3.49
Asp 204 O 3.71
Ser 207 O 3.60
Lys 143 CE Ser 207 O 3.44
Lys 143 NZ Asp 204 C 3.70
S er2 0 7 C 3.43
Contact distances are the maximum allowed values of C-C, 4.1 A; C-N, 3.1 A; C-O, 3.1 A; O-O, 3.3A; 
O-N, 3.4A; N-N, 3.4A; C-S, 4.1 A; 0-S, 3.1 A; N-S, 3.8A. Superscript numbers in parentheses 
represent the number of contacts made by the indicated C3bot residue. The contact distances were 
calculated using the program CONTACT (CCP4, 1994).______________________________________
The interface is centred on the ARTT loop of C3bot with Lysl43 of RalA resting in a 
groove of the ARTT loop, forming hydrogen bonds with the main chain carbonyls of 
Asp204 and Ser207. The main chain carbonyl oxygen of Pro205 in the ARTT loop 
also forms a water-mediated interaction with the main chain carbonyl oxygen of 
Glul40 on helix a4  of RalA. The interface is anchored at both ends, however, by 
three salt bridges (referred to as hydrogen bonds due to their distance and angle, but 
could be partly electrostatic in nature). The two lysine residues, Lys73 and Lys81, 
which lie on helix a2  of C3bot, anchor the bottom half of the interface forming 
hydrogen bonds with Glul40 and Glul55 of RalA respectively, and also water 
mediated interactions with Glul32 and the carbonyl oxygen of Seri29. Lys56 from 
C3bot and Glul47 from RalA form another ion pair and anchor the top end of the 
interface.
A comparison of the RalA-C3bot complex with the native (Han et al, 2001) and 
NAD-bound (Menetrey et al, 2002) C3bot structures shows that part of the ARTT 
loop undergoes a significant conformational change on RalA binding (root mean 
square deviation for 6 Ca atoms of 2.94A between residues Ile206 and Gly211)
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different to that seen for NAD binding. The dynamic change in the conformation of 
the ARTT loop is shown in figure 2.14. The C3bot residues Ser207 and Ala208 are 
slightly twisted in the RalA bound structure so that the carbonyl oxygen of Ser207 is 
positioned optimally for binding to Lys 143 of RalA. The side chain of Ser207 is 
placed on the inside of the loop (aligning with Ala210 in the native structure), 
effectively shortening the loop by a residue and placing Ala208 (in the complex) in 
the same place as Phe209 (in the native structure). In the native structure, the Phe209 
ring protrudes into the solvent, but the effective shortening of the ARTT loop in the 
complex allows it to rotate and face away from the interface, preventing it from 
disrupting the bond between Lys56 (RalA) and Glul47 (C3bot). The shift of this 
hydrophobic residue may also facilitate the interaction of Lys 143 (RalA) and Asp204 
(C3bot) and explains why the F209A mutation had no effect on RalA binding (Wilde 
et al, 2002a). The alternate conformation of the ARTT loop also appears to indicate 
that Ala210 is shifted so that it points inwards, towards the core of C3bot. The 
apparent kink in the loop at Ala210 and Gly211, although unclear in the density, is 
necessary to bring the sequence back in line with the native structure as the position 
of Gln212 is similar in both structures (displacement for Ca of 0.39A).
Although the ARTT loop undergoes a large shift on RalA binding, the catalytic 
residue, Glu214, is in the same position and available for NAD hydrolysis. As the 
mechanism of NAD hydrolysis is not fully understood, how the binding of RalA 
increases its rate (Wilde et al, 2002a) is not clear, although this is similar to the 
increase in NAD hydrolysis observed on binding mutant RhoA with ADP-ribose 
acceptor residue removed (Wilde et al, 2000). However, it is possible that either the 
novel conformation of the ARTT loop or a difference in its mobility may contribute 
towards these observations.
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Figure 2.14. Stereo view of the ARTT loops of wild type C3bot (silver) and the RalA bound C3bot 
(gold). The key catalytic residues (Gin 2121 and Glu214) match up exactly but there are large changes 
in other parts o f the ARTT loop. Ser207 moves into the centre of the ARTT loop displacing Ala210 
and Phe209 undergoes a large shift away the side of the ARTT loop that interacts with RalA.
The previously determined C3bot-NAD structure has shown that the PN loop 
(residues 177-186), connecting strands (33 and [34, rearranges to enclose the 
nicotinamide moiety of the NAD upon binding (Menetrey et al, 2002), and is 
therefore thought to play a key role in NAD hydrolysis. The loss of A rgl86 (in the 
PN loop) has been shown to abolish NAD binding and prevent ribosylation of RhoA 
(Menetrey et al, 2002). NAD is not bound to the C3botl -RalA complex and the PN 
loop, which is 10A away from the nearest RalA residue, adopts a similar 
conformation to the free C3bot structure and is not involved in RalA binding. It has 
been suggested previously that changes in the structure of the PN loop may account 
for the increased rate of glycohydrolysis observed upon C3bot binding to RalA 
(Wilde et al, 2002a), but this is not supported by our structure. It would be supposed 
that the PN loop would change conformation on NAD binding of the C3bot-RalA 
complex, but from comparison with the C3bot-NAD complex, it seems very unlikely 
that this change in conformation would cause it to interact with the RalA.
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2.5.4.1 Implications for other C3 exoenzymes
The structure of C3bot-RalA complex highlights structural elements relevant for the 
recognition of C3 exoenzymes by RalA. It is known that RalA inhibits the 
ribosylation of RhoA by C3cer and C31im, as well as C3bot. This inhibition is to a 
lesser extent than C3botl (63% for C31im and 24% for C3cer, measured as 
percentage ribosylated RhoA compared to C3bot after 30 mins) suggesting a lower 
binding affinity for RalA (Wilde et al, 2002a). Although the binding constant 
between C3bot and RalA was not measured by Wilde, the binding strength between 
C31im-RalA was estimated 12nm through fluorescence quenching experiments 
(Wilde et al, 2002a). The closely related C3 exoenzyme C3stau2 from 
Staphylococcus aureus, which shares 35% similarity with C3bot, shows no binding to 
RalA. A comparison of the sequence alignment of the related C3 exoenzymes; C3bot, 
C31im, C3cer offers an explanation for these differences and is shown below in figure 
2.15 A.
Of the six residues in C3bot involved in direct RalA binding, Lys56, Tyr63, Lys81 
and Asp204 are not conserved in C31im (although it is the backbone carbonyl of 
Asp204 which binds RalA), offering an obvious explanation for the difference in 
binding strength. However, the substitutions are conservative and the ability of C31im 
to bind RalA suggests that they still offer a functional binding face. C3cer appears to 
have a lower affinity for RalA than C3bot and C31im, which is consistent with its 
further sequence differences. C3cer and C3stau2have two extra residues in the ARTT 
loop that could interfere with the binding.
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Figure 2.15A Sequence alignment of the C3 family
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Figure 2.15A. Sequence alignment of the C3 family highlighting the residues at the C3bot-RalA 
interface. The alignment was performed and shaded by T-Coffee (Notredame et al, 2000). Residues 
involved in forming bonds with RalA are highlighted in grey whilst the key catalytic residues are 
highlighted in turquoise.
A superposition of C3stau2 (Evans et al, 2003) with the C3bot-RalA complex reveals 
that the extra length of the ARRT loop may be the cause of its inability to bind RalA. 
The two additional residues in the ARTT loop of C3stau2, Lysl70 and Glul71, both 
extend the ARTT loop forward into the RalA interface region as can be seen in figure 
2.15B.
In particular, the exchange of Pro205 (C3bot) to Glu 171 (C3stau2) would obscure the 
hydrogen bond between Aspl68 (equivalent to Asp204 in C3bot) and Lysl43 (RalA) 
and the water mediated interaction between Glul40 (RalA) and the backbone at this 
position (Pro205 in C3bot). The equivalent residues in the C3cer are smaller (both 
aspartate) and are presumably less detrimental to RalA binding.
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Figure 2.15B K I 4









Figure 2.15B. Companson of the interface region of C3bot (gold) and C3stau (silver) highlighting the 
residues that form bonds at the interface in the C3bot and their equivalents in C3stau. The extra 
residues in the ARTT loop of C3stau (Lysl70 and Glul71) block access to the ARTT loop and would 
hinder RalA interacting with the ARTT loop.
This comparison of the C3 exoenzymes therefore also allows speculation as to which 
residues in the interface are most crucial to the interaction. It is interesting to note that 
the residues that are conserved between C3bot and C31im (Pro205, Ser207 and Lys73 
in C3bot) and the presumably conserved interaction of the backbone oxygen at 
Asp204 in C3bot, are clustered at the centre of the interface. It is also two of these 
interactions (of Asp204 and Pro205 in C3bot) that may be disrupted in C3stau2 by 
the extra length of the ARTT loop. These central interactions would therefore appear 
to be the key residues in the interface, held in position to differing extents by the 
outer interactions. Of the two outer interactions, the bonds formed by the two lysines 
of C3bot (Lys56 and Lys81) would appear to promote a more ideal binding face than 
the equivalent two arginines in C31im, as judged by the biochemical data (Wilde et al, 
2002a).
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2.5.4.2 Implications for other GTPases
The well documented specificity of C3bot for ribosylation of RhoA-C via the ARTT 
loop, and our findings that RalA binds at the same site, lead to the question of 
whether RhoA or other GTPases could bind C3bot in the same orientation as RalA. 
The sequence alignment of RalA with Ras, RhoA and the Rho-related Rac and Cdc42 
in figure 2.16 shows that not all the RalA binding residues are conserved across these 
GTPases. O f the four direct binding residues involved in the RalA interface, only Glu 
147 is conserved in all five GTPases. In particular, Ras replaces Glul40 and Glul47 
of RalA with the positively charged arginines, disallowing interactions with Lys73, 
Tyr63 and Lys56 of C3bot. These sequence differences in Ras would prevent half of 
the direct binding interactions available to RalA. Also, RhoA, Cdc42 and Rac all 
show a conserved change of Glul32 (RalA) to an arginine, which may affect the 
water-mediated interaction with Lys81 of C3botl. Similarly, this residue is replaced 
by an alanine in Ras.
Surprisingly, RhoA shows the greatest degree of similarity to RalA at these residues, 
even though RhoA is ribosylated by C3bot at Asn41. As this ribosylation occurs on 
the opposite side of RhoA from the equivalent RalA binding face, it is presumed that 
the residues around the ribosylation site provide a better interface. These comparisons 
suggest that the interaction between RalA and C3bot is not related to the highly 
specific ribosylating activity that C3bot possesses for RhoA, but is more dependent 
on specific RalA residues, not present in RhoA. In particular, Lysl43 of RalA, which 
makes two of the central interactions of the interface and sits in a groove of the 
ARTT loop, is not conserved in any of the other GTPases. It is this residue and 
Glul40 which form the central interactions presumed to be common between C3botl 
and C31im. Additionally, Lysl43 and Glul40 bury 94A2 and 90A2 solvent-accessible 
surface area, respectively, on complex formation, making them ideal candidates for 
anchoring residues (Rajamani et al, 2004).
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Figure 2.16 Sequence alignment of the GTPase family
1 0  2 0  3 0  4 0  5 0  6 0
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Figure 2.16. Sequence alignment of the GTPase family highlighting the residues at the C3bot-RalA 
interface. The alignment was performed and shaded by T-Coffee (Notredame et al 2000). Residues 
involved in forming bonds with C3bot are highlighted in red.
2.5.5 An alternative structure
The publication of an alternative structure for a C3bot-RalA complex (Pautsch et al, 
2005) and our own findings presented in chapter 5 have now raised some questions 
about the biological relevance of this model. In addition upon re-examination a 
symmetry related molecule positioned C3bot and RalA oriented in such a manner that 
the alternative complex centred on the switch II loop of RalA was formed, suggesting 




We have determined the structure of the C3bot-RalA complex at 2.66A. The complex 
occurs around helix a4 on RalA and the ARTT loop of C3bot. The interaction centred 
on the active site of C3bot readily explains the observed inhibition of Rho 
ribosylation. Sequence analysis can also offer an explanation for the Ral specific 
nature of this in the GTPase family and the broader specificity in the C3 family. 
However, upon re-examination it can be seen that there are symmetry related 
molecules that can form the complex seen in chapter 5 and the structure published by 
Pautsch and co-workers (Pautsch et al, 2005). The consequences of this and an 
examination of the merits of each of the relative complexes are presented in chapter 
8 .
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3. The structure of the C3bot-RalA-NAD complex
3.1 Aims of obtaining an NAD complex
It was recently shown that C3bot binds to RalA in such a manner that inhibits the 
ribosylation of Rho and shows several other interesting properties (Wilde et al, 
2002a). One of the reported properties associated with this interaction was the 5 fold 
increase observed in the rate of NAD glycohydrolysis (Wilde et al, 2002a). Our aim 
was to determine the structure of the C3bot-RalA complex with NAD soaked into the 
active site and examine the structure for any changes that may explain the increased 
glycohydrolytic rate.
3.2 NAD binding and C3bot-RalA interactions
C3bot is an ADP-ribosyltransferase that catalyses the hydrolysis of NAD and the 
transfer of the ADP moiety onto Asn41 of RhoA-C (Aktories & Frevert, 1987; Sekine 
et al, 1989). It has also been shown to be able to auto-hydrolyse NAD without any 
substrate present and the Km for the glycohydrolase reaction is -6 0 pM (Aktories & 
Hall, 1989).
Upon NAD binding the active site of the C3bot molecule has been seen to undergo a 
‘crab claw’ movement involving the PN loop and other elements of the C3bot 
secondary structure moving by as much as 10A to enclose the NAD fully in the active 
site (Evans et al, 2004; Menetrey et al, 2002).
On of the unusual biochemical properties associated with the interaction between 
C3bot and RalA was an increase in the rate of glycohydrolysis by approximately 5 
fold (Wilde et al, 2002a). As the complex between C3bot and RalA centered around 
the switch II region has been shown by Pautsch and co-workers to have no effect 
upon NAD binding (Pautsch et al, 2005) the increased rate of glycohydrolysis must
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come about from changes in the active site when the complex between C3bot and 
RalA forms around the ARTT loop of C3bot (Holboum et al, 2005).
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3.3 Methods
3.3.1 Expression and purification of C3bot and RalA
C3bot and RalA were purified exactly as described before.
3.3.2 Crystallisation
For crystallisation RalA and C3bot were incubated together overnight in a ratio of 2:1 
giving a working concentration of 6.67mg/ml RalA and 3.33mg/ml C3bot. 
Crystallisation was performed inO.lM Hepes pH 7.3, 12-15% ethylene glycol, 14- 
18% PEG8000 at 16°C. Thin needle like crystals appeared over the course of ~3 
days.
3.3.3 Soaking NAD into C3bot-RalA crystals
A solution of 5mM NAD in 10% ethylene glycol 14% PEG 8000, 0.1M Hepes pH 
7.3, lOOmM NaCl was used for soaking the C3bot-RalA crystals. 2pi of the NAD 
solution was added to the crystal containing drops and then incubated at room 
temperature for ~3 hours before being flash frozen in a stream of liquid nitrogen and 
data collection.
3.3.4 Data collection and refinement
Diffraction data to 2.47A were collected from a single cryo-cooled (100K) crystal 
with 25% ethylene glycol on station X I3 of the synchrotron radiation source at 
EMBL Hamburg (Germany) using an ADSC Quantum 4 CCD detector. The data 
were processed and scaled using the HKL2000 package (Otwinowski, 1993a; 
Otwinowski, 1993b). The symmetry and systematic absences were consistent with 
the P2i2j2i space group (unit cell dimensions a=56.52A, 6=92.30A and c=102.36A) 
with one C3bot-RalA complex per asymmetric unit and the crystals containing -54%
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solvent. Data reduction was carried out using the program TRUNCATE (CCP4, 
1994).
The structure of the C3bot-RalA complex was determined by molecular replacement 
method with AmoRe (Navaza, 1994) using the original C3bot-RalA complex (PDB 
code 2BOV) (Holboum et al, 2005) as a search model. Initial refinement of the 
structure was carried out using REFMAC5 (Murshudov, 1997) which improved the 
model and subsequent rounds of refinement was carried out using the CNS suite 
(Briinger et al, 1998) and the model building program O (Jones et al, 1991). In each 
data set 5% of reflections were kept aside forRfree calculation (Briinger, 1992). Water 
molecules were added using the WATERPICK module of CNS. The clear continuous 
density observed (in both the 2Fo-Fc and Fo-Fc SIGMA-A weighted maps) in the 
GTP binding pocket of RalA during the final stages of the refinement was interpreted 
as GDP. Clear continuous density around the NAD binding pocket was interpreted as 
an NAD molecule. The final model contains 3010 protein atoms, 90 water molecules, 
one NAD molecule, one GDP molecule and one Mg2+ ion, has an R-factor of 25.1% 
and an R-free value of 28.7%. The details of the data processing and refinement 
statistics are presented in table 3.1. The stereochemical quality of the finished model 
was checked using PROCHECK (Laskowski et al, 1993).
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Table 3.1. Details of crystallographic data
Resolution range (A) 50-2.47
Wavelength (A ) 0.81
Exposure time (s) 30
Number of images 150
Rotation per image (°) 1
Number of reflections measured 271926
Unique reflections 19844
I/a©  (outer shell3) 9.8 (1.7)
Completeness (outer shell3) % 86.7 (64.8)
R symmb (outer shell3) (%) 13.3 (35.3)
^cryst° (% ) 25.1
*freed (% ) 28.7
Average temperature factor (A  ):
RalA main-chain (side-chain) 37.1 (37.5)





RMSD from ideal values:
Bond lengths (A) 0.007
Bond angles (°) 1.550
aOuter shell is 2.56A -  2.47A
b̂ symm=^h^i |/(h)-/j(h)|/2hXj/(h), where 7j(h) and 1(h) are the z'th and the mean 
measurements of the intensity of reflection h, respectively.
°Kcryst =£h |F0-  Fc|/XhF0, where F0 and Fc are the observed and calculated 
structure factor amplitudes of reflection h, respectively. 
d/?free is equal to R cryst for a randomly selected 886 (4.4%) reflections not 
used in the refinement
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3.4 Results and discussions
3.4.1 Experimental results
Crystals of the complex between C3bot and RalA were obtained as described 
previously in chapter 2 (Holboum et al, 2005). The needle like morphology of the 
crystals suggested that they were crystals of the complex that forms around the ARTT 
loop of C3bot rather than the alternative complex that is centred on the switch II 
region of RalA and described in chapter 5 (Pautsch et al, 2005). Two different 
methods of soaking NAD into C3bot crystals have been reported and both were used 
(Menetrey et al, 2002) (Pautsch et al, 2005). Both methods involved soaking the 
NAD directly into the crystal prior to flash freezing for cryogenic data collection with 
25% ethylene glycol as a cryo-protectant. One involved using a relatively high 
concentration of NAD (20mM) for a short soak (1 hour) (Menetrey et al, 2002) while 
the other that involved a lower NAD concentration (5mM) but a longer soak (~3 
hours) (Pautsch et al, 2005) gave a better data set.
Data to 2.47A were collected from a single cryo-cooled (100K) crystal on an ADSC- 
CCD detector on station X I3 at the Synchrotron radiation source at the EMBL 
Hamburg. The data were processed & scaled using the HKL2000 package 
(Otwinowski, 1993a). The structure of the original C3bot-RalA complex (PDB code 
2BOV) (Holboum et al, 2005) was used as a search model for molecular replacement 
using the molecular replacement program AMoRe (Navaza, 1994). The top solution 
from AMoRe was initially refined with REFMAC5 (Murshudov, 1997) and gave a 
drastic improvement in the model (Rcrys 25.7%, R/ree 30.7, FOM 0.76). Subsequent 
rounds of refinement and model building were performed using CNS (Briinger et al,
1998) and the molecular graphics program O (Jones et al, 1991). During the course of 
refinement a large stretch of contiguous difference density was observed in the 
nucleotide binding site of the RalA molecule and this was modelled as GDP and a 
single magnesium ion. A second patch of contiguous difference density was observed
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in the active site of the C3bot molecule. An NAD molecule was modelled into this 
density as shown in figure 3.1 and led to a drop in Rcrys and Rfree-
Figure 3.1 Electron density in the active site of C3bot
Figure 3.1. A stereo view of the 2fo-fc density at 3 SIGMA-A in the active site of the C3bot molecule 
with a molecule of NAD fitted into the difference density.
Analysis of the Ramachandran plot (*F-0) showed 88.4% of residues lie within the 
most favourable region. The details of the data processing and refinement statistics 
are presented in table 3.1. The stereochemical quality of the finished model was 
checked using PROCHECK (Laskowski et al, 1993) as shown in figure 3.2. The final 
refined structure of C3bot-RalA-NAD complex at 2.47A resolution has a 
conventional R-factor (Rcryst) of 25.1% and a free R-factor { R ^ )  of 28.7% and is 
shown below in figure 3.3. The final model of the complex contains 3010 protein 
atoms, 90 water molecules, one NAD molecule in the active site of C3bot and one 
GDP molecule, with an Mg2+ ion, bound to the nucleotide binding site of RalA.
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-180 3 5  -45 0 45 f55 180
Phi (degrees)
Plot statistics
Residues ia mo«i favoured regions |A.B,L] 40+ H8.49f
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Figure 3.2. A Ramachandran plot o f the refined structure of the C3bot-RalA-NAD structure. No 
residues lie in the disallowed regions and 88.4% of residues he within the most favourable region. The 
Ramachandran plot was calculated with PROCHECK (Laskowski et al, 1993).
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Figure 3.3 Structure of the C3bot-RalA-NAD complex
RalA C3bot
ARTT
l o o p
Figure 3 3 . The structure o f the C3bot-RalA-NAD complex. RalA is shown here with yellow a-helices 
and green (3-strands and a GDP molecule shown in the nucleotide binding site in ball-and-stick. C3bot 
is shown here with blue (3-strands and red a-helices with NAD in the active site in ball-and-stick. The 
position of the PN and ARTT loops are also highlighted.
3.4.2 Overall structure of the C3bot-RalA-NAD complex
The overall structure of the complex shown in figure 3.3 maintains the same structure 
as that of the original complex (Holboum et al, 2005). The C3bot and RalA are 
oriented towards each other with the interface between them taking place primarily 
between helix a-4 of RalA and the ARTT loop and helix a-2 of C3bot. The interface 
between C3bot and RalA maintains the same conformation as described previously in 
chapter 2 and is shown below in figure 3.4 (Holboum et al, 2005).
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Figure 3.4 A detailed view of the interface between C3bot and RalA
NAD
Figure 3 A. A detailed view o f the interface between NAD-bound C3bot and RalA with the same 
colour scheme used in figure 3.3. The residues involved are the same as described for the NAD-free 
complex. The NAD molecule is shown here to illustrate its position in the C3bot active site relative to 
RalA.
A least squares superposition of the original complex onto the NAD-bound complex 
reveals very little difference with an RMSD of 0 .2A over 172 Ca atoms of RalA and 
0.4A over 207 Ca atoms of C3bot.
3.4.3 The NAD binding site
The largest differences of C3bot occur around the PN loop that undergoes a dramatic 
‘crab-claw’ movement to bring Phel83 and Argl86 closer to NAD to stabilise the 
ring of the nicotinamide moiety and the oxygens of one of the phosphate groups 
(Menetrey et al, 2002) (Holboum et al, 2006). The NAD binding site possesses the
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same interactions between C3bot and NAD as observed in the wild-type structure. 
The important interactions are highlighted below in figure 3.5.
Figure 3.5 The NAD binding site highlighting some of the important interactions
Figure 3.5. Stereo view of NAD bound into the active site of C3bot The key interactions that have 
been shown to be important to NAD binding by mutagenesis work are highlighted.
The three arginines that have been shown to be important to NAD binding: Arg91 
from the a-3 motif; Argl28 from the conserved Arg/His motif; and Argl86 from the 
PN loop are highlighted. Also shown are Tyr79 and Asn87 on the a-3 helix. Ans87 
binds directly to one of the (3-phosphate oxygens whilst Tyr79 forms an interaction 
with Seri 74 of the STS loop and through Seri 74 with the catalytic glutamate, Glu214 
(Menetrey et al, 2002; Evans et al, 2003; Holboum e ta l, 2006).
When the structure of the RalA bound C3bot-NAD is superimposed onto the wild 
type C3bot-NAD, shown below in figure 3.6A and B, there are two main areas of 
difference.
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Figure 3.6A. The ARTT loop of the C3bot-RalA-NAD structure. The inversion of Ser207 and Ala208 
introduces additional hydrogen bonds within the ARTT loop that may act to stiffen the ARTT loop. 
3.6B. A close-up view of the PN loop of the wild-type structure in gold (PDB code 1GZF) (Menetrey 
et al, 2002) and the current structure in silver. The loop undergoes an inversion with Vail80 and 
Seri 81 reversing direction and Glnl82 undergoing a slight shift that places it too far from Gln212 to 
form an interaction.
When compared to the wild type the ARTT loop of the RalA bound C3bot is more 
rigid due to the unique conformation of the ARTT loop seen in the C3bot-RalA
Figure 3.6 Differences between wild type and RalA bound C3bot-NAD 
A
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structure. The inversion that takes place about Ser207 to place Ser207 in the centre of 
the ARTT loop (Holboum et al, 2005) allows it to form possible ionic interactions 
with the carbonyl oxygens of Phe209, Ala208 and Asp204. In the wild type with 
Ala210 in the centre of the ARTT loop and the carbonyl oxygen of Ala208 facing 
outwards these interactions would be loss. The increase in NAD glycohydrolysis 
could then come about from the “stiffness” that these interactions give to the 
otherwise floppy ARTT loop. The interaction with only the carbonyl oxygen would 
also support the mutagenic data that a Phe209Ala mutant had no effect on the 
properties of the C3bot-RalA interaction (Wilde et al, 2002a).
The PN loop also undergoes a change in the C3bot-RalA-NAD structure. While the 
critical interactions involving Phel83 and Argl86 are maintained in both the wild 
type and RalA-bound structures there are differences in the rest of the ARTT loop. 
The most pronounced differences are with V ail80 and S eri81 that switch their 
solvent/ active site facings. In the case of the RalA-bound PN loop the Vail 80 now 
faces outwards into the solvent whilst Seri 81 now faces into towards the active site, 
although it is too far from the NAD molecule to form direct interactions. The other 
change is in the position of Glnl82. In the RalA-bound structure Glnl82 is displaced 
slightly with respect to the wild type and thus is positioned too far from the ARTT 
loop to stabilise Gln212. Mutagenesis studies using a Q182A mutant found virtually 
no change in NAD binding (Kd 75pM ±15 compared to 60pM ±6 for the wild type) 
(Menetrey et al, 2002) but a doubling of the rate of glycohydrolysis (Menetrey et al, 
2002).
3.4.4 Electrostatic changes around the active site
Whilst there are some small changes observed in the ARTT loop and the PN loop 
they do not fully explain the increased glycohydrolytic rate increase. A large change 
in the electrostatic nature of the active site may be responsible for the increased rate 
of NAD hydrolysis. The electrostatic surface o f C3bot and C3bot-NAD complexed 
with RalA are shown below in figure 3.7A and B.
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Figure 3.7 Electrostatic surface picture of the C3bot active site
Figure 3.7A . The electroistatic surface of C3bot with NAD. B. The electrostatic surface of C3bot- 
NAD when in complex with RalA. The electrostatic surfaces were generated using APBS tools in 
PYMOL (Baker et al, 2001).
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As can be seen in figure 3.7 the electrostatic surface of C3bot changes dramatically 
upon complexation with RalA. In the uncomplexed C3bot the surface charge is 
predominantly positive, as would be expected with C3bot’s high iso-electric point, 
with small areas of neutral or negative charge. In figure 3.7A there are two patches of 
negative charge. One of these lies around the active site E214 and the exposed 2’OH 
of NAD.The second patch of negative density however is at the beginning of the 
ARTT loop adjacent to D204 and S207 and is the small patch of negative density that 
interacts with K143 of RalA in the interface centred on the ARTT loop. When 
complexed with RalA there is a drastic shift in the overall electrostatic potential of 
the complex with face of the C3bot shifting towards a more neutral charge and large 
changes around the active site including the formerly neutral helix a3 becoming 
slightly negatively charged. This large change in electrostatic potential may be the 
cause of the increased rate of NAD hydrolysis.
3.5 Conclusions
We have determined the structure of the C3bot-RalA-NAD complex. This retains all 
of the features of the already determined C3bot-RalA complex but a close 
examination of the ARTT loop and PN loop may offer an insight into the increased 
rate of glycohydrolysis seen for theC3bot-RalA interactions. This may come about 
from changes in the PN loop that involve the loss of an interaction between Gln212 
and Gin 182 and additional hydrogen bonds to give a more stable ARTT loop. 
However an examination of the electrostatic potential of the surface of the molecules 
illustrates a large change in the surface charge that may also play a role in the 
increase in NAD hydrolysis.
As in the orginal complex described in chapter 2 this complex also posseses a 
symmetry related interface identical to the ‘alternative’ interface centred on the 
Switch II region of RalA. However the changes noted around the PN loop and ARTT 
loop in the structure presented here seem specific to our structure as no alterations 
were reported in the NAD-bound complex reported by Pautsch and co-workers 
(Pautsch et al, 2005).
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4. Mutagenesis of residues central to the C3bot-RalA interface
4.1 Aims of mutagenesis
Analysis of the structure between C3bot and RalA illustrated a network of key ion 
pairs at the interface that seemed to be important for the formation of the C3bot-RalA 
complex. Our aims were to perform site-directed mutagenesis on 5 of the key 
residues from RalA and assess the impact that these mutations had on the binding 
kinetics.
4.2 Interactions between C3bot and RalA
C3bot was long thought to be specific to the Rho family o f GTPases and RhoA-C in 
particular (Aktories et al, 1989; Braun et al, 1989; Chardin et al, 1989). The recent 
work demonstrating its ability to interact with the Ras-like GTPase, RalA, in a novel 
manner that did not result in ribosylation of RalA was intriguing (Wilde et al, 2002a).
The initial structure of C3bot-RalA (Holboum et al, 2005) demonstrated an interface 
that involved helix a-4 of RalA and the ARTT loop and helix a-2 of C3bot. This 
interface lying at the active site of C3bot suggested a possible mechanism for the 
RalA induced inhibition of RhoA ribosylation by direct competition in which the 
binding of RalA physically blocks the access of RhoA to the C3bot active site.
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4.3 Methods
There were several key residues of RalA assessed as being important to the formation 
of the C3bot-RalA complex. These were the residues selected for site directed 
mutagenesis. The mutagenesis involved using the Stratagene quick change 
mutagenesis kit and a KOD polymerase based method.
4.3.1 Mutagenesis using the Stratagene quick change mutagenesis kit
4.3.1.1 Mutagenesis
The human RalA gene clone (as a pGEX-2T fusion) was a kind gift of Dr Hiroshi 
Koide, Department of Stem Cell Biology, Graduate School of Medical Science, 
Kanazawa University, Japan. The following primers were designed to induce the 
point mutations. In each case the altered nucleotides are underlined.
Mutant primer E l32A
GGT TGG TAA CAA ATC AGA TTT AGCAGA TAA AAG ACA GGT TTC TGT 
Mutant primer E140A
AAA GAC AGG TTT CTG TAG CAG AGG CAA AAA ACA GAG C 
Mutant primer E140Q
GAT AAA AAG ACA GGT TTC TGT ACA AGA GGC AAA AAA CAG AGC 
CTG
Mutant primer K143A
GGT TTC TGT AGA AGA GGC AGC AAA CAG AGC TGA GCAGTG 
Mutant primer K143R
GGT TTC TGT AGA AGA GGC AAAGAA CAG AGC TGA GCAGTG 
Mutant primer E l47A
GGC AAA AAA CAG AGC CTG CAC AGT GGA A TG TTA ACT ACG 
Mutant primer E l55A
GG AAT GTT AAC TAC GTG GCA ACA TCT GCT AAA ACA CG
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The PCR was performed using the Stratagene quick change mutagenesis PCR system 
and the following protocol: 95°C 1 minute, 30 cycles of 95°C 1 minute, 55°C 1 
minute, 65°C 12 minutes, followed by a 12 minute hold at 65°C and storage at 4°C. 
The resulting DNA was then digested for 1 hour at 37°C with Dpnl (Stratagene) and 
transformed directly through heat shocking into competent XI-10 cells (Stratagene) 
and grown overnight at 37°C on LB agar plates supplemented with lOOpg/ml 
ampicillin. Single colonies were then selected and used to inoculate 10ml of luria 
broth supplemented with lOOpg/ml ampicillin. Plasmid DNA was extracted using a 
mini-prep wizard (Promega) and sent for T7 forward and reverse sequencing (MWG 
Biotech).
4.3.1.2 Expression of RalA K143A
Following sequencing the RalA K143A plasmid was transformed via heat shock into 
BL21(DE3)codon+ cells (Novagen). A successful colony was inoculated into 100ml 
of Terrific Broth supplemented with 0.5% glucose and lOOpg/ml ampicillin and 
grown overnight at 37°C. The culture was diluted 1:50 into 11 of fresh medium and 
grown for 4 hours at 37°C until an OD600 of ~0.8 was reached. Expression was 
induced by addition of IPTG to a final concentration of ImM and grown for a further 
4 hours at 25°C. Cells were harvested by centrifugation (Beckman Avanti J-25).
4.3.1.3 Purification of RalA K143A
RalA K143A was purified following the protocol used for wild type RalA.
4.3.2 Mutagenesis using a KOD polymerase based method
As only 1 mutation out of 7 had been successful it was decided a different 
mutagenesis protocol would be used.
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4.3.2.1 Mutagenesis
The following forward and reverse primers were used (site directed mutants are 
underlined).
E l32A forward primer
GGT TGG TAA CAA ATC AGA TTT AGC AGA TAA AAG ACA GGT TTC TGT 
E l32A reverse primer
ACA GAA ACC TGT CTT TTA TCTGCT AAA TCT GAT TTG TTA CCA ACC 
E140A forward primer
AAA GAC AGG TTT CTG TAG CAG AGG CAA AAA ACA GAG C 
E l40A reverse primer
GCT CTG TTT TTT GCC TCTGCT ACA GAA ACC TGT CTT T 
E140Q forward primer
GAT AAA AGA CAG GTT TCT GTACAA GAG GCA AAA AAC AGA GCT G 
E140Q reverse primer
CAG CTC TGT TTT TTG CCT CTT GTA CAG AAA CCT GTC TTT TAT C 
K143A forward primer
GGT TTC TGT AGA AGA GGC AGC AAA CAG AGC TGA GCA GTG 
K143A reverse primer
CAC TGC TCA GCT CTG TTT GCT GCC TCT TCT ACA GAA ACC 
K143R forward primer
GGT TTC TGT AGA AGA GGC AAG GAA CAG AGC TGA GCA GTG 
K143 reverse primer
CAC TGC TCA GCT CTG TTC CTT GCC TCT TCT ACA GAA ACC 
E l47A forward primer
AGA GGC AAA AAA CAG AGC TGC ACA GTG GAA TGT TAA CTA CG 
E l47A reverse primer
CGTA GTT AAC ATT CCA CTG TGC AGC TCT GTT TTT TGC CTC T 
E 155A forward primer
GGA ATG TTA ACT ACG TGG CAA CAT CTG CTA AAA CAC G
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E l55A reverse primer
CGT GTT TTA GCA GAT GTT GCC ACG TAG TTA ACA TTC C
The PCR was performed using KOD polymerase (Novagen) PCR system and the 
following protocol: 95°C 1 minute, 18 cycles of 95°C 30 seconds, 60°C 50 seconds, 
68°C 8 minutes, followed by a 7 minute hold at 68°C and storage at 4°C. The 
resulting DNA was then digested for 1 hour at 37°C with Dpnl (Promega) and 
transformed directly through heat shocking into BL21(DE3)codon+ cells (Novagen) 
and grown overnight at 37°C on LB agar plates supplemented with 1 OOpg/ml 
ampicillin. Single colonies were then selected and used to inoculate 10ml of luria 
broth supplemented with 1OOpg/ml ampicillin. Plasmid DNA was extracted using a 
mini-prep wizard (Promega) and sent for T7 forward and reverse sequencing (MWG 
Biotech).
4.3.2.2 Expression and purification of RalA mutants
The expression and purification of the RalA mutants, E l32A, E140A and K143A 
followed the same protocol as used for wild type RalA.
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4.4 Results and Discussion
4.4.1 Experimental results
The choice of residues for mutation was based on the key residues identified at the 
interface between C3bot and RalA (Holboum et al, 2005). The 5 residues that have 
side chains involved in hydrogen bond formation were all selected. Additional 
mutants of Lysl43 and Glul40 were designed as they both bury ~90A in the interface 
and are involved in numerous hydrogen bonds and seem to be key residues involved 
in the formation of the interface.
Generation of the mutants using the Stratagene quick change mutagenesis kit proved 
more difficult than expected as in the initial mutagenesis experiments only 1 of the 7 
mutations was successful (K143A) as the rest failed at the PCR step or when 
sequencing results were analysed showed no mutation present.
After several failed attempts to generate mutations using the Stratagene kit it was 
decided to alter the protocol to avoid using the Stratagene kit. KOD polymerase 
(Novagen) was used as a fast, high fidelity polymerase and the cells were treated with 
Dpnl from Promega rather than Stratagene. After digestion the plasmids were then 
transformed directly into BL21(DE3)codon+ expression cells, avoiding the use of the 
XL-10 cells (Stratagene). This alternative protocol successfully managed to generate 
3 more mutations; E132A, E140A and E155A, although E155A was never expressed 
on a large scale for purification.
Purification of the mutants was straight forward as all of them expressed as a soluble 
GST-fusion protein and were purified in the same manner as the wild type RalA to a 
high degree of purity as shown below in figure 4.1. Though yields of all the mutants 
produced was lower than the wildtype RalA, less than 2mg/l of culture.
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4.4.2 Effects of the mutations on the formation of a C3bot-RalA complex
The mutants were going to be used alongside the wild type RalA for a kinetic 
analysis of the binding between C3bot and RalA. However, as the mutants were 
being prepared Pautsch and co-workers published their work that included extensive 
mutagenesis results and an alternative structure of the C3bot-RalA complex, though 
very similar to that of the one described in chapter 5 (Pautsch et al, 2005).
Figure 4.1. Purification of RalA mutants
^  Wild E140A  
Type
K J43A
Figure 4.1. SDS-page Gel illustrating the purity of two of the RalA mutants, E140A and K.143A, 
following GST affinity and gel filtration chromatography.
It was reported that the binding constant between C3bot and RalA was fairly strong 
(Kd ~60nM (Isothermal calorimetry) KD ~35nM (fluorescence titration)) (Pautsch et 
al, 2005) though weaker than the measured interaction between C31im and RalA (K d 
~12nM) (Wilde et al, 2002a). Mutational analysis also indicated that mutation of 
many of the C3bot residues at the interface of the original complex presented in 
chapter 2 had no effect on the inhibition of RhoA or precipitation of C3bot by GST- 
RalA. This was demonstrated with several C3bot mutants: K73L; K81E and P205A
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(Pautsch et al, 2005). Two of these mutations, K73L and K81E are the partners for 
the RalA residues Glul47, Glul55 and Glul40. The results for the third mutation, 
P205A, were unsurprising as Lysl43 of RalA interacts with the man chain carbonyl 
of Pro205. Mutations of the two most heavily buried residues at the interface (K143E 
and E140A of RalA) were also analysed and shown to have no effect on the 
inhibition of RhoA ribosylation or precipitation of C3bot on a GST pull down assay 
(Pautsch et al, 2005).
Taken together the mutagenic analysis of the residues around the original C3bot-RalA 
interface (Holboum et al, 2005) suggests that it may not be the true biological dimer 
though the structure of the alternative complex, both the published structure [PDB 
code 2A78] (Pautsch et al, 2005) and the one presented in chapter 5 still do not 
answer all of the biochemical questions raised by the interaction between C3bot and 
RalA (Wilde et al, 2002a).
4.5 Conclusions
We have managed to purify 3 mutant variants of RalA (E140A, K143A and E132A) 
and clone an additional mutant (E l55A). However due to the work published by 
Pautsch and co-workers (Pautsch et al, 2005) we have not used these mutants in an 
activity study. The results of mutagenic work carried out by Pautsch and co-workers 
(Pautsch et al, 2005) however do support the complex being centred on the Switch II 
loop of RalA and, when taken with the late observation that the Switch II interface is 
present in the orginal structure presented in chapter, suggests that the Switch II 
interface the true biological interface rather than the one centred on the ARTT loop.
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5. The structure of the alternative C3bot-RalA complex
5.1 Aims of determining the structure of the alternative complex
A second crystal form of the C3bot-RalA complex gave rise to an alternative form of 
the complex that has 2 C3bot and 2 RalA in the asymmetric unit and a different 
binding interface to the one already described. By analysis of the structure of this 
alternative complex it was hoped that some of the unanswered questions about the 
C3bot-RalA interaction would become clearer.
5.2 An alternative arrangement of the C3bot-RalA complex
C3bot and the related C31im and C3cer have been found to bind to RalA in a manner 
that does not result in the ribosylation of RalA and inhibits the activity of the C3 
exoenzyme involved (Wilde et al, 2002a). This interaction is strong both for C3bot 
and C31im with Kd 60nM (Pautsch et al, 2005) and 12nM (Wilde et al, 2002a) 
respectively. The interaction between C3bot and RalA, although resulting in 
inhibition of ribosylation of RhoA, does not result in the ribosylation of RalA and 
increases the rate of NAD-glycohydrolysis by C3bot five fold (Wilde et al, 2002a). 
This interaction has also been reported as being nucleotide independent (Wilde et al, 
2002a) or GDP dependant (Pautsch et al, 2005).
The structure of the C3bot-RalA complex has now been determined in two alternative 
complexes (Holboum et al, 2005; Pautsch et al, 2005). Both complexes are formed 
from one C3bot molecule binding to one RalA molecule; the differences lie in the 
orientation and positioning of the molecules. In the original complex (Holboum et al, 
2005) the C3bot is bound around the ARTT loop and the RalA at helix a4. In the 
second complex the C3bot is bound at helix 3 and 4 distant from the C3bot active site 
and at the RalA switch I region (Pautsch et al, 2005). However neither complex 
answers the entire set of questions raised by the biochemical information.
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5.3 Methods
5.3.1 Protein Expression and purification
The C3bot and RalA were purified as described previously.
5.3.2 Crystallisation
Crystals resembling square plates were observed after using C3bot-RalA solutions 
that had been stored for greater than 1 month at 4°C. C3bot-RalA crystals were grown 
by the hanging drop vapour diffusion method in 0.1M Hepes pH 7.3, 12-15% 
ethylene glycol, 14-18% PEG8000 at 16°C over 3-4 days with protein concentrations 
6.67mg/ml RalA, 3.33mg/mlC3bot.
5.3.4 Data Collection
Data to 2.4A were collected from a single cryo-cooled (100K) crystal on an ADSC- 
CCD detector on station 9.6 at the Synchrotron radiation source at Daresbury, UK. 
The data were processed and scaled using the HKL2000 package (Otwinowski, 
1993a; Otwinowski, 1993b). The symmetry and systematic absences were consistent 
with a P2 i space group and a unit cell with dimensions a=91.7, b=56.7, c=90.8A, 
(3=124°. The Matthews coefficient indicated that there were two C3bot and two RalA 
molecules in the asymmetric unit.
Initial phases were found with PHASER (McCoy et al, 2005) using the C3bot and 
RalA molecules from the original complex as search models (PDB code 2BOV). 
PHASER gave two solutions and the first solution was used for refinement (R-factor 
48.2%, log likelihood gain +709, Z score +26.8 for the first solution and R-factor 
48.3%, log likelihood gain +560, Z score +20.3). Initial refinement of the structure 
was carried out using REFMAC5 (Murshudov, 1997) which improved the model and 
subsequent rounds of refinement were carried out using the CNS suite (Briinger et al,
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1998) and the model building program O (Jones et al, 1991). In each data set 5% of 
reflections were kept aside for Rfree calculation (Brunger, 1992). Water molecules 
were added using the WATERPICK module of CNS (Brunger et al, 1998). The 
continuous density observed in the nucleotide binding pocket (in both the 2Fo-Fc and 
Fo-Fc SIGMA-A weighted maps) during the final stages of the refinement was
^  I
interpreted as an Mg ion and a GDP molecule. The stereochemical quality of the 
finished model was checked using PROCHECK (Laskowski et al, 1993).
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5.4 Results and discussion
5.4.1 Experimental methods
The expression and purification of the C3bot and RalA were identical to that 
previously described and the solutions used for crystallisation of this ‘alternative’ 
complex were from the same protein batch that gave rise to the complex described 
previously (Holboum et al, 2005).
Crystallisation in the same conditions as that used to generate the original complex, 
0.1M Hepes pH 7.3, 12-15% ethylene glycol, 14-18% PEG8000, but using protein 
stocks that had been stored for longer than 1 month at 4°C gave rise to a different 
crystal morphology. These large plate-like crystals were easily distinguishable from 
the expected needle-like crystals obtained before as can be seen in figure 5.1A and B.
Figure 5.1 Crystals of the different C3bot-RalA complexes 
A B
Figure 5.1A. Crystals o f the original C3bot-RalA complex grown in 0.1M Hepes pH 7.3, 12-15%
ethylene glycol, 14-18% PEG8000. 5.1B. The square crystals of the alternative C3bot-RalA crystal 
also grown in 0 .1M Hepes pH 7.3,12-15% ethylene glycol, 14-18% PEG8000.
The final model contains 2 molecules of RalA and 2 molecules of C3bot, 5996 
protein atoms, 337 water molecules and 58 ligand atoms, has an R-factor of 23.3% 
and an R-free value of 31.0% and is shown in figure 5.2. A molecule of GDP and an 
Mg2+ ion was identified and modelled bound to each of the RalA molecules in the
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nucleotide binding site. Residue 42 on the first RalA molecule and a further 10 
residues on the second RalA molecule including residues 178-181 had their side 
chains modelled with occupancy 0 due to weak density. 4 Residues on the first C3bot 
molecule and 11 residues on the second C3bot were disordered and modelled on the 
basis of weak density with their side chains modelled with 0 occupancy due to weak 
density. Analysis of the Ramachandran plot (O-'F) in figure 6.3 showed 85.3% of 
residues lie within the most favourable region with 4 residues in disallowed regions 
(Al 84 on both C3bot molecules and K235 on the 2nd C3bot molecule and A48 on the 
1st RalA molecule). The details of the crystallographic data are presented in table 5.1.








Figure 5.2. The alternative C3bot-RalA structure. This possesses 2 C3bot and 2 RalA within the 
asymmetric unit. The two interfaces; the switch II interface and crystal interface are highlighted with
boxes.
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Figure 5.3 Ramachandran plot of the alternative C3bot-RalA complex
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Figure 5 3 . A Ramachandran plot of the refined structure of the C3bot-RalA structure. Four residues 
lie in the disallowed regions (Ala 184 on each C3bot, Ala 84 on RalA ‘1 ’ and Lys 235 on C3bot ‘2 ’) 
and 85.3% of residues lie within the most favourable region. The Ramachandran plot was calculated 
with PROCHECK (Laskowski et al, 1993).
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Table 5.1 Table of Crystallographic statistics
Resolution range (A) 50-2.40
Wavelength (A) 0.98
Exposure time (s) 20
Number of images 120
Rotation per image (°) 1
Number of reflections measured 205496
Unique reflections 30637
I/o(I) (outer shelf) 17.82 (3.0)
Completeness (outer shell4) % 85.8 (83.8)
#sym m b (outer shell4) (%) 5.4 (29.1)
^c ry s t (%) 23.3
*  free' ( % ) 31.0
Average temperature factor (A2):
RalA main-chain (side-chain) 37.0 (38.3)
RalA main-chain (side-chain) 40.2 (40.9)
C3 main-chain (side-chain) 37.2 (38.2)
C3 main-chain (side-chain) 49.8 (50.6)
Ligand 33.8
Solvent 42.7
RMSD from ideal values:
Bond lengths (A) 0.007
Bond angles (°) 1.247
aOuter shell is 2.49A -  2.40A
b̂ symm=Sh î |7(h)-/,(h)|/rhLj/(h), where 7j(h) and 1(h) are the ith and the mean
measurements of the intensity of reflection h, respectively.
c/?cryst |F0-  Fc|/ShF0, where F0 and Fc are the observed and calculated
structure factor amplitudes of reflection h, respectively.
d/?free is equal to 7?cryst for a randomly selected 1526 (5.0%) reflections
not used in the refinement.
5.4.2 Analysis of the alternative complex
The 2 C3bot molecules (C3bot 1 and C3bot 2) are both consistent with previously 
determined structures of C3bot with a mixed a/p core that possesses a five stranded 
mixed p-sheet (p i, p2, p4, P7, P8) stacking perpendicularly against a three stranded 
anti-parallel p-sheet (P3, p5, P6) with four helices (a l, a2, a3, a4) arrayed around the
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sheets and a fifth helix (a5) flanking the five stranded sheet.. Superposition with the 
C3bot from the original C3bot-RalA complex presented in chapter 2 yields a root 
mean square deviation of 0.6A for 207 Ca atoms. The largest differences occur 
around the ARTT loop, 1.0A between residues 204-212, and on a short loop region 
connecting strands p7 and p8; 1.9A between residues 232-235.
The two RalA molecules (RalA 1 and RalA 2) are both consistent with the previously 
determined structures of RalA and other related GTPase molecules composed of a six 
stranded mixed P-sheet sandwiched between two helices (a l, a5) above the plane of 
the P-sheet, and three helices (a2, a3, a4) below. A superposition of RalA 1 with 
RalA from the original C3bot-RalA complex (Holboum et al, 2005) reveals little 
difference in the position of the atoms with a root mean square deviation of 0.3 A  for 
all of the Ca atoms.
5.4.3 C3bot-RalA interfaces
The asymmetric unit possesses two interfaces between C3bot and RalA molecules; 
the first is the interface first observed by Pautsch and co-workers between C3bot “1”
and RalA “1” (Pautsch et al, 2005). This interface has a total buried surface area of
2
1663A and involves helices a3 and a4 from C3bot and helix a3 and the switch II 
region from RalA. This interface will hereafter be referred to as the “switch II 
interface”. The second interface is smaller and is observed between the a4 helix of 
RalA and the C-terminus of C3bot and can be seen twice in the unit cell: between
C3bot “1” and RalA “2” and between C3bot “2” and RalA “1” (total buried surface
2
area of 710.4A ). This will be referred to as the “crystal interface”.
5.4.4 The switch II interface
The main interface between C3bot 1 and RalA 1 involves parts of helix 3 and 4 of 
C3bot fitting into a groove of RalA between helix 2 and 3 and making contact with 
the important switch II region (figure 5.4). This mode of binding and the residues
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involved around the interface are consistent with the interface reported by Pautsch 
and coworkers and listed in tables 5.2 and 5.3. The interface contains a total of 11 
hydrogen bonds and 81 van der Waal interactions involving 15 residues from C3bot 
and 14 residues from RalA.
Table 5.2 Potential hydrogen bonds between C3bot and RalA
C3bot residue RalA residue Distance (A)
Gin 92 ND2 Glu 99 O 3.19
Asn 93 0 Gly 23 N 3.12
lie 97 N Gly 71 O 3.10
Asn 98 OD1 Tyr 82 OH 2.44
Asn 98 0 Arg 79 NH1 2.52
Gly 99 0 Gin 110 OE1 3.12
Phe 100 0 Arg 79 NH2 3.09
PhelOOO Gin 110OE1 3.28
Asp 112 OD2 Tyr 75 OH 3.09
Arg 219 NH1 Gin 72 O 2.99
Arg 219 NH2 Gin 72 O 3.26
Table 5.3 Contacts between C3bot and RalA
C3bot residue RalA residue
Gin 92 Glu 99, Ala 102
Asn 93 Ser 22 (2), Gly 23, Phe 107
Lys 94 Gly 23
Gly 95 Gin 7 2 (3)
Val 96 Ser 22, Gly 23 (2), Gly 71 (2), Gin 72, Phe 107
lie 97 Gly 71 (2), Asp 74, Tyr 75 (3)
Asn 98 Arg 79 (3), Tyr 82 (4), Phe 107 (2),
Gly 99 Asp 106, Phe 107 (4), Gin 110 (4)
Phe 100 Arg 79 (2), Gin 110(4)
Pro 101 Gin 110
He 105 Asp 74, Tyr 75 (2), Ala 7 6 (3), Arg 79 (2)
Glu 109 Tyr 75 (,8)
Asp 112 Tyr 75 (3)
Arg 219 Gin 72 (3)
His 220 Gin 72
Numbers in superscript are the number of contacts between the listed residues
The area of C3bot involved in the formation of this interface is distant from the active 
site of C3bot. Although part of helix-3 is involved in the biding to RalA none of the 
residues that form part of the a-3 helix (Tyr 79, Asn87, Arg91) are involved 
(Holboum et al, 2006) and when superposed onto the structure of wild type C3bot 
(PDB code 1G24) (Han et al, 2001) none of them have suffered a significant 
alteration in position or side chain conformation.
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Figure 5.4 A detailed view of the switch II interface
C3botl
Figure 5.4. Detailed view of the switch II interface. The RalA molecule is shown with green p-strands 
and yellow a-helices and the switch II region loop is highlighted in orange. C3bot is shown with red a- 
helices. The residues involved in forming the hydrogen bonds are shown here. Gln92 from C3bot 
forms bonds that anchors the ‘top’ of the interface whilst hydrogen bonding and van der Waals 
interactions between Tyr75 of RalA and helix a-4 o f C3bot anchor the base of the interface.
Unlike the original complex of C3bot-RalA (Holboum e ta l, 2005) the binding region 
of RalA has changed dramatically and occludes the nucleotide binding site and has 
several bonds with residues on the important switch II loop. Gly71, Gln71 and Tyr75 
are all part of the switch II loop and form the central segment of the interface, Tyr75 
in addition to forming a hydrogen bond with A spll2 of C3bot is also involved in 
over 20 van der Waal interactions.
The involvement of switch II in this interface also results in a change in the 
nucleotide dependence of the C3bot-RalA interaction. In wild type RalA upon GTP 
binding switch II undergoes a large conformational shift and interacts heavily with 
the third phosphate group of the GTP molecule. However, when C3bot is bound as 
shown here it prevents switch II undergoing any movement and results in GDP 
dependant binding as reported by Pautsch and co-workers (Pautsch et al, 2005).
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This interface is highly similar to an already determined structure (PDB code 2A78) 
(Pautsch et al, 2005) though there are some subtle differences in the hydrogen 
bonding patterns. In the reported structure there are two additional hydrogen bonds 
involving the RalA residues Glu97 and Asp 106 that are missing in this structure. 
Additionally in this structure there is an additional hydrogen bond between Glnl 10 of 
RalA and Gly99 of C3bot. The largest change involves the C-terminal of C3bot that 
in the reported structure (Pautsch et al, 2005) is involved in van der Waal interactions 
with a segment of switch II of RalA. In our structure the C-terminal is involved in 
forming the crystal interface described below.
5.4.5 The crystal interface
The second interface that forms between C3bot 1-RalA 2 and RalA l-C3bot 2 is 
much smaller and involves helix a4 of RalA packing against the C-terminus of the C3
molecules (figure 5.5). The residues involved in this interface are listed below in
2
tables 5.4 and 5.5. This interface has a buried surface area of 710.4A and involves 
some of the important residues seen in the original C3bot-RalA complex (Holboum et 
al, 2005). This interface is made up of the C-terminus of C3bot and part of p-strand 2 
that stacks against the face of helix 4 of RalA as shown in figure 5.4.
This interface is small and contains only 3 hydrogen bonds and 11 residues involved 
in van der Waal interactions (5 from C3bot and 6 from RalA). This interaction does 
however involve helix a4 of RalA. This is the helix that forms the centre of the 
interface in the original C3bot-RalA structure and involved residues from this helix 
interacting directly with the ARTT loop of C3bot. In this complex two of the residues 
involved in forming the interface with the ARTT loop are involved here, Glu 140 and 
Glul47.
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Figure 5.5 A detailed view of the crystal interface
C3 bot 1 
C-terminal
N 1 4 4
T 2 4 6
V I2 4 4
D I 6 6
Figure 5.5. A detailed view o f the crystalinterface between the C-terminus of C3bot (in grey) and 
helix a4 of RalA (in yellow). Two of the RalA residues, Glul40 and Glul47, are involved in the 
interface between C3bot and RalA in the original structure of the C3bot-RalA complex.
5.4.6 The ARTT loop
The original complex between C3bot and RalA (Holboum et al, 2005) demonstrated 
a novel conformation of the ARTT loop that involved a kink being formed and the 
side chain of becoming twisted to place it in the centre of the ARTT loop in the area 
normally occupied by the Cp atom of Ala210 for the wild type (Han et al, 2001) and 
the initial reported structure around the switch II interface (Pautsch et al, 2005). In 
this structure the ARTT loop of both of the C3bot molecules resembles that of the 
wild type and does not possess the conformation seen in the previous C3bot-RalA 
structure. This would suggest that the ARTT loop only folds into that unique 
orientation upon the binding of RalA directly at the ARTT loop.
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Table 5.4 Potential hydrogen bonds between C3bot and RalA
C3bot residue RalA residue Distance (A)
Asp 166 OD2 Glu 140 OE1 2.92
Met 244 O Asn 144 ND2 3.03
Thr 246 O Asn 144 OD1 3.02
Table 5.5 Contacts between C3bot and RalA
C3bot residue RalA residue_______________
Asp 166 Glu 140
Met 244 Ser 138, Glu 140, Glu 141
Gly 245 Asn 144
Thr 246 Asn 144
Asn 249 Glu 147, Gin 148
5.4.7 Implications for other proteins
The unusual interaction between C3bot and RalA was also seen for the related C3 
exoenzymes C31im and C3cer but not for the closely related C3stau (Wilde et al, 
2002a). A sequence alignment of the C3 exoenzymes is shown below in figure 5.6 
highlighting the residues involved in the interactions around the switch II interface. A 
similar alignment of RalA and related GTPases is presented in figure 5.7.
C3bot, C31im and C3cer are all seen to interact with RalA whilst C3stau does not. In 
the original complex (Holboum et al, 2005) there were clear protein sequence 
differences that could explain the results from amongst the C3 family. In this 
structure the residues around the switch II interface vary dramatically between all 4 
C3 exoenzymes. The lack of binding observed by C3stau can be explained by serious 
differences at many of the binding residues. In the case of the charged residues 
C3botGln92 and C3botAsn93, C3stau instead has a serine and alanine respectively. 
Similarly at C3botGly"  C3stau has a lysine. The importance of the loss of this glycine 
has been observed for a Gly99Asp mutant that demonstrated drastically reduced 
binding (Pautsch et al, 2005).
For C31im and C3cer that also show binding to RalA there are still differences 
between some of the residues at the interface. In the case of C31im these changes are
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fairly minor save for the exchange of asparagine 92 to alanine that would result in the 
loss of the hydrogen bonds and van der Waal interactions with Glu99 and Alai 02 of 
RalA. Importantly C31im maintains Gly99 that is important for formation of this 
interface. C3cer has several substitutions including Gln92 becoming methionine, 
Asn93 to histidine, Asn98 to aspartate and Gly99 to serine. These may result in the 
low level of binding seen between C3cer and RalA, the lowest of the three C3 
proteins that do interact with RalA. Unlike the larger changes for C3stau none of 
these alterations is substantial enough to completely disrupt the interface.
The specificity seen amongst the GTPases is less pronounced. Although the sequence 
differences between RalA and the related Rho, Rac and Cdc42 GTPases are obvious 
and include the universal substitutions of Gly23 to alanine, Tyr82 to serine and 
Glnl 10 to glutamate the differences between RalA and Ras are limited. RalA and Ras 
share all of the residues around the switch II interface save for Glu99 which is a 
lysine in Ras. However the interaction between C3bot and RalAG,u"  takes place 
involves the main chain carbonyl of Glu99 and so an exchange to lysine should not 
make such a large difference. Mutagensis work however has suggested that the 
important difference between RalA and Ras is actually at A lai03 (aspartate in Ras) 
(Pautsch et al, 2005). Presumably the extended length of aspartate cause steric 
clashes with the nearby residues of C3bot (Gln92 and Asn93) and disrupt their 
important interactions around the interface region.
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Figure 6.6 Sequence alignment of the C3exoenzymes o
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Figure 6.6. Sequence alignment of the C3 exoenzymes constructed using the web-based program T-Coffee (Notredame et al, 2000). The residues involved in 
hydrogen bonds at the switch II interface are highlighted in turquoise. The three residues involved in hydrogen bonds at the crystal interface are highlighted in 
grey.
Figure 6.7 Sequence alignment of RalA and related GTPases
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Figure 6.7. Sequence alignment of the GTPases constructed with the web-based served T-Coffee (Motredame et al, 2000) highlighting in turquoise the residues 
involved in forming hydrogen bonds at the switch II interface. Residues involved in interactions at the crystal interface are highlighted in red.
5.4.8 Unanswered questions
While there is much mutagenic data (Pautsch et al, 2005) to support the formation of 
a complex centred around the switch II interface as the biologically significant one 
there are also several problems with this model.
The interactions around the switch II interface do block access to RalA711146 on the 
switch I region of RalA that is glucosylated by C. sordelli lethal toxin and so in 
agreement with that observation made by Wilde and co-workers (Wilde et al, 2002a). 
However the regions of C3bot involved in binding to RalA are distant (>20A) from 
the active site and so do not offer a mechanism to inhibit Rho binding and 
ribosylation. Additionally Pautsch and co-workers (Pautsch et al, 2005) found that 
their “switch II” complex illustrated no changes compared with wild type C3bot upon 
binding of NAD (PDB code 2A9K) and so cannot explain the 5-fold increase in NAD 
glycohydrolysis observed for the C3bot-RalA interaction. Equally the switch II 
interface may only form when RalA is in its GDP bound form rather than in either the 
GDP or GTP bound forms as initially reported (Wilde et al, 2002a).
5.5 Conclusions
We have determined an alternative arrangement of a complex between C3bot-RalA 
that is centred on switch II of RalA. This complex is highly similar to an already 
published structure with a different space group with 2 RalA molecules and 2 C3bot 
molecules in the asymmetric unit. Whilst the interface around the switch II region is 
larger than the original complex centred on the ARTT loop it does not offer a means 
by which the ribosylation of RhoA can be inhibited, nor how the glycohydrolytic of 
NAD can undergo such a dramatic increase in rate. However the recent finding that 
this alternative arrangement can be found in the original complex due to 
crystallographic symmetry lends more support to this structure being the true 
biologically relevant complex and the implications of this will be discussed further in 
chapter 8.
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6.0 The (almost) structure of the C3bot-RhoA complex
6.1 Aims of obtaining the structure of the C3bot-RhoA complex
The interaction between C3bot and RhoA is highly specific. This specificity is 
shared with the other members of the C3family, save for C3stau that extends the 
specificity to RhoE (Wilde et al, 2001). In spite of mutagenesis data the exact nature 
of the interaction between C3bot and RhoA is still unknown. The aim of this part of 
the project was to determine the structure of the C3bot-RhoA complex and gain a 
complete understanding of the mechanism and specificity of the interaction.
6.2 Interactions between C3bot and RhoA
The RhoA-C GTPases have long been identified as the sole substrates for the C3 
family o f ADPRTs (Aktories et al, 1989; Sekine et al, 1989). The Rho GTPase 
family is a large one that acts as a key regulator of a wide range of cellular 
functions. The number of proteins regulated by RhoA amounts to approximately 1% 
of the human genome (Jaffe & Hall, 2005) making the Rho GTPases essential 
cellular switches. Their functions include, but are not limited to: regulation of actin 
cytoskeleton and stress fibres, regulation of NADPH oxidase, cell cycle control, 
secretion, apoptosis, transcriptional activation, cell adhesion, cell transformation and 
transcriptional activation (Wilde & Aktories, 2001; Etienne-Manneville & Hall, 
2002; Aktories et al, 2004; Jaffe & Hall, 2005).
The Rho GTPases have a similar structure to other members of the GTPase super 
family with a central 6 stranded p-sheet surrounded by a variable number of a- 
helices, seven in the case of RhoA. RhoA is modulated by nucleotide exchange 
between an inactive GDP bound form and an active GTP bound form (Wilde & 
Aktories, 2001). The two switch regions which undergo large conformational 
changes upon GDP/GTP exchange are central to this process and switch I includes 
Asn41, the exposed asparagines that is the target for ribosylation by C3bot and its
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relatives (Sekine etal, 1989). The location of the switch regions and Asn41 adjacent 
to the nucleotide binding site can be seen in figure 6.1 (Wei et al, 1997).
Figure 6.1 The structure of RhoA
iwitch IIGDI*
Asn41Switch I
Figure 6.1. The crystal structure of RhoA (PDB code 1FTN) (Wei et al, 1997) in its inactive GDP 
bound form. The switch regions are highlighted in gold, GDP is shown bound in the nucleotide 
binding site and the target residue of the C3 family of exoenzymes (Asn41) is shown in ball-and-stick 
form.
The areas of Rho that are necessary for ribosylation by C3bot have been studied 
extensively. Mutagenic and chimeric studies using Rho-Ras chimeras has confirmed 
that the N-terminal half of RhoA contains all of the residues necessary for C3bot 
recognition. As can be seen in figure 6.1 Asn41 is solvent exposed. Several other 
residues around the switch I region are also solvent exposed and mutagensis of 
Val38, Phe39 and Val43 all resulted in inhibition of ribosylation by C3bot. Similarly 
a Ras mutant with the equivalent Ras residues mutated to those found in RhoA 
became a viable target for C3bot ribosylation (Wilde et al, 2000). Another residue
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that may be important for recognition and ribosylation is Glu40 that may play a role 
in the transferase reaction by interacting directly with the 2’OH of the ribose ring in 
a similar manner to that of Asp696 in the recently determined PAETA-eEF2 
structure (Jorgensen et al, 2005).
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6.3 Methods
The expression and purification was based on methods previously described by 
Evans et al (Evans et al, 2004) and myself (Holboum et al, 2005). Initial attempts to 
obtain a complex of C3bot and RhoA followed a similar route to that used to 
generate the C3bot-RalA complex. A second attempt was made using conditions 
that C3bot and RhoA were known to form a complex in, with the absence of NAD.
6.3.1 Expression and purification of C3bot
A C3bot-MBP fusion construct in BL21(DE3) cells was kindly provided by Dr. J.M. 
Sutton (Health Protection Agency UK). C3bot was purified exactly as described 
earlier.
6.3.2 Expression of RhoA
The human RhoA gene clone (as a pGEX-2T fusion) was a kind gift of Dr Hiroshi 
Koide, Department of Stem Cell Biology, Graduate School of Medical Science, 
Kanazawa University, Japan. The plasmid was then transferred to the host strain 
JM109 for expression. The clone was inoculated into 100ml of Terrific Broth 
supplemented with 0.5% glucose and lOOpg/ml ampicillin and grown overnight at 
37°C. The culture was diluted 1:50 into 11 of fresh medium and grown for 4 hours at 
37°C until an OD600 of ~0.8 was reached. Expression was induced by addition of 
IPTG to a final concentration of ImM and grown for a further 4 hours at 25°C. Cells 
were harvested by centrifugation (Beckman Avanti J-25).
6.3.3 Purification of RhoA
Cell pellets were resuspended in 50mM BisTris, 0.5M NaCl pH7.0 1 mg/ml 
lysozyme and left on ice for 45 minutes. The cells were lysed by sonication
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(Soniprep 150) and the cell debris removed by centrifugation (Beckman Avanti J- 
25).
The clarified cell lysate was applied to a GST-trap column (GE Healthcare) 
equilibrated with 50mM BisTris pH 7.0, 0.5M NaCl, and was eluted with 20mM 
Tris pH 8.0, 0.2M NaCl, lOmM reduced glutathione as a single peak. The peak was 
dialysed into 20mM Hepes pH 7.3, 150mM NaCl, 5mM MgCk, 2.5mM CaCl2 
overnight at 4°C. It was then treated with 1U thrombin (New England Biolabs) 
/lOOpg protein overnight at 4°C. RhoA was separated from the GST fusion tag by 
reapplication to the GST-trap column. The RhoA protein was concentrated in a 
lOkDa centrifugal concentrator (Amicon) and applied to a Superdex 200 gel 
filtration column (GE Healthcare) equilibrated with 20mM Hepes pH 7.3, 20mM 
NaCl, 5mM MgCb, ImM EDTA. The purified sample was further concentrated to 
lOmg/ml in a lOkDa centrifugal concentrator (Amicon) and stored for 
crystallisation.
6.3.4 Crystallisation of the C3bot-RhoA complex
Attempts were made through two methods to obtain a stable C3bot-RhoA complex. 
The first method was simply mixing the proteins together in a 1:1 ration and 
incubating at 4°C. The second method was similar to the one used by Christian 
Wilde and co-workers and involves using an excess of RhoA and a specific binding 
buffer (Wilde et al, 2000).
6.3.4.1 Incubation at 4°C
For crystallisation RhoA and C3bot were incubated together overnight in a ratio of 
1:1 giving a working concentration of 5 mg/ml. Crystallisation trials were performed 
as hanging drops using 2pl of protein with 2pi of reservoir solution in the drop. 
Structure screens I and II (Hamptons Research) were used to generate initial
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crystallisation conditions. Small crystals were observed in condition 43 of structure 
screen I (0.2M (NH4)2S 04, 30% PEG 4000).
6.3.4.2 Incubation with C3bot-RhoA binding buffer
Pure C3bot and RhoA were independently buffer exchanged into binding buffer, 
50mM Hepes pH 7.3, 2mM MgCl2, ImM EDTA, ImM DTT, 0.3mM PMSF, using 
a lOkDa spin column (Amicon). RhoA and C3bot were then mixed together in a 
ratio of 5:2 and incubated at 4°C for >6 hours. Crystallisation trials were performed 
at 4°C as hanging drops using 1.75pl of protein with 1.75pl of reservoir solution in 
the drop, giving final protein concentrations of 3.5mg/ml RhoA and 1.5mg/ml C3bot 
in the crystallisation drops. Structure screens I and II (Hampton Research) were used 
to generate initial crystallisation conditions.
6.3.5 Data collection and refinement
Diffraction data were collected from a single cryo-cooled (100K) crystal with 25% 
ethylene glycol on station PX14.2 of the synchrotron radiation source at Daresbury 
(UK) using an ADSC Quantum 4 CCD detector. The data were processed and 
scaled using the HKL2000 package (Otwinowski, 1993a; Otwinowski, 1993b). The 
symmetry and systematic absences were consistent with the C2 space group (unit 
cell dimensions a=104.8A, b=15.lh  and c=102.5A, p=102.5°) with two copies of a 
C3botl-RhoA complex per asymmetric unit and the crystals containing -53% 
solvent. Data reduction was carried out using the program TRUNCATE (CCP4, 
1994).
The molecular replacement program PHASER (McCoy et al, 2005) was unable to 
find any copies of RhoA in the asymmetric unit however and subsequent molecular 
replacement with 4 copies of C3bot obtained a viable molecular replacement 
solution (RCryS 28.3, Rfree 34.6 and a figure of merit of 70%). The space group was 
also consistent with one of the published structures of C3bot (Menetrey et al, 2002).
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6.4 Results and discussion
6.4.1 Experimental results
Expression and purification of RhoA followed the same protocol as RalA and 
yielded ~6mg/l of culture. The crystals grown in 0.2M (N R ^SO ^ 30% PEG 4000 
at 4°C grew over the course of ~48 hours and are shown below in figure 6.2. Data 
collection at station PX14.2 of the SRS Daresbury was straightforward and the data 
was processed in space group C2 with the following unit cell dimensions: a= 
104.8A, b=75.7A, c=120.6A, P=102.5°.
Figure 6.2 Potential crystals of the C3bot-RhoA complex
Figure 6.2. Crystals o f  the potential C3bot-RhoA crystals grown in 0.2M  (NH O 2 SO 4 , 30% PEG 
4000. Crystals were grown at 4°C and grew over ~48  hours.
Molecular replacement using AMoRe (Navaza, 1994), MolRep (Vagin & 
Teplyakov, 1997) and PHASER (McCoy et al, 2005) foiled to find any copies of 
RhoA in the unit cell. However a molecular replacement solution with 4 C3bot 
molecules as search model was produced with an R ^  28.3% and Rfree 34.6%. 
Comparison with the published structures of C3bot found that the unit cell
1 1 0
dimensions were very similar to those of the C3bot structure published by Menetrey 
and co-workers (a=109A, b=75.6A, c=123.5A, p= l02.4) (Menetrey et al, 2002) that 
crystallised in 80mM citric acid pH 3.0,22.5% PEG3350, lOOmM Li2S0 4 .
The crystallisation trials performed using the C3bot-RhoA binding buffer has failed 
to yield crystals to date.
6.5 Conclusions
We have managed to purify pure C3bot and RhoA. Attempts to determine the 
structure of a C3bot-RhoA complex have so far been unsuccessful although we have 
discovered a previously unreported crystallisation condition for C3bot.
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7. Streptococcus pyogenes ADP-ribosyltransferase SpyA
7.1 Aims in purifying SpyA
SpyA from S. pyogenes has been identified as an ADPRT from sequence analysis 
and conserved motifs and more recently has been biochemically shown to ADP- 
ribosylate actin and other host cell proteins. We hope to purify, crystallise and 
determine the structure of SpyA and compare it with the structures of other members 
of the ADPRT family.
7.2 SpyA from Streptococcus pyogenes
Streptococcus pyogenes is a Gram positive pathogenic bacteria that is responsible 
for a host of pathogenic effects ranging from the potentially fatal toxic-shock 
syndrome and necrotising facitis to mild pharyngitis and tonsillitis. S. pyogenes is 
carried as a commensal bacterium in 5-15% of healthy individuals and only when 
the immune system is compromised or when it gains entry to the blood stream (e.g. 
from an infected wound) does it show a pathogenic effect.
In order for S. pyogenes to cause such a wide range of diseases it produces a variety 
of toxins and effectors to facilitate it pathogenic effects. These include: highly 
potent streptococcal superantigenic toxins such as SpeA and C (Barsumian et al, 
1978; Schlievert, 1993); a cysteine protease, SpeB, that cleaves a range of cellular 
targets (Ohara-Nemoto et al, 1994); 2 potent cytolysins, Streptolysin S and O 
(Billington et al, 2000; Palmer, 2001); and the clot dissolving streptokinase 
(Lottenberg et al, 1987).
The SpyA ORF in the S. pyogenes genome was identified by two groups as an 
ADPRT from its sequence. In the first case from the genomic analysis that defined 
ORF Spy0428 as an ADPRT (Ferretti et al, 2001); in the second ART STREPY 
was identified from a PSI-BLAST search (Pallen et al, 2001). In both cases the 250
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amino-acid gene product was identified from the 3 conserved motifs common to all 
ADPRTs: (i) A potentially catalytic glutamate; (ii) a p/a region with a 
serine/threonine motif; and (iii) a conserved arginine (Domenighini & Rappuoli, 
1996). This protein was termed SpyA (Coye & Collins, 2004) and is 250 amino 
acids in length with a molecular mass of 24.9kDa and a putative 30 residue signal 
peptide at its N-terminus that may be involved in pathogenesis (Pallen et al, 2001). 
The SpyA gene has a high degree of identity with both C3stau (25% identity and an 
additional 22% similarity) and C3bot (23% identity and an additional 23% 
similarity). SpyA has now been characterised as an ADPRT and is able to hydrolyse 
P-NAD and ribosylate poly-L-arginine (Coye & Collins, 2004).
Eukaryotic expression of SpyA has been linked with a breakdown in cell 
cytoskeleton (Coye & Collins, 2004), a tactic used by many pathogens used to resist 
phagocytosis (Gruenheid & Finlay, 2003). SpyA may thus play a role in preventing 
the phagocytosis of S. pyogenes (Coye & Collins, 2004). Although, like the related 
C3 exoenzymes, SpyA lacks an obvious eukaryotic binding domain it has been 
shown that Streptococcal NAD-glycohydrolase gains access to host cells via a pore 
formed by the cholesterol dependant streptolysin O (Madden et al, 2001) and SpyA 
may follow a similar route into eukaryotic cells (Coye & Collins, 2004).
The intracellular targets of SpyA are still being examined although radio-labelling 
experiments have highlighted actin, tropomysin and vimentin as possible targets of 
SpyA. All three of those proteins are heavily involved in the regulation of, or 
formation of, the cell cytoskeleton. ADP-ribosylation of actin prevents 
polymerisation of actin and results in the eventual destruction of the actin 
cytoskeleton (Wegner & Aktories, 1988). Tropomysin is another structural protein 
that binds to actin filaments in cells providing them with structural stability and 
vimentin forms intermediate filaments in eukaryotic cells (S. V. Perry, 2001).
Amongst the ADPRT family SpyA is unusual falling into two different categories. 
Based on its small size (24.9kDa), high pi (pi 9.1), sequence similarity and lack of a
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binding domain it should fall into the same category as C3bot and the related Rho- 
modifying ADPRTs ( Wilde & Aktories, 2001; Coye & Collins, 2004). However, 
SpyA ADP-ribosylates actin placing it amongst the binary ADPRTs like Iota toxin 
(Stiles & Wilkins, 1986), VIP2 (Han et al, 1999) and the Clostridial C2 toxin 
(Aktories et al, 1986).
SpyA is a novel ADPRT from S. pyogenes that ADP-ribosylates actin and possesses 
all of the motifs common to ADPRTs. Due its chemical characteristics, small size 
and sequence similarity it is probably a unique member of the C3bot family.
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7.3 Methods
The SpyA gene in the pET15b vector (Novagen) was a kind gift from Dr. Carleen 
Collins, Department of Microbiology, University of Washington.
7.3.1 Expression of SpyA
The SpyA plasmid was transformed through heat shocking to B121(DE3)codon+ 
expression cells (Novagen) and grown overnight on LB-gar plates supplemented 
with lOOpg/ml ampicillin. Single colonies were used to inoculate 10ml of ZYM-505 
auto-induction media overnight at 37°C (Studier, 2005) (1% N-Z amine, 0.5% yeast 
extract, 5mM NA2S 04, 2mM M gS04, 25mM (NH4)2C12, 25mM KH2P 0 4, 20mM 
Na2P 0 4, 0.5% glycerol, 0.05% glucose, 50nM FeCl3, 20nM CaCl2, lOnM MnCl2, 
lOnM ZnS04, 2nM CoCl2, 2nM CuCl2, 2nM NiCl2, 2nM Na2M o04, 2nM Na2Se04, 
2nM H3BO3) supplemented with 100jig/ml ampicillin. The overnight cultures were 
then diluted 1:1000 into 11 fresh ZYM-5052 media (1% N-Z amine, 0.5% yeast 
extract, 5mM NA2S04, 2mM M gS04, 25mM (NH4)2C12, 25mM KH2P 0 4, 20mM 
Na2P 0 4, 0.5% glycerol, 0.05% glucose, 0.2% lactose, 50nM FeCE, 20nM CaCl2, 
lOnM MnCl2, lOnM ZnS04, 2nM CoCl2, 2nM CuCl2, 2nM NiCl2, 2nM Na2M o04, 
2nM Na2Se04, 2nM H3BO3) supplemented with 100mg/l ampicillin and left to grow 
for overnight at 37°C. Partially soluble protein expression was observed on an SDS- 
page gel. Cells were harvested by centrifugation (Beckman Avanti J-25).
7.3.2 Isolation of inclusion bodies
Cell pellet was resuspended in ~40ml of lysis buffer (20mM Tris pH 8.0, 0.5M 
NaCl, 0.33mg/ml lysosyme) and stirred for ~30 minutes at room temperature. The 
cells were then lysed through two passes through the French press and inclusion 
bodies isolated through centrifugation (Beckman Avanti J-25). Both passes through 
the French press and centrifugation were performed at room temperature. Inclusion 
bodies were then solubilised in ~20ml of solubilisation buffer (50mM Tris pH 8.0,
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0.5M NaCl, 6M Guanidine HC1) and stirred at room temperature for ~2 hours. Any 
remaining inclusion bodies were removed through centrifugation (Beckaman Avanti 
J-25) and by passage through a 0.45pm syringe filter (Millipore).
7.3.3 Purification via Ni2+ affinity chromatography
The clarified inclusion bodies were loaded onto -10ml of fast flow H6 affinity resin 
(GE Healthcare) equilibrated with solubilisation buffer and charged with 0.4M 
M SO4. The column was then washed with ~3 column volumes of wash buffer 
(50mM Tris pH 8.0, 0.5M NaCl, 7M urea) and the SpyA eluted by an isocratic step 
into elution buffer (50mM Tris pH 8.0, 0.5M NaCl, 7M urea, 0.5M imdazole). 
Fractions containing pure SpyA were pooled prior to refolding.
7.3.4 Refolding of SpyA
A 24 condition refolding screen based on an amalgam of commercially available 
was performed to obtain refolding conditions suitable for SpyA. 50pl of purified 
SpyA was added slowly to 1ml of each refolding condition and then left overnight at 
4°C. Precipitate was removed using centrifugation and the supernatant containing 
refolded protein was visualised on an SDS-page gel.
The remaining pure SpyA was then dripped slowly over ~2 hours into 500ml of 
refolding buffer containing 50mM Tris pH 8.5, 9.6mM NaCl, 0.4mM KC1, 0.5% 
triton X-100, 0.05% Peg3350, 0.4M sucrose, 2mM MgCb, 2mM CaCl2 and 5mM P- 
Mercoptoethanol and left for 24-48 hours without stirring at 4°C. This was then 
centrifuged at high speed for 1 hour to remove precipitate and other contaminants 
(Beckman Avanti J-25).
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7.3.5 Purification of refolded SpyA
The refolded SpyA was applied by very slow overnight loading onto a 5ml Hitrap 
column (GE Healthcare) charged with 0.4M NiSC>4 and equilibrated with refolding 
buffer. SpyA was eluted as a single peak with 20mM Tris pH8.5, 120mM NaCl and 
0.5M imidazole and stored at 4°C.
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7.4 Results and discussion
7.4.1 Experimental methods
SpyA has proved a challenging and difficult protein to purify. Initial purification 
strategies focused on a soluble purification protocol. When expressed in 
autoinduction media SpyA overexpresses well and in large amounts. The expressed 
SpyA was found to be partially soluble. Soluble purification strategies using Ni2+ 
affinity chromatography followed by size exclusion chromatography failed to yield 
pure, homogenous SpyA suitable for crystallisation. Efforts to improve the purity of 
the soluble SpyA involved trials with SP-sepharose ion exchange chromatography to 
take advantage of the relatively high pi (pi 9.1) of SpyA, and trials with a Cibracon 
blue (GE Healthcare) dye column to take advantage of the NAD binding 
characteristic of SpyA. Reverse phase chromatography was also attempted but even 
this failed to yield pure SpyA, in addition solubility problems were encountered 
after lyophilisation of the sample after reverse phase chromatography.
It was decided that after the success of the refolding screen for several other proteins 
that inclusion body purification may yield better results. To increase the yield of 
insoluble SpyA the cell lysis steps: treatment with lysosyme, mechanical lysis in the 
French press and centrifugation were all performed at room temperature. This 
resulted in the vast majority of expressed SpyA being present in the inclusion 
bodies. Initially attempts were made to refold the SpyA before any purification steps 
were taken but this led to very poor refolding results and many problems with 
precipitation. The lack of refolding may have been due to other contaminating 
protein species present in the inclusion bodies and the refolding sample so it was 
though that purification of the solubilised proteins before refolding may remove 
many contaminants and increase the efficiency of refolding.
Initial attempts at this using pre-packed Hitrap (GE Healthcare) and His-select 
(Promega) columns resulted in the columns malfunctioning and losing the protein
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sample. Changing the protocol to non-prepacked FF H6 affinity media resulted in 
effective purification of the unfolded SpyA as see in the figure 7.1.
Figure 7.1 Insoluble purification of SpyA







Figure 7.1. SDS-page gel illustrating the partial purification o f  SpyA after histidine affinity 
chromatography performed in the presence o f  7M urea.
The refolding screen is based on an amalgam of several commercially available 
refolding screens. Initial trials with the refolding screen resulted in 4 of the 
conditions giving positive results: (1) Condition A5 containing 50mM Tris pH 8.5, 
9.6mM NaCl, 0.4mM KC1, 0.05% PEG3350, 0.5% triton X-100 2mM MgCl2, 2mM 
CaCl2, 400mM sucrose and 5mM (3-Mercaptoethanol; (2) Condition A6 containing; 
50mM Tris pH 8.5, 9.6mM NaCl, 0.4mM KC1, 0.5% triton X-100 and 5mM |3- 
Mercaptoethanol; (3) Condition B1 containing lOOmM Tris pH8.5, 240mM NaCl, 
lOmM KC1, 0.05% PEG3350, 5mM (3-Mercptoethanol; and (4) condition B2 
containing 50mM Tris pH 8.5, 240mM NaCl, lOmM KC1, 2mM CaCl2, 0.4M 
sucrose and ImM DTT. When done on larger scale than the 50pl trial scale buffer 
A5 gave better results than either A6 or B1 and buffer B2 was discarded as DTT can 
lead to problems with Ni affinity columns. After refolding the sample was purified 
again using Ni2+ affinity chromatography. This second step served two purposes: (1) 
to remove any further contaminants; and (2) to concentrate the 500ml volume of
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refolded SpyA to a more manageable volume. After refolding and the second stage 
of purification SpyA was also seen to dimerise (figure 7.2).
Figure 7.2 Pure SpyA and dimerised SpyA
Figure 7.2. An SDS-page gel illustrating the purity o f  SpyA after a refolding and a second round o f 
histsidine affinity chromatography. The peak from the Hitrap column contained a mixture o f  
monomer and dimerised SpyA. After storage for -2 4  hours at 4°C the SpyA had either formed a 
dimmer o f  precipitated out o f  solution.
Whether this dimerisation is biological or merely due to the buffer conditions is 
unknown at this time, though no members of the C3 family of ADPRTs are known 
to exits as dimers.
Due to ongoing solubility problems no crystallisation has been possible as yet. The 
solubility problems may be due to the buffer exchange from refolding buffer into 
20mM Tris pH8.5, 120mM NaCl and 0.5M imidazole following the second 
purification step, and eluting the SpyA in refolding buffer supplemented with 
imidazole may result in stable, soluble SpyA.
Fractions after 24 hours 






7.4.2 Homology modeling with the C3 exoenzymes
SpyA shows a high degree of sequence identity with C3bot (23%) and C3stau (25%) 
and a sequence alignment of the members of C3 family with SpyA show large 
regions of conserved sequence.
Figure 7.3 Sequence alignment of SpyA with related ADPRTs
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Figure 1 3 . Sequence alignment o f  SpyA with the related C3 ADPRTs, C3bot and C3stau, and the 
catalytic domain o f  the actin modifying Iota toxin. Secondary structure features are assigned from the 
C3bot structure. The conserved residues that make up the 5 motifs are highlighted according to the 
colours used in figure 8.5. The ARTT loop in blue, the STT m otif in purple, the Arg/His m otif in 
yellow , the PN  loop in green and the residues o f  the a3-helix in red. The sequence alignment w as 
performed using ClustalW (Wilbur & Lipman, 1983).
The sequence alignment in figure 7.3 was constructed with T-coffee (Notredame et 
al, 2000) and highlights the key regions of the ADPRT family. A homology model 
of SpyA was constructed using C3bot [PDB code 1G24] (Han et al, 2001) as a
1 2 1
template and the SWISS-MODEL web server (Schwede et al, 2003). The SpyA 
model is shown below in figure 7.4.
Figure 7.4 The homology model of SpyA
Figure 7.4. The homology model of SpyA built by the SWISS-MODEL database (Schwede et al, 
2003) using C3bot as a model (PDC Code 1G24) (Han et al, 2001).
Like C3bot the model of SpyA consists of a mixed a/p core. A five stranded mixed 
p-sheet (pi, P2, P3, p4, p6) stacks perpendicularly against a two stranded anti­
parallel P-sheet (P5, P7) with four helices (a l, a2, a3, a4) arrayed around the three 
stranded sheet plus a fifth long helix (a5) flanking the five stranded sheet. The two 
smaller helices at the top of the model (a6, a7) are likely to only be loop regions in 
the actual structure. The structural motifs that are common to all of the C3bot-like
1 2 2
and Iota-like toxins are also conserved in SpyA, both in the sequence and in the 
structural model.
Like the ADPRT family SpyA has many of the conserved features common to ADP- 
ribosyltransferases. It has a catalytic glutamate residue (Glu 187) on the ARTT loop 
and in common with all of the actin ribosylating ADPRTs a second glutamate two 









Figure 7.5 A close-up view of the active site of the SpyA model 
PN loop
R159
Figure 7.5. A close-up view of the active site of SpyA showing the 5 motifs common to the a-3 helix 
ADPRTs. This includes the ARTT loop (in blue) containing the catalytic glutamate and a second 
substrate determining Glu/Gln two residues upstream. Although in the case of SpyA there is no 
conserved aromatic residue. The STT motif (puiple), the Arg/His motif (yellow) and the PN loop 
(green) are also shown. The a-3 helix (red) contains a conserved tyrosine and asparagine but lacks the 
arginine seen in C3bot.
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It is likely that the change in this second glutamate from glutamine to glutamate is 
plays a part in the altered substrate specificity. All of the actin modifying toxins 
possess a Glu-x-Glu motif at the ARTT loop and alterations to this Gln/Glu have 
been seen to cause dramatic changes in substrate specificity, either from asparagine 
to arginine for C31im (Vogelsgesang & Aktories, 2006) or from cell surface to 
cytoplasmic targets in EctoART (Ritter et al, 2003). An E187A mutant has been 
shown to abolish both the hydrolysis and transferase reactions confirming Glul87 is 
the catalytic glutamate (Coye & Collins, 2004). Unlike the C3 or Iota like toxins 
however it appears that SpyA lacks a conserved aromatic residue equivalent to 
Phe209 of C3bot instead possessing a valine residue. This is thought to be critical 
for the action of both the actin modifying Iota toxin (Tsuge et al, 2003) and the Rho- 
modifying C3bot (Wilde & Aktories, 2001) it is possible that SpyA may have a 
slightly different way of recognising its substrate. A hypothesis partially bom out by 
the observation that SpyA appears to target actin, tropomysin and vimentin (Coye & 
Collins, 2004). This broad substrate specificity has not been observed for the other 
actin modifying toxins. The other structural motifs are also intact in SpyA. It 
possesses an STS motif, although, in the case of SpyA this changed to an STT motif. 
The conserved Arg/His motif maintains the hydrophobic-aromatic-arginine pattern 
seen in the other C3-like amino acids and it also possesses the a-3 motif with a Y- 
X7-I-N sequence, though in common with the Iota-like toxins it lacks the arginine 
immediately after this motif.
7.5 Conclusions
We have managed to optimise a refolding based purification protocol for SpyA, a 
novel ADPRT from S. pyogenes. SpyA has been shown to be an ADPRT with broad 
substrate specificity and a high sequence similarity to the C3 family of ADPRTs. 
Small changes in the sequence, particularly in the normally conserved ARTT loop 
may account for this broad substrate specificity. Physical similarity to the C3 family 
whilst possessing enzymatic action more closely related to the Iota-toxin family has 
led to it being classified as a unique member of the C3bot family.
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8. General discussion
8.1 Interactions between C3bot and RalA
We have managed to purify and determine the structure of two alternative 
complexes of C3bot and RalA alongside a structure of the first complex with NAD 
bound into the active site of C3bot. However in the initial complex determined, a 
symmetry related arrangement also gives rise to an interface that is the same as the 
“alternative complex” detailed in chapter 5. This gives reason to suspect that initial 
complex centred on the ARTT loop may in fact be a crystallographic artefact and 
not a true biological interface necessitating a close examination of the two 
complexes to investigate which is more likely to be the true biological interface.
The two complexes are highly different binding to vastly different areas of each 
molecule. The ARTT loop complex involves C3bot being bound directly at the 
active site completely blocking the ‘face’ of the molecule and obscuring the active 
site (Holboum et al, 2005). By contrast the areas involved in RalA binding in the 
‘switch II’ complex are distant from the active site (>25A) (Pautsch et al, 2005). 
The different areas are highlighted below in figure 8.1 A. Similarly the areas of 
RalA involved in the different modes of binding are distant from each other. In the 
original complex (Holboum et al, 2005) the area is on the far side of the RalA 
molecule with respect to the nucleotide binding site. In the second complex the 
interface is formed in a groove formed by helix a3 and the switch II loop of the 
nucleotide binding site. In the switch II complex the position of the binding interface 
also results in the complex only forming being with GDP bound RalA. The areas 
that form the interfaces are highlighted below in figure 8. IB. Both of these different 
complexes, the original one based around the ARTT loop and the second one similar 
to that reported by Pautsch and co-workers (Pautsch et al, 2005) centred around the 
switch II region of RalA do not fully answer the questions posed by the initial 
biochemical experiments (Wilde et al, 2002a).
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Figure 8.1 Surface models of C3bot & RalA
A
Figure 8.1 A. Surface model of C3bot highlighting the NAD binding site (yellow), the area involved 
in binding with RalA centred on the ARTT loop (red) and the area of C3bot that binds at switch II of 
RalA (blue). B. Surface model of RalA highlighting the nucelotide binding site (yellow), helix a-4 
and the other residues that interact with C3bot at the ARTT loop (red) and the area of groove of RalA 
formed by switch II and helix a3 (blue).
8.2 Biological basis of the competing interfaces
Each of the proposed models fits some of the criteria that the original biological 
work ascribed to the interaction between C3bot and RalA. The initial complex 
(Holboum et al, 2005) described in chapter 2 offers a clear mechanism to bring 
about the inhibition of Rho ribosylation. The interaction of RalA about the ARTT 
loop obscures the front of C3bot and prevents access of other proteins, such as 
RhoA, to the active site, thereby inhibiting the ribosyltransferase reaction. The 
second structure however involves binding to the rear of the C3bot distant from the 
active site and does not involve any residues crucial to NAD binding. Equally the 
position of the RalA binding site towards the rear of the C3bot molecule leaves the 
active site open to solvent and would allow RhoA easy access to the binding site.
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The position of the interface region in the second, switch II, model of the complex 
also offers no explanation for the increased rate of glycohydrolysis observed upon 
C3bot interacting with RalA (Wilde et al, 2002a). The original complex by 
interacting directly with the ARTT loop may be able to offer a plausible explanation 
for this. The unique conformation of the ARTT loop involves the side chain of 
Ser207 flipping into the centre of the ARTT loop and forming ionic interactions 
with additional residues of the ARTT loop possibly granting the normally flexible a 
level of rigidity. Also the PN loop in the structure detailed in chapter 4 possesses 
some subtle changes including a shift in the position of Gin 182 that prevents it 
interacting with the Gln212 of the ARTT loop. However as both the ARTT loop 
interface and switch II interface are present in the asymmetric unit it is quite difficult 
to draw a meaningful conclusion from the small re-arrangements in the PN loop. A 
mutant replacing Glnl 82 with alanine and removing this same interaction has been 
seen to almost double the rate of glycohydrolysis without having a significant effect 
on the NAD binding strength (Menetrey et al, 2002).
However as in the complex presented in chapter 2 an electrostatic surface 
representation of the complex centred around the Switch II interface shows a huge 
change in the electrostatic surface around the active site of C3bot. This is shown 
below in figure 8.2. Similar to the ARTT loop complex there is a large change in 
surface electrostatic potential upon complexation with RalA that may account for 
the increase in NAD hydrolysis without any structural change in C3bot. Similar to 
the changes seen in the ARTT loop interface the potential of the NAD site becomes 
increasingly negative. As this interaction also occurs on the ‘back’ of C3bot relative 
to the active site it may be possible that this large shift in electrostatic charge may 
the be the reason that Rho ribosylation is inhibited as unlike in the ARTT interface 
where RalA blocks access to the active site there is no obvious method of inhibition 
in the complex based around the Switch II interface.
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Figure 8.2 Surface electrostatic charge depiction of the switch II interface
C3Bot
Figure 8.2. Electrostatic surface potential of the C3bot-RalA complex arranged around the switch II 
interface. The C3bot-NAD is on the left and the RalA is on the right.
The nucleotide dependant nature of the interaction also varies between the differing 
complexes. In the original complex the interaction takes place around the a4-helix of 
RalA distant from the nucleotide binding site and the important switch regions. This 
allows the RalA to be present in both GDP and GTP bound form in accordance with 
the initial biochemical findings (Wilde et al, 2002a). The work by Pautsch and co­
workers reporting the structure of the switch II complex found that this complex 
between C3bot and RalA is only permissible when RalA is bound to GDP (Pautsch 
et al, 2005). The restriction of this complex to RalA-GDP is due to the involvement 
of switch II in the interface preventing it from moving into its GTP bound 
conformation due to steric clashes with C3bot. The mutagenesis work performed by 
Paustch and co-workers suggesting that loss of several of the residues of RalA 
involved at the ARTT loop interface had no effect on binding and their complex 
only forming with RalA-GDP may have been caused by their preparations only
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forming the a single species of the complex, namely the complex centred around 
switch II.
8.3 Biochemical comparison of the interfaces
In addition to biological evidence there are numerous biochemical tools that can be 
used to analyse each interface and give an indication as to which interface is more 
likely to represent the true biological interface. One set of criteria has been 
developed that analyses the buried surface area between the sub-units and includes 
statistics on the shape and bonds at the interface (Jones & Thronton, 1996). This has 
been compiled into a web-based resource; the protein-protein interaction server, and 
the results for the ARTT loop interface and the Switch II interface are displayed 
below in table 8.1.
Table 8.1 Protein-protein interaction server results
Protein interface parameters A R T T  loop interface Switch I I  interface
Accessible surface area (A 2) 362.1 855.9
% total surface area 4.0 9.7
Length & Breadth (A ) 23.0 & 21.2 26.2 & 27.8
% Polar atoms 46.0 42.8
% Non-polar atoms 54.0 57.2
Hydrogen bonds 6 11
Gap volume 5750.4 4753.1
Gap volume index 8.5 2.73
The data listed in table 8.1 suggest several pertinent facts when comparing the two 
interfaces. The accessible surface are is the most obvious difference between the two 
interfaces. When compared to a structural comparison of the interfaces in the PDB 
the average accessible surface area (ASA) for proteins of 24kDa was found to be 
-1000A2 (Jones & Thornton, 1996); close to the size for the switch II interface but 
much larger than the ARTT loop interface. The strength of the switch II interface 
compared to the ARTT loop interface is also apparent from its dimensions that are 
roughly similar to the ARTT loop interface but contains almost double the number
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of hydrogen bonds (6 compared with 11). A second method of assessing the 
‘quality’ o f an interface is the “gap volume index” that gives a score to the shape 
complementarity of the two surfaces. This is defined as a ratio between the gap 
volume between the two molecules and the interface accessible surface area. For the 
hetero-complexes examined the gap index varied between 0.35A to 5.17A with a 
mean of 2.5A. An assessment of the two interfaces using gap index as a measure of 
the quality would also suggest that the switch II interface is a chemically ‘better’ 
interface.
Analysis of the individual residue B-factors can also give an indication of which 
residues are involved in formation of the interface as when compared to the free 
C3bot or RalA there should be a corresponding drop in B-factors of the residues that 
are involved in forming an interface. Graphs of the B-factors comparing the wild- 
type C3bot and RalA with the structures presented in chapter 2 and chapter 5 are 
shown below in figure 8.3A and B. The B-factors for C3bot comparing the 
structures presented in chapters 2 and 5 and the original wild type structure (Han et 
al, 2001) do not show a great deal of difference when the important binding residues 
are compared. A similar trend is seen for RalA when the structures from chapter 2 
and 5 are compared with the wild type GDP bound RalA (Nicely et al, 2004) when 
there is no stabilisation of the binding residues observed. Whilst this lack of change 
doesn’t give an indication in favour of either of the possible interfaces the similarity 
between the B-factor plots of the two complexes could suggest that there is little or 
no difference between them as they both contain the Switch II interface and the 
addition of the ARTT loop interface does not make a substantive alteration to the 














Figure 8.3 B-factor plots of C3bot and RalA
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Figure 83A . B-factor plot of C3bot with the ARTT interface structure (blue), Switch II interface 
structure (green) and the wild type (PDB code 1G24) (Han et al, 2001). B. The B-factor plots of 
RalA with the ARTT interface structure (blue), Switch II interface structure (green) and the wild type 
(PDB code 1U8Z) (Nicely et al, 2004). The blue and green bands mark the residues at the ARTT 
loop interface and Switch II interface respectively.
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8.4 Crystal polymorphism
The growth of both forms of the C3bot-RalA complex in the same crystallisation 
conditions is an unusual example of crystal polymorphism as polymorphism 
normally involves changing of some conditions in the crystallisation conditions. 
This change can be in pH, temperature (Jolles & Berthou, 1972), salts (Vaney et al, 
2001) or changes in other crystallisation components (Berthou & Jolles, 1973). The 
nature of how this polymorphism comes about may suggest an equilibrium related 
formation in which the initial conditions favour the ARTT loop complex then as 
time progresses the equilibrium shifts to favour the larger and more stable complex 
presented in chapter 5.
8.5 Conclusions
Initially it was thought that the complexes presented in chapters 2 and 5 were 
competing complexes that answered different biological questions. It was only 
recently that a symmetry related interface identical to the Switch II interface was 
found in the initial published complex (Holboum et al, 2005). The presence of the 
Switch II interface in all of the structures found to date and the strong mutagenic 
data suggests that it may be the biologically relevant interface.
The biophysical characteristics o f the two interfaces also favour the Switch II 
interface as a tme interface as the ARTT loop interface has a very small accessible 
surface area with respect to all other published complexes and a very large gap 
volume index that lies far outside the expected range. By comparison the Switch II 
interface falls into the expected range of surface area and gap volume index for a 
complex between two proteins of approximately 24kDa.
The comparison of the two possible interfaces has shown that mutagenic and 
crystallographic factors strongly favour the interface centred at “switch II” over the 
ARTT loop interface. However this is still troubling as despite this wealth of
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evidence the Switch II interface does not show an obvious method through which 
the inhibition of Rho ribosylation comes about suggesting that there may still be 
elements of the interaction by C3bot and RalA that are poorly understood.
8.6 Future work
With the multiple forms of the interface between RalA and C3bot there is still some 
confusion as to which is the biologically active one, or, if  the biological observations 
come about from a an equilibrium between the two forms. We are in the process of 
attempting to produce crystals of C3bot-RalA with GTP rather than GDP soaked 
into the binding site of RalA to confirm that the interaction between C3bot and RalA 
is nucleotide independent.
Several other biophysical methods of determining the biological complex also exist. 
Both nuclear magnetic resonance (NMR) and mass spectroscopy tools could be used 
to determine which parts of the C3bot and RalA molecules are involved in the 
interface. Mass spectroscopy has been successfully used to investigate the 
accessibility of surface residues in other protein complexes. The most common 
methods for using mass spectroscopy in this manner involve either using hydrogen -  
deuterium exchange (HDx) or labelling the reactive primary amine side chains of 
surface lysine residues with small groups such as acetate or biotin (Borch et al, 
2005)(Suckau et al, 1992)(Scholten et al, 2006). In HDx the the protein is 
suspended in D2O and mass spectroscopy can give information as to the parts of the 
molecule that are surface assessable due to hydrogen- deuterium exchange on the 
backbone amides. With labelling strategies exposed lysines become labelled by a 
small molecule, such as using acetic anhydride to acetylate exposed lysine residues 
(Scholten et al, 2006)(Suckau et al, 1992), in order that after tryptic digest 
fragments of the molecule were surface exposed show a change in their mass. NMR 
can also be used in a similar manner to probe intermolecular contacts. The most 
common method of NMR used to study protein interfaces and one that would be 
applicable to the complex between C3bot and RalA is “chemical shift perturbation
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mapping”. In this method one of the proteins is labelled with 15N and its l5N -!H 
NMR profile is monitored as the second protein is added. The molecules that are 
involved closely at the interface will then show a degree of chemical shift allowing 
you to observe which part of the molecule is forming the biologically relevant 
interface (Zuiderweg, 2002). Ideally either of these methods may resolve the 
question and definitively illustrate which complex is formed in solution.
The fine details of the recognition and binding between C3bot and RhoA is still 
unknown. To achieve a stable complex between C3bot and RhoA suitable for 
crystallisation we are awaiting Carba-NAD (Slama & Simmons, 1988) (Slama & 
Simmons, 1989) from collaborators. This non-hydrolysable NAD analogue would 
bind to the C3bot active site and allow the C3bot to move into its NAD-bound form 
and successfully bind RhoA.
The unique C3-related ADPRT SpyA has now had a purification protocol optimised 
for it. The next stage will be to begin crystallisation studies to obtain diffraction 
quality crystals of SpyA. This may also lead to attempts to obtain crystals of a 
complex between SpyA and its substrates.
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A p p en d ix  A
B asic introduction to crystallography
X-ray crystallography is the most commonly used tool for determining the three 
dimensional structure of biological macromolecules at, or near, atomic resolution. 
This has allowed understanding of drug binding, enzymatic mechanism and the 
underlying factors that are involved in protein-protein recognition. It is a complex 
process involving biochemistry, physics and mathematics. The science of 
crystallography improved over the years as more powerful sources of X-rays, 
advances in computing and automation of many of the steps of the process have 
allowed more structures to be determined and more information to be gleaned from 
the experimental data obtained. These steps are shown below in figure A1 and will 
be discussed throughout this chapter. The basic principles of X-ray diffraction and 
the steps involved in the determination of a structure will also be discussed.
Figure A1 The process of structure determination
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Prior to crystallisation a large amount of homogenous pure protein must be acquired. 
With modem techniques this has been simplified by the availability of recombinant 
vectors that are designed with ready to use cloning sites and a wide selection of 
affinity tags to aid in the purification process. The selection of vector and 
subsequent method or purification can have a profound effect on the quality of 
protein obtained and the conditions of any resulting crystals. There are several 
factors to consider when selecting a purification method:
• Source of the protein
• Expression system
• Selection of fusion tag ability to cleave off the tag
• Method of purification
The choice of vector can affect the final product considerably. The most commonly 
used expression system is E. coli as it is cheap and straightforward. As it is a 
prokaryotic system it does not allow for any post-translational modification of the 
recombinant protein. Yeast and insect cell expression are more complex eukaryotic 
systems that allow post-translational modification of recombinant proteins and other 
difficult to generate eukaryotic proteins.
Purification is most commonly performed with affinity chromatography using a 
variety of fusion protein tags. The most common of these are hexa-histidine (His6) 
tags, glutathione S-transferase (GST) fusion proteins and maltose binding protein 
(MBP) fusion proteins. The use of affinity tags allows a straightforward initial 
purification before more traditional chromatography methods such as ion-exchange, 
gel filtration or reverse phase chromatography are employed to obtain the -99%  
purity required for crystallisation.
The purity of the protein produced is of paramount importance as contaminants or 
heterogeneity of the sample may produce a sample that will fail completely to
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crystallise or produce crystals that do not diffract. This may come about from 
contaminating species that disrupt the orderly structure of the crystal and interfere in 
the orderly nature of the crystalline lattice (Rhodes, 2000; Blow, 2002).
Crystallisation
Crystals are ordered arrays of molecules held together by non-covalent interactions. 
The growth of ordered protein crystals of suitable size that diffract X-rays to a 
usable resolution is the limiting step of structure determination. The complexity 
involved in producing suitable protein crystals is understandable when one considers 
the variables that may affect crystal grow. These vary from more controllable 
variables such as the homogeneity of the protein, concentration of the protein, pH, 
temperature, salt and precipitant concentrations to less obvious variables such as 
cleanliness of the crystal trays, vibrations, gravity, convection and the age and 
source of the protein. The process of crystallisation involves the controlled 
precipitation of a protein from solution to form ordered crystals. It involves 
aggregation of protein molecules that form interactions that resemble those found in 
the eventual protein. This aggregate exists in an equilibrium that supports both 
growth and dissolution of the crystal nuclei until it achieves a critical size where 
only growth is supported and addition protein molecules occurs in an orderly 
manner expanding the crystalline lattice. These processes occur in supersaturated 
solution where the concentration of protein exceeds its solubility value. The 
supersaturation phase can be further divided into the labile zone where both 
nucleation and growth can occur and the metastable zone where only crystal growth 
occurs and these phases can be seen in figure A2A.
137












S ilicon ised  co v er  slip
R eservoir  so lu tion
[ Protein ]
Figure A2A; The phase diagram for the crystallisation o f  proteins. B; Experimental set-up for the 
hanging drop vapour diffusion method. Adapted from (Rhodes, 2000)
The most commonly used technique for growing protein crystal is through vapour 
diffusion techniques. In vapour diffusion experiments the protein concentration is 
increased through diffusion of water from a drop containing protein and mother 
liquor to a reservoir of more concentrated mother liquor. In hanging drop vapour 
diffusion shown above in figure A2B the drop containing protein is suspended from 
a silconised coverslip above the reservoir and once supersaturation occurs both 
nucleation and crystal growth can occur simultaneously. Other methods of vapour 
diffusion techniques include the sitting drop and sandwich drop techniques. Due to 
the wide range of precipitants, salts, ions, additive and buffer conditions that can be 
used to induce crystal growth a common starting point is to use pre-made crystal 
screens such as the Molecular Dimensions structure screens (Jancarik et al, 1991) or 
Hamptons strategy screens (Jancarik et al, 1991) to try and find an initial condition 
that yields small crystals or crystalline precipitate. These pre-made screens of 
different conditions contain ready made solutions that span a wide range of common
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buffers, salts and precipitants. Such a beginning can be used to obtain an initial 
condition to that can then be optimised to yield crystals that are suitable for X-ray 
diffraction experiments. Optimisation of crystal conditions commonly includes 
screening around the initial condition varying all of the conditions and components 
by small increments in an effort to improve the size or quality of the crystals (Blow, 
2002; Rhodes, 2000).
T h e u n it cell
Crystals are ordered three-dimensional arrays of molecules held together by non- 
covalent interactions. The smallest repeating unit that contains the protein is defined 
as the ‘unit cell’. This unit cell is representative of the crystal as a whole, the crystal 
being built of many repeated unit cells arranged together like bricks in a wall. 
Within the unit cell all atoms are assigned Cartesian co-ordinates (x, y and z) to 
define their position with one of the vertices selected as the origin and assigned the 
co-ordinates x=0.0, y=0.0 and z=0.0 (0,0,0). The edges of the unit cell are defined 
by 3 vectors a, b and c with lengths a, b and c. The angles separating these vectors 
are assigned as a, p and y, a generalised unit cell is shown figure A3.
F igu re A 3: T h e un it cell Z
X
Figure A3 The generalised Unit Cell with edges a, b and c and angles a, p, and y separating them.
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The unit cell may also possess its own internal symmetry, known as crystallographic 
symmetry, and the smallest unit within the unit cell that can be rotated and translated 
to form the unit cell is called the asymmetric unit. The combination of the shape of 
the unit cell and the possible internal symmetries within the unit cell give rise to the 
crystallographic ‘space group’. There are seven classified crystal systems that derive 
from the basic six dimensions of the unit cell as shown in table A l.
Table A l The fourteen Bravais Lattice
Name Bravais lattice types Lattice
Triclinic P a ^ b ^ c  a ^ p ^ y
Monoclinic P ,C a ^ b ^ c  a  = y = 90°^ P
Orthorhombic P, c, I, F a ^ b ^ c  a  = p = y = 90°
Tetragonal P ,I a = b ^  c a  = p = y = 90°
Trigonal P a = b = c a  = p = 90° y = 120°
orR a = b = c a  = p = y <120° ^  90°
Hexagonal P a = b ^  c a  = p = 90° y =  120°
Cubic P, I,F a = b = c a  = P = y = 90°
These seven crystal systems give rise to 14 Bravais lattices depending on the 
arrangement of lattice points within the unit cell. When combined with internal 
symmetry operators such as rotation, translation, inversion and screw axes gives rise 
to 230 space groups though only 65 are allowable for proteins due to the chiral 
nature of amino acids. (Blow, 2002)
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Bragg’s Law
W.L. Bragg was the first to discover in 1913 that diffraction of X-rays by crystals 
may be compared with reflection of light by two parallel planes (Bragg, 1913). This 
has given rise to Braggs Law which predicts the angle of reflection for any 
diffracted beam of X-rays by sets of parallel planes. For this diffraction to result in a 
‘diffraction spot’ constructive interference must take place and the path difference in 
the waves must be an integral number of wavelengths.
To demonstrate this rule consider the construct given in figure A 1.4 where two 
parallel planes (PI and P2) are separated by an interplanar space (d) and illuminated 
with X-rays at an angle of incidence and reflection (0) giving rise to the incident 
rays (1 and 2) and reflected waves (1 * and 2’).
For diffraction to occur the path difference between two waves must be an integral 
number of wavelengths apart to create constructive interference. In the construction 
above the path difference is equal to 2L.
2L = nA [1]
The length of L may also be expressed trigonometrically as;
L  =  d  sin0 [2]
Combining [1] with [2] gives Braggs Law;
nA = 2d sin0
As in X-ray crystallography the wavelength of the X-ray source (A) is known, and 
the angle, 0, can be measured directly. The interplanar spacing can be calculated for 
each measured reflection.
141
Figure A4 Bragg’s Law
Figure A4. Braggs Law occurs when two parallel planes (PI and P2) are illuminated with X-rays at 
an angle of incidence and reflection (0) and separated by an interplanar space (d) that is equal to an 
integral number of wavelengths.
Resolution
Resolution in crystallography is a measure of the minimum interplanar distances in
the measured dataset. Due to the atomic scale of crystallography the angstrom (A
- 1 0
=10 m) is the unit of measurement used. The resolution also determines the 
amount of information that can be drawn from a crystallographic structure as 
summarised on table A2.
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Table A2 Limits of resolution
Resolution (A ) Details Visible
The outline of the molecule and positions of secondary structural 
6.0A features such as helices and sheets.
The polypeptide backbone can be traces and with the amino acid
3.0 A sequence the peptide side chains can be fitted
Bound water molecules, co-factors, ions and ligands can be
2.0 A *
observed
Individual atoms are almost visble and details of solvent structure
1.5 A
are visible
Multiple confirmations of side chains are visible as are individual
1.0 A y
hydrogen atoms
From reflections to structure
In X-ray diffraction the X-rays striking the crystal are diffracted by the electron 
clouds around each atom and arrive at the detector in an ordered array of spots 
known as the diffraction pattern as shown below in figure A5. These spots are 
termed ‘reflections’ as they are diffracted from the crystal as if  reflected by planes of 
atoms, each spot representing a discrete plane of atoms.
The position of the spot can be measured accurately and assigned three indices in 
reciprocal space of the diffraction pattern. These indices, termed Miller indices, are 
designated by h, k and / with the central beam position taken as the origin with co­
ordinates (h,k,l) = (0,0,0) or hkl =000 and other reflections numbered as whole 
numbered co-ordinates counting out form this origin.
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Figure A5: A typical diffraction pattern
I0A3.5A,
2.5 A
Figure A5: An example of a diffraction pattern obtained at the SRS Daresbury. The black spots each 
represent one reflection and the large white circle in the centre is the beam stop that blocks the direct 
beam. The circles illustrate the resolution ranges as you move away from the direct beam. This data 
were collected with crystals of a complex between C3bot-RalA at station Al .6 at SRS Daresbury.
The greater the intensity of the X-rays reaching the detector the darker the spot and 
this may be measured by the optical absorbance. Thus from each reflection there are 
two piece of information available (1) the position, hkl, of the reflection and (2) the 
intensity, Ihki, of the reflection.
The Ewald sphere is a geometric construction that can aid in visualising the 
reciprocal lattice and is constructed from a sphere of radius 1A, drawn around the 
crystal position with the direct beam terminating at the origin of reciprocal space.
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Figure A6 The Ewald Sphere
Diffracted Beam
1 / X
D irect beamC rysta l
Figure A6: The Ewald sphere. A sphere of radius 1/A. is drawn around the crystal with the direct 
beam passing through the origin of the reciprocal lattice. A diffraction spot appears whenever the 
reciprocal lattice point contacts the Ewald sphere. Adapated from (Blow, 2002).
A diffraction ‘spot’ will be produced whenever the circle of radius 1A. touches a 
reciprocal lattice point, an example of this is shown in figure A6. When a reciprocal 
lattice point comes into contact with circle Bragg’s law is satisfied as the angle 
between the incoming and outgoing beams is 20 and the length of the vector, V, is 
1/dhki- Extrapolated into 3 dimensions as a crystal rotates in an X-ray beam different 
reciprocal lattice points come into the contact with the Ewald sphere and as they do 
so give rise to a diffraction spot conforming to a particular set of equivalent parallel 
real-space hkl planes (Rhodes, 2000; Blow, 2002).
The vector, amplitude and phase from a particular set of Bragg planes are termed the 
structure factor (F). The structure factors for the points of the crystal lattice 
correspond to a Fourier transform of the electron density at each point within the
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unit cell. The structure factor equation relies on treating the reflections as waves, 
and is permitted due to the electromagnetic nature of X-rays. The equation for a 
simple wave form can be defined as follows:
f(x) = F cos2n(hx + a)
Where f(x) specifies the height of the wave at any particular horizontal position 
measured in wavelengths. F specifies the amplitude; h specifies the frequency and a 
specifies the phase. In a structure factor calculation the contribution from every 
atom in the unit cell must be considered, however any waveform no matter the 
complexity can be described as the sum of many simple waveforms, where Fn is the 
contribution from atom n.; this is termed a Fourier series.
f(x) = Fo cos2n(0x + ao) + Fi cos2tc(7x + « ; ) . . . +  Fn cos27i(nx + a„)
In Fourier theory any periodic wave function may be used to describe the function 
and another basic wave description may be used in place of f(x) = F cos2n(hx + a);
f(x) = cos27r(hx) + i sin27i(hx)
In this equation the waveform is split into a complex number in the form of a + zb 
and the term cos27t(hx) + z sin27t(hx) can be compressed into e27Cl(hx). However the 
equations for electron density are 3 dimensional wave forms so the (hx) term must 
be expanded to (hx + ky +zx).
In terms of electron density the Fourier series must reflect the contribution of all the 
atoms in the unit cell and must include an additional term, jJ, that represents the 
scattering factor of the atom based upon a mathematical function treating the atom 
as a simple sphere of electron density and varies form element to element dependant 
on differing Z values (number of electrons) of the elements. This results in the 
structure factor equation having the following form:
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Fhki = E" „fj e2”i(hxj+kyj+zxj)
This describes the atomic structure factor of reflection hkl as a Fourier series with 
the amplitude contribution from its atomic type (fj) and its phase contribution from 
its location in the unit cell (xj, yj, zj). The same equation may also be written as the 
sum of contributions of electron density;
Fhki = Evp(x,y,z) e2”'<hx+ky+zx)dV
Where p(x,y,z) is the average value of a volume element centred at (x,y,z)9 and dV 
represents the total values of all the possible integral values of x,y and z in the unit 
cell. The volume elements taken are small enough so that the average density at each 
point becomes precisely equal to the value at that point.
Due to the reversible nature of a Fourier series this equation may be rewritten in 
terms of electron density as the transform of structure factors, where V is the volume 
of the unit cell;
p(x,y,z) = l / V S ^ F m  e'2' i<hx+ky+zx)
X-ray sources and data collection
The goal of data collection in an X-ray crystallography experiment is to collect a full 
data set accurately, rapidly and as efficiently as possible. To enable this there have 
been advances in technology at every stage of this processes including X-ray 
sources, detector design and data collection strategies and experimental design.
The most basic requirement of crystallography is an X-ray source that can produce 
intense, tightly focused monochromatic X-rays with wavelengths ranging from 0.5- 
1.6A. X-rays sources in protein crystallography are of one of two types; laboratory 
sources or Synchrotron radiation sources. Laboratory sources such as sealed tube or 
rotating anode devices accelerate electrons to approximately 45-50kV towards metal
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targets such as copper or molybdenum that then emit X-rays at a characteristic 
wavelength (CuKa =1.54A, MoKa =0.71 A). These X-rays are then filtered through 
a crystal monochromator before being focused by curved mirrors. Laboratory 
sources however are of quite low intensity and low flux and the inability to tune the 
wavelength results in some techniques such as MAD or MIR not being easy to 
exploit. Synchrotron radiation sources result in X-rays that are very intense with a 
very high flux, high brilliance and tuneable wavelengths. This allows very fast, high 
resolution data collection from crystals and the ability to select suitable wavelengths 
for Isomorphous replacement or anomalous scattering experiments. Synchrotron 
radiation is produced from particle storage rings where very high energy electrons 
(2GeV) are accelerate to 99% of the speed of light and as they are curved around the 
ring emit high energy X-rays. These X-rays are further tuned by insertion devices 
such as undulators and wigglers that cause additional bending of the light to further 
increase the radiation. Through a series of monchromators and focusing mirrors X- 
rays of a selected wavelength can then be focused on the crystal.
Detection of X-rays is an important part of the crystallographic process and there are 
several types of X-ray detector available to collect the diffraction pattern. In modem
X-ray experimental set-ups there are 3 types of detectors used: (1) Image plates are
2+
plastic sheets coated with phosphorescing crystals such as BaF:Eu that absorb the 
X-rays and can be read by laser scanners. (2) Area detectors combine a wide 
dynamic scanning range with the ability to read directly without a scanning step. 
They are constmcted from sets of perpendicular detector wires, one set is the anode, 
the perpendicular set the cathode and the X-rays hitting these wires are recorded. 
The most recent detector systems are (3) charge coupled devices (CCDs). These are 
solid state devices that are coated with phosphors that emit light when excited by X- 
rays. These are formed into arrays of pm sized pixels connected to optical fibres that 
directly count the photons.
Data collection can take place at either room temperature or at cryogenic 
temperatures. At room temperature crystals are mounted in thin walled glass
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capillary tubes partially filled with mother liquor. Glass capillaries are used as glass 
has minimal X-ray absorption and can be corrected for. Cryogenic data collection is 
the normal mode of data collection now for most biological macromolecules. In 
cryogenic data collection the crystals are flash frozen in a stream of liquid nitrogen 
(80-100K) into an amorphous glass. A cryoprotectant is added to prevent the 
formation of ice crystal during data collection. The cryogenic temperatures also 
prevent the diffusion of free radicals from the sites of radiation damage. Commonly 
used cryoprotectants include glycerol, various weight polyethylene glycols and 
xylitol. Cryogenic collection has the advantage of limiting the amount of radiation 
damage to the crystal by the X-ray beam giving the crystal a longer lifetime in the 
beam and allowing a complete dataset to be collected from a single crystal. It also 
reduces the mechanical stress on crystal allowing the use of smaller and more 
delicate crystals and allows collection at higher resolutions due to reductions in 
atomic thermal factors. Cryogenic collection unfortunately does have several 
drawbacks; it can lead to an increase in crystal mosaicity due to small unfavourable 
changes in the crystal and lead to small changes in the unit cell volume which can 
lead to non-isomorphism between native and heavy metal data sets. Finally if the 
cryoprotectant is not optimal it may lead to the formation of ice rings that interfere 
with the diffraction information from the protein.
Data collection is a complex process and in order to collect a high quality data set it 
is important to formulate the correct strategy based upon the quality of the crystal 
and the X-ray experimental set-up. A preliminary examination of a single diffraction 
image can supply information on the unit cell, internal symmetry and the resolution 
limit of the crystal. This information can then be used to formulate a data collection 
strategy that will maximise the amount of reflections recorded. There are many 
factors that must be considered and these include: crystal to detector distance, 
exposure time, mosaicity and oscillation of the crystal. The crystal to detector 
distance determines the resolution the data can be collected to and has an effect on 
the spot size on the diffraction pattern. Longer exposure times can increase the 
intensity each spot allowing better recording of weak high resolution reflections.
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Long exposure times can also lead to overloads as spots become saturated and 
longer exposure times lead to an increase in radiation damage to crystals. The 
molecules in a protein crystal do not form a perfect lattice but a mosaic of roughly 
aligned structures. The amount of disorder in a crystal is termed the ‘mosaicity’ and 
causes the tight collimated X-ray beam to become spread into a narrow cone. This 
results in some reflections being spread over two or more images. These reflections 
are termed partial reflection while reflections recorded as a single image are fu ll 
reflections. As the mosaicity increases the amount of partial reflections increase and 
the spots are broadened, high levels of mosaicity result in spots overlapping and data 
being lost. The angle of oscillation required to collect a complete data set is related 
to the symmetry of the unit cell. As Friedel’s law states that reflection hkl is 
equivalent to -h-k-l rotation of 180° will result in a complete dataset being collected. 
In higher symmetry unit cells the angle of rotation required is less as there are more 
symmetrically related reflections. In practice data collection is carried out over a 
larger range of oscillation than required to increase the redundancy of the data to 
improve the signal-to-noise ratio (Blundell & Johnson, 1976; Rhodes, 2000; Blow, 
2002).
Data reduction and scaling
Data reduction and scaling involves processing the raw data collected to index each 
reflection in a diffraction pattern and then scaling all of the patterns into a complete 
dataset of indices and measured intensities. This process can be automated using one 
of several computer programs, the HKL package (Otwinowski, 1993a; Otwinowski, 
1993b) and MOSFILM (CCP4, 1994) being the most commonly used. The HKL 
package consists of 3 separate programs: (1) DENZO- which carries out 
autoindexing, refinement and integration of each image. (2) XdisplayF- for 
visualising each mage and intensity measurements. (3) SCALEPACK- for scaling of 
the indexed dataset. With increased speed of detector readout and data processing 
the indexing and data collection can be performed in synchrony giving a real time 
assessment of the quality of the data being collected (Otwinowski, 1993a;
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Otwinowski, 1993b). In autoindexing Fast Fourier Transforms are used to determine 
the values for indices in each direction, equivalent to finding the independent real 
space axes, and then once indices are determined in all three directions a set of 
possible lattices are selected based on the rules of symmetry laid down in the 
International Tables for Crystallography (Hahn, 1987). The unit cell lattice with the 
highest symmetry and least amount of distortion is used as an initial reference for 
the rest of the data processing. A complete dataset may include distinct blocks of 
data from different crystals or different areas of the same crystal, the intensity of the 
X-ray beam may vary over the time course of the experiment and radiation induced 
damage may adversely affect diffraction from the crystal. These factors result in the 
absolute intensities not being consistent from one block of data to the next. For this 
reason the data requires scaling. Scaling requires comparing reflections of the same 
index but in different blocks of data and rescaling the intensities so that they become 
identical relative to each other. SCALEPACK in the HKL suite performs this 
process and the quality of the data may be monitored through three statistical 
measures. The completeness is measure of how inclusive the data is and is 
calculated by dividing the number of unique reflections measured by the total 
number of unique reflections possible. A completeness of less than 95% may 
indicate a problem in the data collection strategy. The signal to noise ratio, or I/oI, is 
the ratio of intensity divided by the error in intensity. The I/oI effectively defines the 
resolution limit as data with an I/gI of less than two cannot be reliably distinguished 
from the background and cannot be used. Finally the Rsym gives an indication of the 
reliability of the data by comparing the mean difference between the symmetrical 
related reflections to the man magnitude of the measured values and is calculated 
from the following equation:
Rsym =  S ; |Ih -  Ihi 1 x l  0 0
£ h  2 j  Ihi
Where Ih is the weighted mean measured intensity of the observations Ihi- Essentially 
the Rsym is a measure of the disagreement between the symmetrical related intensities
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that should be identical. For a typical dataset of 2A an acceptable Rsym ranges from 
10-12%. (Blow, 2002)
The phase problem
When X-rays are diffracted by a crystal they give rise to reflections that correspond 
to points in the reciprocal lattice. Each reflection therefore represents a wave with 
both amplitude and a phase. However when the diffracted ray hits the detector all of 
the phase information is lost and only the amplitude, intensity, of the wave can be 
recorded. This loss of phase information is known as the “phase problem ” There 
are several methods that can be utilised to solve this problem: (1) Molecular 
replacement (MR) that involves using a previously solved similar structure as a 
search model to obtain initial phase information (Rossmann & Blow, 1962). (2) 
Isomorphous replacement (IR) that involves soaking several heavy metals into the 
structure and estimating the phases from the changes in the vector components of 
the hkl co-ordinates (Green et al, 1954). (3) Anomalous scattering involves the use 
of an atom that has its absorption frequency close to the wavelength of the X-ray 
source and phase information is gleaned from disruptions to Friedel’s law 
(Hendrickson, 1991).
Molecular replacement
Molecular replacement relies on starting with a search model that has a good degree 
of similarity to the target molecule. One of the most important factors that determine 
the success of molecular replacement is the quality of the search model chosen. A 
sequence identify of at least 30% is generally needed to find a solution. A well 
refined structure search model of at least 2.0-2.5A will also result in calculated 
phases that are closer to the true (observed) phases.
The next step is to obtain a rotation matrix, [R], and translation vector, t, to apply to 
the search model, M, to solve the solution of the target structure, X:
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X=  [R]M+ t
This search is a six dimensional search involving 3 rotational and 3 translational 
parameters. This can be solved be separating the search into 2 3-dimensional 
searches: one for the rotation matrix, the second for the translation vector as shown 
in figure A7.






F i g u r e  A 7 :  A schematic o f  the steps involved in molecular replacement. This involves rotating a 
search model by a rotation matrix [R] and applying a translation vector (t) to find the target molecule.
These searches are performed by calculating the structure factors for the search 
model and using the Patterson function. The Patterson function is used as it relies 
only on the squared intensities of the data and requires no phase information. An 
intramolecular Patterson map is independent of the positions of the atoms within the 
unit cell and comparing the intramolecular maps of the targets and search model can 
supply the correct rotation matrix to apply to the search model. Once the rotation 
matrix has been applied to the search model and intermolecular Patterson function is 
performed to supply the translation vector to place the search model in the correct 
position within the unit cell (Rossmann & Blow, 1962). There are several programs 
available that automate this process including AMoRe (Automated Molecular
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Replacement) (Navaza, 1994), MolRep (Vagin & Teplyakov, 1997) and most 
recently PHASER (McCoy et al, 2005) all of which are part o f the CCP4 program 
suite (CCP4, 1994).
Isomorphous replacement
Isomorphous replacement relies upon adding heavy atoms to the molecule in an 
effort to perturb the structure factors and from the manner in which they are 
perturbed make an informed deduction of the likely phase (Green et al, 1954). In 
practice two data sets are collected, one with the native protein and the second with 
the heavy metal derivative soaked protein. The atoms in this case are ‘heavy’ in the 
sense that they possess many more electrons and as atoms scatter proportionally to 
the square of the number of electrons a few heavy atom may have an obvious effect. 
For example a uranium atom will have a contribution equivalent to 225 carbon 
atoms as it possesses 15 times as many electrons. It is important when using heavy 
metal soaked crystals that the heavy metals replace are integrated into the crystal 
without significant disruption to the crystal lattice and that the only differences in 
the dataset are due to the heavy metals.
By treating structure factors as vectors it is possible to construct the following 
equation in which the structure factors for the heavy metal derivative, Fph, represents 
the structure factor of the heavy metals, Fh, plus the structure factors of the protein, 
Fp. This vector addition results in two possible phases for Fp if the vectors are added 
together to form a pair of triangles as shown below in figure A8.
To resolve the ambiguity between the two solutions a second derivative may be 
prepared that binds to the protein at different sites to the first one, in this case the 
technique is labelled multiple isomorphous replacement (MIR). The information 
derived from the second heavy metal will prove consistent with only of the two 
possible solutions for the phase. As shown in figure A8B adding a second
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derivative, Fh2 , gives two possible phases for the protein, Fpi and Fp3 , however only 
one of these will be in agreement with the phases obtained from the first soak.
F i g u r e  A 8 :  V e c t o r  s u m m a t i o n  f o r  i s o m o r p h o u s  r e p l a c e m e n t  a n d  a n o m a l o u s  s c a t t e r i n g
A
F i g u r e  A 8 :  A .  Summing o f  vectors results in two possible phases for FP. B. When a second  
derivative is added there will be only choice o f  FP that fits both solutions.
In practice errors in the model for the heavy atoms in the derivative crystal, errors in 
measuring the amplitudes of the structure factors and tiny changes to the crystal 
lattice mean that the vectors do not exactly meet up and the points where they meet 
become smeared. The ambiguity is related to lack of closure between the vectors and 
is monitored by the value Rcuiiis- A high value of Rcuiiis may indicate that the 
derivative data set is unusable (Rhodes, 2000; Blow, 2002).
Anomalous scattering
Anomalous scattering/ dispersion also relies on certain properties of heavy metals. 
In anomalous scattering it is the small changes in phase and amplitude that occur 
when the wavelength of the X-rays lie near the absorption edge of the heavy metal. 
It is this small change in both amplitude and phase that gives the technique its name. 
The lighter atoms of the protein do not exhibit this behaviour as their absorption 
edges lie far from the range of wavelength used in crystallography. The most
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common use of this technique now relies on introducing selenomethionine into the 
protein structure in place of methionine as the selenium will give strong anomalous 
dispersion within the range of wavelengths commonly used in synchrotron sources 
(Hendrickson, 1991).
The effect of anomalous scattering is to break Friedel’s law as the amplitude of the 
mates is no longer equal. That is the amplitude of (h k 1) ^  (-h -k  -1). This alteration 
in the amplitudes in the structure factors of Friedel pairs can be illustrated by vectors 
on a Harker diagram in a similar manner to that of Isomorphous replacement. By 
performing the data collection at several wavelengths around the absorption edge we 
can build up a Harker diagram with multiple solutions analogous to that built in 
MIR. Using multiple wavelengths to obtain the phases is called multiple- 
wavelength anomalous dispersion (MAD) (Blow, 2002) (Rhodes, 2000).
Model building and refinement
The phases obtained from molecular replacement, isomorphous replacement or 
anomalous scattering can then be used to construct a model of the structure in a 
molecular graphics programs such as O (Jones et al, 1991) or COOT (Emsley & 
Cowtan, 2004). This allows an electron density map of the phases to be displayed 
and a model of the protein structure to be fitted into it. In the case of molecular 
replacement this can be done fairly quickly if the search model used is sufficiently 
similar to the target protein. In the case of novel proteins or proteins that have no 
suitable relatives then the entire protein must be fitted carefully into the electron 
density map. This can however now be automated by several programs such as 
ARP/wARP (Lamzin & Wilson, 1993) or SOLVE/RESOLVE (Terwilliger & 
Berendzen, 1999; Terwilliger, 2002). This initial model is then ready for refinement.
To improve the quality of the electron density and obtain a high quality interpretable 
structure the model obtained from molecular replacement, MIR or MAD must be 
refined. Refinement is a cyclical process in which the aim is to improve the
156
agreement between the observed data and the atomic model. Iterative cycles 
continue to improve the fit between the observed and calculated data allowing for 
improvement in phases and the observation of finer details of the structure. Every 
atom has at least 4 parameters (an x, y and z co-ordinate, B-factor and sometimes 
the occupancy) which leads to a poor observation : parameter ratio and overfitting of 
the data is possible so validation is an important aspect of refinement. The 
traditional method of measuring validation is by monitoring the R factor, the 
fractional agreement between the observed and calculated structure factors.
R c ry s t  =  2  IIFnhsl -  IFcalcIl 
2 |F o b s |
Where F 0bS represents the structure factors derived from the recorded intensities and 
Fcaic represents the calculated structure factors of the current model. The standard 
technique to avoid overfitting the data is to exclude a test-set of data (5-10%) from 
refinement. This test set is then used to calculate Rfree which uses only this sub-set of 
data and avoids the problem of overfitting leading to a more valid model. This 
process, known as cross-validation, was first introduced by Alex Briinger (Briinger,
1992).
The target for crystallographic refinement is the search for a global energy minimum 
and can be expressed by the following equation:
E Echem WxrayExray
Where Echem is the empirical potential energy for all the atoms describing covalent 
and non-covalent interactions, Wxray is the weighting given to each term and can be 
critical in achieving a valid model and Exray represents the difference between the 
observed and calculated diffraction data.
Echem = 2  kb(r-r0)  +  2  ke(d-60)  +  2  k^cos(n<p -d )  +  S  km(co-co0)  +  2  (ar + br +  cr )
bonds angles dihedrals chiral, planar atom pairs
157
The parameters of EChem stem from experimental and theoretical observations and by 
introducing these restraints it is possible to improve the ratio of refined parameters : 
observations as the restraints introduced force a parameter to have certain values or 
set up relationships between different parameters.
In order to improve the model and find the global energy minima of the target 
function complicated mathematical optimisation programs are used. The two main 
methods o f optimisation employed in crystallography software use either Least 
Square (LSQ) method or a maximum likelihood model for optimising the target 
function. LSQ moves the target function to the weighted sum of squares of the 
differences between the observed and calculated quantities. Though LSQ methods 
may have problems with the many local minima of the target function and rely on 
the assumption that initial phase is correct. Maximum likelihood selects the model 
that is most consistent with the observed data, the consistency being a ratio between 
the probable and all the possible models. In order to utilise a maximum likelihood 
optimisation method it is important to account for all sources of error, including co­
ordinate errors, missing atoms and errors in the B-factors. The B-factors represent 
the thermal motion of each atom and large B-factors can indicate errors in the 
model.
Practically this optimisation is achieved through simulated annealing. Annealing is a 
physical process in which a solid is heated to a sufficient temperature to form a 
liquid of randomly arranged particles and then slowly cooled in order for the 
particles to order themselves in the lowest energy state. In simulated annealing the 
model is ‘heated’ to a temperature of 5000K and then slowly cooled in small steps to 
fall into the lowest energy state to improve the quality of the model. The most 
common refinement programs used are REFMAC (Murshudov et al, 1997), as part 
of the CCP4 suite, (CCP4, 1994) and CNS (Briinger et al, 1998). With each cycle of 
refinement the parameters defining each atom are brought closer to the observed 
values. Each atom may be defined by at least 6 parameters: three spatial co-ordinates
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(x, y, z), the scattering factor, the occupancy and the B-factor. Neither of these 
optimisation protocols can correct large errors in the model however. In order to 
correct gross errors manual rebuilding of the model in molecular graphics such as O 
(Jones et al, 1991) or COOT (Emsley & Cowtan, 2004) must be performed with aid 
of the electron density maps calculated from a given set of phases. The electron 
density maps normally used are the 2F0bs-FCaic and the F0bS-FCa]c maps. The F0bS-Fcaic 
highlight areas in the electron density that show the greatest disagreement between 
the observed and calculated phases and can also be used to identify the location of 
solvent atoms, ions or ligands that are present in the crystalline lattice. Solvent 
atoms can be added automatically to a model during refinement by the 
WATERPICK module of CNS (Briinger et al, 1998). Ligand molecules and ions 
generally have to be added manually and the atomic models and parameters of 
common ligands and ions can be accessed from web based databases such as the 
Hicup web-server (Kleywegt & Jones, 1998). Manual rebuilding to correct gross 
errors leads to an improved model that can then be further refined to give a better 
agreement between the observed and calculated data and lead to an improvement in 
the R factor. This iterative process of refinement followed by manual rebuilding 
continues until no further rebuilding can be performed and the structure has a 
satisfactory R-factor and satisfies a range of validation criteria. Satisfactory values 
for both Rcryst and R/ree are approximately 0.2 for R cryst and 0.25-0 .28 for Rfree (Blow,
2002).
Structural analysis, validation and deposition
Once a model structure has been refined to a suitable Rcryst there are several 
programs and methods available to ascertain the validity of the structure. The most 
commonly used method to evaluate of the geometry is the Ramachandran plot. This 
is a method to assess the (p and \jt angles of the polypeptide backbone to ensure that 
they lie within the allowed ranges to form secondary structure elements. An 
indicator of the accuracy of the structure may also be taken from the root mean 
square deviation (RMSD) of bond angles and bond lengths from the ideal. In the
159
case of a well refined structure the RMSD of the bond lengths should be 0.005- 
0.010A. The program PROCHECK (LaSkowski et al, 1993) assesses various factors 
o f the overall geometry of the structure including bond lengths, bond angles, torsion 
angles of side chains and planarity of aromatic rings. The role of PROCHECK in 
this is to assess how closely the values of these parameters in the model match those 
of the ‘ideals’ and highlight residues or parts of the model that have chemically 
unfavourable parameters and may indicate a poor model. The web based servers 
“What i f ’ (Vriend, 1990) and “MolProbity” (Davis et al, 2004) are alternatives to 
PROCHECK and validate the structure based on the same chemical criteria.
If these all point to a valid and structurally sound model then the functional analysis 
of the structure can be performed. Examination of the intra- and intermolecular 
interactions, ligand binding sites and superposition of the native structure over 
mutant or wildtype structures yield a large of amount important information on 
protein structure and function. Additionally structures involving large multi-domain 
proteins can illustrate important information about domain folding and domain 
architecture while structures of protein complexes can give important insights into 
the nature of protein-protein interactions and the protein-protein recognition. To 
assist in this process there are many programs that are designed to assist in this 
process such as parts of the CNS program (Briinger et al, 1998) or programs such as 
CONTACT and AREAIMOL in the CCP4 program suite (CCP4, 1994).
Once a structure has been completed it can then be submitted to the Protein Data 
Bank (PDB) (Bernstein et al, 1977), which is a global repository of all X-ray, NMR 
and theoretical models. Deposition normally involves depositing the atomic co­
ordinates, structure factors and experimental details with the PDB through an online 
deposition program such as AutoDep.
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Appendix B
Bacterial pathogens that utilise Type III secretion systems
Enteric pathogens lead to very large amounts of morbidity and mortality worldwide 
and are a major focus for microbial, genetic and medical research. These gram 
negative gastrointestinal pathogens have evolved a large number of strategies 
designed to withstand the diverse responses of the immune system, rapidly colonise 
a host and cause disease. Genetic analysis of pathogenic bacteria has shown that 
many of the proteins and virulence factors responsible for harmful effects of these 
enteropathogens are organised into genetic clusters termed pathogenicity islands and 
it is the presence of these pathogenicity islands that are linked to the disease causing 
effects of the bacteria. These pathogenicity islands may be shared through horizontal 
gene transfer allowing many species of otherwise unrelated bacteria to harbour 
closely related virulence genes. The type III secretion system (TTSS) is an example 
of this possessing an elaborate and complex secretion system that is found in 
organisms as distantly related as the Yersinia and Erwinia species (Hueck, 1998). 
The type III secretion system is an elaborate organisation of genes that results in a 
contact dependant ‘syringe’ that injects virulence factors into host cells directly 
crossing the bacterial inner and outer membrane and the host outer membrane in one 
step. This enables pathogens to directly inject effector protein into the cytosol of the 
host cell where they may interact with their cellular targets resulting in the 
symptoms of pathogenisis. This specialised system is large with over 20 proteins 
forming the secretion apparatus and are conserved across the whole range of bacteria 
possessing this system suggesting a common ancestor (Hueck, 1998) (Galan & 
Bliska, 1996). The range of bacteria that posses this TTSS is very large and includes 
many human pathogens that are responsible for highly dangerous diseases such as 
the Yersinia spp. (bubonic plague and tuberculosis), Salmonella spp (typhoid fever 
and gastroenteritis), Shigella flexneri (dysentery), enteropthaogenic (EPEC) and 
enterohemorrhagic (EHEC) Escherichia coli, Burkholderia pseudomallei 
(mellidosis), Pseudomonas aeruginosa, Chylamidia pisitachii (chlamydia), the
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animal pathogen Heamophilus somnus and several plant pathogens including 
Pseudomonas syringae, Ralstonia spp, Erwinia spp and Xanthomonas spp. Type III 
secretion (TTSS) is the most complex of the bacterial secretion systems. It allows 
bacteria to in one step translocate toxins directly into the cytosol of a eukaryotic cell 
bypassing the periplasm and the eukaryotic membrane entirely. The TTSS was first 
discovered in Yersinia (Rosqvist et al, 1994) and has been extensively studied in the 
three Yersinia species, Y. pestis, Y. pseudotuberculosis and Y. enterocolitica. The 
TTSS apparatus is highly complex and features cytoplasmic, transmembrane and 
extracellular domains (Blocker et al, 2001). The cytoplasmic and transmembrane 
domains combine to form the basal body that is responsible for protein export and 
provide the energy for the transport of the effectors into the eukaryotic cells. The 
basal body is composed of a large number of different proteins, 24 in Yersinia 
(Comelis et al, 1998) of which 11 are common to nearly every gram negative 
bacteria possessing a TTSS (Hueck, 1998). Many of the proteins common to the 
basal body also exhibit similarity to proteins found in the bacterial flagellar system 
(Galan & Bliska, 1996; Hueck, 1998). The basal body also possesses an ATPase that 
is required to drive the proteins through the needle complex (Comelis, 2000b; 
Hueck, 1998). Is common to all o f the TTSS found to date and is one of the most 
highly conserved constituents of the TTSS aparatus. In Yersinia, the ATPase, YscN 
shows a high degree of similarity to the a  and p sub-units of the Fi component of the 
bacterial FoFi proton translocating ATPase. Although its precise location is still 
unknown its similarity to the soluble Fi component of the ATPase suggests that it is 
cytosolic and associates with the membrane bound proteins that form the secretion 
apparatus (Hueck, 1998). The basal body itself is comprised of two upper and two 
lower rings that cement a long needle to the bacterial membrane and an example of 
this shown in figure B l . l . The basal body structure has a pore through the centre of 
it, approximately 25A in diameter that runs the full length of the needle through the 
pore at the other end gaining direct access to the eukaryotic cytosol. All effector 
molecules, either fully or partially unfolded must pass through this pore. Although 
the basal body is composed of many proteins there are believed to be three main 
proteins that form the bulk of the assembly. These were originally identified from
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the Salmonella TTSS apparatus (Kimbrough & Miller, 2000; Sukhan et al, 2001; 
Yip et al, 2005) and include InvG, PrgK and PrgH. InvG which has orthologues in 
Yersinia (YscD), Shigella (MxiD) and EPEC (EscC) is a member of the secretin 
superfamily and forms a large multimeric annular complex in the outer membrane 
that can mediate protein passage (Crago & Koronakis, 1998) PrgK similarly has 
orthologues present in other TTSS bacteria; MxiJ {Shigella), YscJ (Yersinia) and 
EscJ (EPEC). PrgH however has one ortholgue found so far, MxiG in Shigella. 
PrgH and PrgK are both believed to be associated with the inner membrane of the 
bacteria and form the base of the basal body though little is known about PrgH. The 
structure of EPEC orthologue of PrgK, EscJ, has been determined (Yip et al, 2005) 
and has been modelled as a 24 monomer ring structure with extensive regularly 
spaced charged regions that may act as anchoring points for the other 
transmembrane components of the basal body in EPEC cells such as EscR, EscS, 
EscT, EscU and EscV. A deep negatively charged trench on the periplasmic side of 
the ring may also act as an anchor for the needle-like superhelix of EscF that forms 
the syringe like needle that protrudes from the membrane into the extracellular 
environment (Yip et al, 2005). The dimensions of the needle itself vary from 
bacteria to bacteria and in EPEC the length can vary from 75-260nm with a diameter 
of 10-12nm (Daniell et al, 2001) though the needle itself is formed from a 
superhelix of a single protein. In Yersinia the length of the needle formed by 
monomers of YscF is controlled by YscP that acts as a molecular ruler to halt the 
extension of the needle when YscP is fully extended from tip of the nascent needle 
to the base of YscP that is anchored in the membrane (Joumet et al, 2003). The 
NMR structure of the needle protein, BsaL, from Burkholderia pseudomallei has 
been determined (Zhang et al, 2006) and is seen to be a small 2-helix bundle 
stabilised by inter-helix hydrophobic contacts that can be modelled to form a large 
superhelix needle structure. The needle may also carry an extension at the tip that is 
involved in the penetration of and pore forming at the eukaryotic membrane. The 
structures of two extension proteins, EspA from EPEC (Yip et al, 2005) and LcrV 
from Yersinia (Derewenda et al, 2004) has been determined. EspA is part of the 
needle extension proteins in the EPEC needle whilst LcrV acts to insert the tip of the
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Yersinia translocon into the eukaryotic membrane and form part of the pore through 
the eukaryotic membrane (Derewenda et al, 2004).
Figure B1 Schematic diagram of a typical TTSS apparatus
BsaL
EscJ
Figure B l. A typical TTSS needle showing the two ring structure o f the basal body andthe needle 
like projection with its extension and pore tip complex. The bacterial inner (IM) and outer 
membranes (OM) and eukaryotic membrane (EM) are shown as well. Recently determined 
components of the TTSS are shown as well. The needle protein BsaL from B. pseudomallei [PDB 
code 2GOU] (L. Zhang et al, 2006) and the basal body protein EscJ from E.coli [PDB code 1YJ7] 
(Yip et al, 2005) are shown.
Though many of the components of the TTSS apparatus are known there is little 
structural information on most of them as the majority exist in multimeric states or 
are membrane associated. A generic TTSS needle is shown in figure Bl alongside 
the determined structures of the known TTSS components. While the components of 
the TTSS apparatus have shared sequence and structural homology the range of 
virulence factors and effectors and chaperones vary widely between bacterial 












been determined showing the diversity of the TTSS. A selection of effectors and 
chaperones are shown below in figures B2 and B3 respectively. Bacterial specific 
effectors and chaperones are discussed in more detail below.







Figure B2. The structures of a selection of TTSS effectors. They include HrcQB [PDB code 109Y] 
(Fadouloglou et al, 2004) YopM [PDB code 1G9U] (Evdokimov et al, 2001) and YopH [PDB code 
1QZO] (Phan et al, 2003) from Yersinia, AvrPphF [PDB code 1S21] (Singer et al, 2004), and 
AvrpPhB [PDB code 1UKF] (Zhu et al, 2004) from Pseudomonas syringae, Tir [PDB code 1F02] 
(Luo et al, 2000) from E.coli, SptP [PDB code 1G4W] from Salmonella (Stebbins & Galan, 2000), 
secretin [PDB code 1Y9L] (Lario et al, 2005) from Shigella and ExoS [PDB code 1HE1] (Wurtele et 
al, 2001) from Psuedomonas aeruginosa.
AvrPphF
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Figure B3 A selection of TTSS effector chaperone structures
AvrpPhF chaperone
SycT
Figure B3. A selection of TTSS chaperone molecules. These include the Yersinia chaperone SycT 
[PDB code 2BHO] (Locher et al, 2005), the P. syringae chaperone AvrpPhF [PDB code 1S21] 
(Singer et al, 2004) and the generic chaperone Spal5 [PDB code 1RY9] (van Eerde et al, 2004) from 
Shigella flexneri.
TTSS in Yersinia spp.
There are 3 Yersinia species that have been found to be pathogenic to human and 
rodents. They are: Y. pestis the causative agent of bubonic plague; Y enterocolita 
that causes a broad range of gastrointestinal problems (Hueck, 1998) and Y  
pseudotuberculosis that also causes gastrointestinal problems. Yersinia enterocolita 
and Yersinia pseudo tuberculosis are transmitted via contaminated foods and water 
(Hueck, 1998) where they localise to the small and large intestine and Peyer’s
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patches. The bacteria colonise the Peyer’s patches and are taken up by M-cells 
(Zaharik et al, 2002). The bacteria may then destroy the M-cells thus gaining access 
to the underlying tissue and bypassing the epithelial barrier. Invasin mediated uptake 
via pi-integrin promotes efficient bacterial attachment and entry into the M-cells 
(Bergman et al, 1994). Once through the epithelial barriers and through the M-cells 
the Yersinia can then enter the lymphatic system (Hanski et al, 1989; Siebers & 
Finlay, 1996). Y. pestis infections initiated by fleabite result in the development of 
bubonic or septicemic plague (Perry & Fetherston, 1997). Symptoms of plague 
include fever, headaches, local edema and swelling regional lymph nodes that 
results in black swellings called buboes. Septicemic plague occurs when the bacteria 
bypass the lymphatic system and enter the bloodstream and disseminate around the 
body. In all 3 species once the bacteria enter the lymph system they are disseminated 
around the body and gather near the spleen and liver where the replicate rapidly in 
the extracellular space leading to necrotic lesions and eventual death (Holmstrom et 
al, 1995; Straley & Cibull, 1989). The ability of yersinia to disseminate via the 
lymphatic system and replicate extracellularly stems from its unusual ability to 
evade the immune system in which the TTSS plays a crucial role. It does this 
through three general methods: (Aepfelbacher, 2004) Antagonising uptake by 
phagocytes and other immunological components allowing it replicate 
extracellularly (Hacker et al, 1997; Hanski et al, 1991; Simonet et al, 1990; 
Aepfelbacher, 2004). Counteracting pro-inflammatory cytokine release; and 
(Aepfelbacher, 2004) Apoptosis of macrophages (Ruckdeschel, 2002; Zhang & 
Bliska, 2005). These three effects are brought about wholly by the TTSS of the 
Yersinia bacteria. The TTSS apparatus is found on a single 70kB plasmid in 
Yersinia called the pYV plasmid that contains the genes encoding the TTSS needle, 
the secreted effectors, regulators of Yop secretion/translocation and the adhesion 
YadA that can mediate attachment and uptake of Yersinia by M-cells (Comelis, 
1998; Hoiczyk et al, 2000). The Yersinia TTSS apparatus was discovered in the 
1900’s through investigation into the calcium and temperature dependence of 
Yersinia (Michiels et al, 1990) where it was noticed that Yersinia, in the absence of 
Ca2+ ions and at 37°C, do not grow, but instead, secrete large numbers of proteins
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into media. This led to genetic analysis that identified the 29 Yop secretion genes 
(Bergman et al, 1994) involved in the TTSS needle, the eight effector Yersinia outer 
proteins (Aepfelbacher, 2004) and their specific Yop chaperones (Buttner et al, 
2005). Of the 29 Ysc proteins involved 10 have orthologs found in all other TTSS 
identified. YscC is a secretin protein and forms a 200A ring in the outermembrane 
with 50A pore in the centre of it and is linked with another lipoprotein YscW 
(Koster et al, 1997) YscD, -R, -U, -V, -S and -T  have been shown to span the inner 
membrane (Comelis, 2000a) and interacts with the cytoplasmic ATPase YscN 
(Woestyn et al, 1994). The function of YscJ, the counterpart to EscJ in E.coli, is not 
known yet though it is probable that it spans the inner and outermembranes in a 
similar manner to EscJ (Yip et al, 2005). While the Ysc genes that form components 
of the injectisome are conserved in many other TTSS there is a much larger 
variation amongst the effectors produced.
There are three broad categories of effector produced by Yersinia spp: 
(Aepfelbacher, 2004) Mediators that regulate secretion and expression of other 
Yops; (2) translocators that play an important role in transporting the cytotoxic Yops 
into the host cells; and (3) the Yops with direct antihost functions (Hueck, 1998). 
YopN is the most well studied of the regulatory effectors and is directly responsible 
for the Ca2+ dependant nature of Yop secretion by acting as calcium sensor (Boland 
et al, 1996; Forsberg et al, 1991; Torruellas et al, 2005). YopN in complex with 
YscB (Day & Plano, 1998) and another protein termed TyeA (Iriarte et al, 1998) 
blocks the secretion channel from the bacterial cytosol (Cheng et al, 2001) until 
contact with a eukaryotic cell occurs accompanied by an increase in temperature to 
37°C and a drop in Ca2+ levels. When a drop in Ca2+ ions is registered by the needle 
protein, YscF, it undergoes a conformational change that results in the YscD-YopN- 
TyeA complex moving and subsequently leaving the channel unobstructed for the 
secretion of the cytotoxic Yops (Day et al, 2003; Hoiczyk & Blobel, 2001; 
Torruellas et al, 2005). The recent structure of the YscD-YopN-TyeA offered 
structural details on how this pore blocking and unblocking can occur (Schubot et 
al, 2005). There are three translocation associated effectors in Yersinia: YopB,
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YopD and LcrV. All of these are necessary to form a pore in the eukaryotic 
membrane to allow the efficient translocation of the cytotoxic yops directly into the 
host cytoplasm (Boland et al, 1996; Comelis, 2002c; Hakansson et al, 1996; 
Ramamurthi & Schneewind, 2002). Both YopB and YopD show hydrophobic 
domains in their sequence (Hakansson et al, 1993). YopB contains a domain 
reminiscent of the RTX toxins (Hueck, 1998) and both have been show to be able to 
form pores in liposomes (Comelis, 2002b). In addition to the pore forming 
translocases there is also YopK a modulator of YopB/D that is essential for 
translocation of effectors across the eukaryotic membrane (Holmstrom et al, 1997).
The Yop effectors
There are 6 well characterised effectors that have been found to contribute to the 
anti-phagocytotic and pathogenic effects of Yersinia spp: YopH, a phosphotyrosine 
phosphatase, YopE, a Rho-GAP, YopT, a cysteine protease, YopJ, a cysteine 
protease, YopO, a serine/threonine kinase and YopM, a leucine rich protein.
YopH is a 468 residue protein tyrosine phosphatase. It has distinct N and C terminal 
domains linked by a proline rich linker region and structures of the individual 
domains have been determined. The N-terminal domain contains a TTSS secretion 
signal, the chaperone binding site and a cleft that functions as a substrate targeting 
domain, binding directly to tyrosine phosphorylated proteins (Khandelwal et al,
2002). The C-terminal domain contains the active site phosphate binding loop with 
the characteristic C(X)sR(S/T) motif and a second substrate targeting site (Ivanov et 
al, 2005; Zhang & Bliska, 2003). The catalytic activity of YopH inhibits several 
phagocytotic pathways (Fallman et al, 1997) including the pi-integrin pathway 
required for phagocytosis and in doing so inhibits oxidative bursts by preventing 
degranulation in neutrophils (Persson et al, 1999) along with suppressing the release 
of macrophage chemoattractant protein 1 (Sauvonnet et al, 2002).
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The targets for YopH include focal adhesion kinase (FAK), Fyn-binding protein 
(Fyb) and Crk-associated substrate (Cas) all of which are involved in activation of 
Rac-1 GTPase leading to actin polymerisation and internalisation of bacteria 
(Aepfelbacher, 2004; Comelis, 2002a; Isberg & Bames, 2001; Weidow et al, 2000). 
The importance of YopH has been shown in mice assays were a YopH null mutant 
was attenuated over 3.4million fold (Kerschen et al, 2004).
YopJ (also called YopP in Yersinia enterocolita) acts as a potent inhibitor of the 
MAPK and NF-kB signalling pathways and results in blocking of cytokine 
production and induction of apoptosis in macrophages (Aepfelbacher, 2004; 
Aepfelbacher et al, 1999; Ruckdeschel, 2002; Zhang & Bliska, 2005). YopJ is a 288 
residue cysteine protease of the CE clan (Viboud & Bliska, 2005) that is thought to 
cleave ubiquitin or a ubiquitin-like modification on its targets marking them for 
destruction. As the NF-kB pathway is controlled at several stages by ubiquination 
the exact target of YopJ being unknown at present (Orth, 2002). The importance of 
YopJ in infection is still unclear as with mouse studies YopJ null mutants showed a 
1.5 fold or 64 fold change in virulence in Y. pestis (Perry & Fetherston, 1997) and Y. 
pseudotuberculoisis (Monack et al, 1998) respectively.
The YopM protein is the only effector not to have a clear enzymatic activity 
(Viboud & Bliska, 2005) and also varies in size dramatically between the Yersinia 
species. The YopM effector contains a variable number of a ~20 amino acid lecuine 
rich repeating unit. The number of repeats can vary from 12-20 and in the structure 
of Y pestis YopM (Evdokimov et al, 2001) shown in figure 1.3 there are 15 repeats 
organised into a horseshoe shape and four of these monomers may be arranged as a 
ring with an inner pore of 35A (Evdokimov et al, 2001). Though it is known that 
YopM is transported to the nucleus via a vesicle associated pathway (Skrzypek et al, 
2003) its exact role in virulence and its biological function in the nucleus is 
unknown. It has been shown that YopM is associated with a depletion in several 
cytokines and YopM knockout mutants have their virulence attenuated by 100,000 
fold (Kerschen et al, 2004; Viboud & Bliska, 2005).
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While the three Yops mentioned above have diverse targets, the remaining three 
Yop effectors, Yop E, -O and -T , all target the Rho-GTPases, a common target for 
many bacterial toxins (Barbieri et al, 2002). The Rho-GTPases are good targets for 
effectors exerting anti-phagocytotic effects as they manage aspects of the cell 
cytoskeleton, especially the formation of actin filaments, as well as mediating many 
other downstream pathways.
YopE is a GTPase activating protein (GAP) on RhoA, Rac-1 and Cdc42. The GAP 
activity encourages the hydrolysis of GTP to GDP thus switching the GTPase from 
an active to inactive form. YopE is a 219 residue protein and the GAP domain 
(residues 96-219) is homologous to the GAP domains in other TTSS effectors such 
as SptP from Salomonella and exoS from Pseudomonas aeruginosa (Aepfelbacher, 
2004; Andor et al, 2001; Black & Bliska, 2000; Fu & Galan, 1999; Goehring et al, 
1999). The active site of the YopE contains an arginine finger motif that intrudes 
into the GTP binding site of the GTPase and promotes efficient hydrolysis of GTP 
to GDP inactivating the GTPase.
Through deactivation of RhoA the actin cytoskeleton is heavily disrupted and 
phagocytosis of the Yersinia is prevented. YopE mediated antiphagocytotic 
behaviour has been observed in macrophages, neutrophils and epithelial cells 
(Fallman et al, 1995; Grosdent et al, 2002; Ruckdeschel et al, 1996). In addition to 
the antiphagocytotic activity YopE has also been implicated in reducing cytokine 
production through blocking of the Rac-1 - Caspase-1 interactions in macrophages 
(Schotte et al, 2004). The antiphagocytotic effects of YopE are important to the 
overall virulence of Yersinia spp. and YopE null mutants have been shown be to 
10,000 fold less virulent than wild type strains (Perry & Fetherston, 1997).
YopO (called YpkA in Y. pseudotuberculosis) is a multi-domain protein with 
multiple properties of -730 amino acids (729 in Y. enterocolita, 732 in Y. pestis and 
Y pseudotuberculosis). It contains an N-terminal serine/threonine kinase domain
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and actin binding and Rho-GTPase binding domains. The actin binding domains and 
Rho-GTPase binding domains are contained within the C-terminal domain of YopO 
(Barz et al, 2000; Comelis, 1998; Dukuzumuremyi et al, 2000). YopO kinase 
activity is activated by actin binding results in autophosphorylation and 
phosphorylation of basic substrates, including actin (Juris et al, 2000).










Figure B4. The targets of Yersinia effectors. During infection GEF’s are activated via pi-integrin 
signalling. GTPase activation then triggers phagocytosis and also, via MAP kinase (MKK) and NH- 
k B  (IKK) pathways, gene transcription. The Yop effectors interfere with these pathways at nearly 
every step. YopH inhibits the initial steps o f the (31-integrin pathways halting phagocytosis. YopT 
inhibits phagocytosis by cleaving RhoA off the membrane. YopE inhibits phagocytosis and cytokine 
release via its GAP activity and YopO also targets GTPases, though via an unknown mechanism. 
YopJ prevents the release o f cytokines by blocking activation of MKK and IKK and YopM is 
trafficked to the nucleus where it has its cytoxic effect via an unknown mechanism. This figure was 
adapted from (Viboud & Bliska, 2005).
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The Rho/Rac binding of YopO is independent of both the nucleotide bound state of 
the Rho GTPase and the kinase activity of YopO (Juris et al, 2002). Although YopO 
has been shown to inhibit phagocytosis and disrupt the actin cytoskeleton (Fallman 
et al, 1997) the cellular function of YopO is still unclear. There is no clear substrate 
or mechanism for its action though it has been shown to synergise with other Yops 
to allow the bacteria to colonise and persist in different tissues (Logsdon & Mecsas, 
2003).
YopT is a 322 residue cysteine protease of the CA (papain) family that 
proteolytically cleaves RhoA, Rac and Cdc42 just before a C-terminal cysteine 
linked geranylygeranyl group that anchors the GTPase to the cellular membrane 
(Shao & Dixon, 2003). This results in the GTPase becoming released from the 
cellular membrane thereby inactivating it. This inactivation of RhoA disrupts the 
formation of stress fibres and leads to cell rounding and inhibition of phagocytosis, 
similar to the effects of YopE. A more detailed discussion of YopT and the work 
performed on this protein follows.
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YopT of Yersinia Pestis
Aims of cloning and purifying YopT
Yersinia spp. produce a range of effector molecules that modulate their 
pathogenicity. Amongst them is YopT, a cysteine protease, that catalyses the 
proteolytic cleavage of RhoA away from the plasma membrane leading to a 
breakdown of the actin cytoskeleton. YopT has also been identified as the defining 
member of a large family of cysteine proteases from many different organisms. The 
aim of this project was to clone, purify and subsequently determine the structure of 
YopT to understand its catalytic mechanism and substrate selectivity.
The history of YopT
Yersinia spp. are able to resist the immune system of their host and replicate 
extracellularly due to the presence of a complicated TTSS apparatus. In Yersinia 
spp. this is TTSS is called the Yop virulon and is encoded on a single 70kb plasmid, 
the pYV plasmid (Comelis & Wolf-Watz, 1997; Iriarte & Comelis, 1998). This 
plasmid carries a series of 29 Ysc proteins that are required to construct the TTSS 
and a series of effector Yops that give rise to the characteristic pathogenic behaviour 
of the Yersinia (Iriarte & Comelis, 1998).
When the sequence of the pYV plasmid was analysed (Comelis & Wolf-Watz, 
1997) two previously unrecognised ORFs (ORF1 and ORF2) were identified located 
between YopQ and YopM. These two ORFs were adjacent, the start codon of ORF2 
actually overlapping with the stop codon of ORF1 by one nucleotide. ORF1 coded 
for a 322 residue protein and ORF2 coded for a smaller acidic (pi 4.4) 130 residue 
protein. ORF2 was shown to be 69.7% and 23.0% similar, to SycE and SycH 
respectively (Iriarte & Comelis, 1998; Wattiau et al, 1994; Wattiau & Comelis,
1993) and hydrophobic moment plots of ORF2 strongly resembled those of SycE 
suggesting that ORF2 may also have been a chaperone protein. By analogy with the
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SycE-YopE (Wattiau & Comelis, 1993)and the SycH-YopH (Wattiau et al, 1994) 
gene arrangements this suggested that ORF1 was a new Yop effector.
Using a polymutant Yersinia strain (YopH, YopO, YopP, YopE and YopM null) 
called AHOPEM (Boland & Comelis, 1998) expression of a 35.5kDa protein band 
representing ORF1 was easily observed. This was only expressed alongside ORF2 
and at 37°C in the absence of Ca confirming its identity as a new Yop protein 
subsequently titled YopT (Iriarte & Comelis, 1998). Initial work performed also 
showed that the cytotoxic effect of YopT led to disruption of the actin cytoskeleton 
and cell rounding (Iriarte & Comelis, 1998). As YopT was seen to interfere with the 
actin cytoskeleton of cells initial identification of the YopT target focused on RhoA 
and the related Cdc42 and Rac-1. RhoA, Rac-1 and Cdc42 are known regulators of 
the cell cytoskeleton. RhoA is crucial to the regulation of stress fibres, Cdc42 and 
Rac-1 mediate filopdia and membrane ruffles respectively (Hall, 1998). YopT was 
shown to affect the electrophoretic mobility of [32P]-labelled RhoA and induce an 
acidic shift in the pi of RhoA (from pi 6.3 to pi 5.9) through covalent modification 
(Zumbihl et al, 1999). This covalent modification of RhoA also led to its 
localisation in the cytosol (Sorg et al, 2001; Zumbihl et al, 1999) away from the 
membrane where it is active (Hall, 1998).
YopT’s identity as a cysteine protease came to light when Shao and co-workers 
(Shao et al, 2002) identified 19 sequences from a wide array of bacterial pathogens 
infecting both animals and plants that showed a degree of sequence similarity and 
contained highly conserved cysteine, histidine and aspartate (C l39, H258 and D274 
in YopT) residues (Shao et al, 2002). Subsequent mutational analysis of the C l39, 
H258 and D274 confirmed that all three residues are required for YopT cytotoxicity. 
Yeast Cdc42 was found to be a target of YopT from a multi-copy suppressor screen 
and subsequent GST pull-down assays demonstrated that RhoA and Rac-1 were also 
substrates for YopT. However, these interactions were only observed when the 
GTPases were post-translationally prenylated. RhoA, Rac-1 and Cdc42 all undergo a 
similar post-translational modification at their C-terminal CAAX box (C, cysteine;
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A, aliphatic; X, any residue) (Zhang & Casey, 1996). The CAAX box is a 
recognition motif for prenylation, either geranlygeranylation or fameslylation, of the 
cysteine residue prior to the proteolytic removal of the -AAX tripeptide and methyl 
esterification of the cysteine (Zhang & Casey, 1996). This modification allows the 
GTPase to be anchored into the membrane. YopT was unable to bind GTPase 
mutants missing the CAAX box and a GFP-CAAX box mutant could be co­
precipitated with YopT, indicating that the CAAX box is vital for the interaction 
between YopT and the Rho-GTPases (Shao et al, 2002). Cleavage at the C-terminal 
of the Rho-GTPases leads to the loss of the prenyl group and displacement of RhoA 
from the membrane into the cytosol (Shao et al, 2002). The target for YopT 
recognition has been identified as a polybasic sequence of amino acids upstream of 
the prenylated cysteine (Shao et al, 2003). The exact point of cleavage, directly N- 
terminal to the prenylated cysteine, has been confirmed with biochemical and mass- 
spectroscopic methods. As illustrated in figure B5, a polybasic sequence is present 
in RhoA, Rac-1 and Cdc42 adjacent to the CAAX box and the prenylated cysteine. 
As the interaction between YopT and Rho-GTPase occurs at the C-terminus the 
cleavage is independent of the nucleotide bound state of RhoA (Shao & Dixon,
2003) and is independent of the prenyl group attached to the cysteine (Shao & 
Dixon, 2003).
Figure B5 C-termini cleavage sites of the Rho-GTPases
RhoA i 8 i A R R G K K K S G C L V L i93
Rac-1 1 7 7 L C P P P V K K R K R K C L L L 1 9 2
Cdc42 i 78E P P E T Q P K R K C C I F i 9 i
r~
Figure B5. The C-terminus sections of RhoA, Rac-1 and Cdc42. The polybasic sequences rich in 
arginines and lysines are shown and the CAAX box is underlined. The arrow denotes where the 
YopT cleavage takes place. This figure is adapted from (Shao et al, 2003).
To summarise, YopT is a cysteine protease that assists Yersinia in overcoming 
phagocytosis by targeting RhoA, Rac-1 and Cdc42. In the host cell it binds to a C-
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terminal polybasic sequence and the CAAX box, and cleaves the GTPase N-terminal 
to the prenylated cysteine that anchors the GTPase to the membrane. The GTPase is 
then left in the cytosol, where it is inactive leading to a disruption of actin 
cytoskeleton and inhibition of Yersinia phagocytosis. In Yersinia pathogenesis the 
role of YopT and YopE overlap somewhat as both target the RhoGTPases leading to 
disruption of the actin cytoskeleton. Both are necessary for resistance to 
phagocytosis and YopT* mutants have been shown to be less resistant to 
macrophages (Grosdent et al, 2002). However, it may be that YopE and YopT act 
synergistically as YopE disrupts the formation of actin-rich phagocytic cups almost 
immediately, whilst the YopT effect is slower requiring 15-30 minutes. Also the 
YopE effect is reversible and transient, whilst the YopT effect is a permanent effect. 
This co-operation and redundancy between YopE and YopT generates phagocytotic 
resistance (Aepfelbacher et al, 2003).
The initial studies into YopT by Shao and co-workers uncovered a wide variety of 
ORF’s that showed similar invariant C/H/D residue suggesting that YopT may 
define a new family of cysteine proteases common to plant and animal pathogens 
(Shao et al, 2002). The sequence alignment is shown below in figure B6 and 
includes ORFs from all three Yersinia species, Haemophilus somnus, the plant 
pathogen Pseudomonas syringae and the enteropathogenic Escherichia coli 0157. 
Cysteine proteases are grouped together into ~40 different families related by 
sequence identity (Barrett, 1994; Barrett et al, 2001). YopT however shows very 
low sequence identity to any of the current families, but the secondary structure 
predictions for YopT, shown in figure B6, and many of the related ORFs show some 
similarity to the papain family (CA clan) of cysteine proteases. This hypothesis was 
confirmed by the recent report of the structure of AvrpPhb a P. syringae type III 
effector that is part of the YopT family of cysteine proteases (Zhu et al, 2004) and 
strongly resembles the papain family cysteine proteases, part of the CA clan. 
Biochemical inhibition studies using the aspartyl protease inhibitor pepstatin, the 
serine protease inhibitor PMSF, EDTA, thiol protease inhibitor N-ethylmaleimide 
and the CA-clan specific inhibitor E64 (L-trans-epoxysuccinyl-leucylamide-(4-
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guanido)-butane) (Barrett et al, 2001) are also consistent with YopT being a cysteine 
pro tease in the CA clan (Shao et al, 2002).
Analysis of the related ORFs also highlighted interesting features including three 
broad groups of related proteins. (1) Small type III effectors proteins ranging from 
30-40kDa in size such as the Psuedomonas effectors. (2) Large >300kDa multi­
domain proteins that possessed a YopT-like domain such as LifA from E. coli or 
toxinB from the enteropathogenic E. coli 0157  and (3) the Haemophilus P76 
immunoglobin binding proteins. YopT along with the Haemophilus proteins from 
both H. somnus and H. ducreyi may also form a sub-family as they have a much 
higher sequence similarity than the other proteins found to date (Shao & Dixon,
2003).
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Figure B6 Sequence alignment of the YopT-like proteases ^
r-
> YopT --------------------------------- MN3IHGHYHIQL3NY5AGENLQ3ATLTEGVIGAHRVKVETALSHSNLQKKLSATIKHNQSGRSMLDRKLTSDGKA.NQR3SFTF3M ^
> P76 MEFLKELAKKGSKEDNEOHLEKTDRTS7DLTESAVEN3AALS3GTVRSATVSETVTETEC'AKAKPVSDLVSSKDLVECQRWLORIODOFOPLKVKSKI-
>HopPtoC ------------------------------------------------------------------ MTIVSGHIGKHPSLTTVQ  ------------------------------------------------------------ - - - - -
> to x E  ---------------------------------------------------------------------------------- MLNLEGLIKKYKYLS LSEIHRTLTNSTSFADI5IPLLQTICPSITTIIKKTEYYGHQL7NAM
> Y opT  IMYRMIHFVLS7RV--------------------------- PAVREJHAN YGGWIN- -  FK^AGT^fGAFLHKI IK  HS DTABgVCEALCAHIi RSHAQG^S
>P 76 ---------------------------------------------------------- d a v r g s v e c f :-g e v s - - fk | a g s | g e v y k e iv k ---------------------------------HIE I oI gVCE S ?C Al l | :  AKNVN PTD
> Hop P t 0C ---------------------------------------------------------- AGSGAgVENCMPDP AQfSDGfk'KKLPTQLSSITLARFtX^NICTNNHGISalAMCFGLGLsllHMIHAGKD
> t& *B  TVASWKPYDFSNLGAINSIDKSVSDVPALHTIVE'.'AKYNLLSWNDtYNTiASIWCyriAROIIKSTNIEFHPQSLLFDRDMGKCLGLSLlJlDrrGG--------
> YopT LFDQL---------------- | vB r KGKFQI---------------------------------------------------------------------C ® Y  SIKQLQIDGCKA-------------------------------------------------------------D
> P 76 ENFFNTL----------- |eH k.K G H L K K ---------------------------------------------------------------------EflgDGIKKLQTEFINSGSATQOFKLTDSWLQEQGWPKEKKVADF
o p P to C  HVTPYASAERMRfLggFEGWHAIlWHNFYRTEHKFllffiQASANPGVSSGAMAGTEBLaAAELKGLKLQPVLEDKSNSGLPFLIACKQSGB.---------------0
> to x B   -RUN- DTA---------- ----  SgY O T K  YN DMLK--------------------------------------------------------------------------------- L
> YopT IcoBVTLDW FKKHGI S ERMI ERHCLLRPVDVTGTTE G E G L D q Iln M H tH G  : GYGYKKIHLS GGHSAIaIaAYVNEK -  GGVT e Id In F G
> P7 6 I rrS v SGTVS KNDV-------------------------------------------------------- 3 3 |V K ^ H t G D DTAGVKKI S IN ------------------- LEGGSHTf SAAVDG—  S K V T E K flH |
> H o p P t  OC J S t B a AL------------------------------------------------------------------------G s |c  L'AJVEN KRGVMVIY----------------------------- 3GEI AEA§G FS VS 3 OS KRA7
> tO xB  I nrH f FLRKTQRI ITM3NELGN---------------------------------------N Rj*KNgf^^r,«rLE LKDPILTEGILYQRRI3 3 LL IT7E YHS&ALQQI S -  -  S FWRVBDBItFG
> YopT Bril FS DKEKFRKWF--------------------------7 |G  FMGN SMY HY PLGVGQRFRVLTFDSKEV-
> P7 6 ■4TFPTHQQFENWL------------------------   -  KMAFVQKSGYAGKQEGRRFFNWNYKKNNEF
> H O pPt OG ■TIITIIS KALADTIENIS S ADGLPLIGvjvFAS KIH------------------------------------------ » —
> tO x B  ilD FH SL A O A L T F I----------------------------Ki-TSNRNFGSLYGSGIVKIYFSE 5LNNEF-
Figure B6. Sequence alignment of YopT and three other related cysteine proteases; P76 from H. somnus; HopPtoC from P. syringae and; toxB from E. coli 0157.H7. The 
secondary structure assignment was determined by the YopT model build by the 3d-Jigsaw server (Bates et al, 2001). The catalytic triad (C139, H258 and D274 in YopT) are 
shaded in yellow. The 3 conserved aromatic residues that form stacking Van der Waals interactions are shaded in red, as is the conserved glutamate that interacts with the 
conserved tryptophan. The amide contributing residue that forms the oxyanion hole is shaded in turquiose. Other areas of conserved sequence are shaded in grey.
Methods
YopT expression and purification was attempted through two different strategies. 
The first was cloning into pET22b (Novagen Inc., UK) and following a similar 
protocol to that employed in the purification and structural determination of the 
related cysteine protease AvrpPhb from P. syringae (Zhu et al, 2004). The second 
strategy was to clone YopT into the solubility enhancing pMalp2x vector (New 
England Biolabs) as an MBP fusion protein that ultimately failed.
Expression and purification of the YopT-pET22b construct
The YopT gene was received as freeze-dried plasmid in the pDR4TOPO plasmid 
provided by Etelechon GmbH. Primers were designed to introduce a 5’ Ndel site 
and a 3’ Sail site prior to cloning YopT into pET22b (Novagen Inc., UK).
Forward primer (Ndel site underlined):
5 ’ GGG CAT ATG ATG AAC AGC ATT CAT GGC 3 ’
Reverse primer (Sail site underlined):
5 ’ CGC GTC GAC GAA TTC CAC TTC TTT TGA 3 ’
The PCR was performed using the Boehringer Expand™ PCR system and the 
following protocol: 95°C 30 seconds, 30 cycles of 95°C 30 seconds, 45°C 1 minute, 
72°C 1 minute and 30 seconds, followed by a 7 minute hold at 72°C and storage at 
4°C. The resulting DNA visualised on a 1% agarose gel and purified using the 
Qiagen DNA purification kit (Qiagen Ltd. UK).
The purified YopT DNA and the pET22b plasmid (Novagen Inc., UK) underwent 
restriction digestion using the Ndel and Sail (Promega) restriction enzymes with a 2 
hour incubation at 37°C. Restriction digested plasmid and YopT DNA were ligated 
overnight at 4°C with T4 DNA ligase (Promega). Ligated plasmids were then 
transformed by heat-shock into BL21 cloning cells and the resulting transformants
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were plated out onto LB-agar plates supplemented with lOOpg/ml ampicillin and 
incubated overnight at 37°C.
Successful transformants were screened for by PCR using Taq polymerase 
(Promega) and the following protocol: 95°C 1 minute, 25 cycles of 95°C 30 
seconds, 45°C 1 minute, 72°C 1 minute and 30 seconds, followed by a 7 minute 
hold at 72°C and storage at 4°C. The resulting DNA visualised on a 1% agarose gel 
and successful colonies were used to inoculate 10ml of luria broth supplemented 
with lOOpg/ml ampicillin overnight at 37°C. The plasmid DNA was recovered using 
the Promega wizard miniprep kit and 1.25pi of the purified YopT-pET22b was then 
used to transform BL21(DE3) expression cells (Novagen Inc., UK). Successful 
insertion of the YopT gene was confirmed with T7 forward and reverse sequencing 
(MWG Biotech).
Initial expression of soluble YopT proved difficult and optimisation of the growth 
conditions resulted in a low temperature expression scheme strategy. With the 
advent of the work by Studier and colleagues (Studier, 2005) autoinduction media 
was used instead of the low temperature expression in terrific broth and yielded 
significantly higher yields of soluble YopT.
Single colonies of pET22b-YopT were grown overnight at 37°C in 10ml ZYM-505 
media (1% N-Z amine, 0.5% yeast extract, 5mM Na2S0 4 , 2mM MgSC>4, 25mM 
(NH4)2C12, 25mM KH2P 0 4, 20mM Na2P 0 4, 0.5% glycerol, 0.05% glucose, 50nM 
FeCl3, 20nM CaCl2, lOnM MnCl2, lOnM ZnS04, 2nM CoCl2, 2nM CuCl2, 2nM 
NiCl2, 2nM Na2MoC>4, 2nM Na2SeC>4, 2nM H 3 B O 3 )  supplemented with lOOpg/ml 
ampicillin. The overnight cultures were then diluted 1:1000 into 11 fresh ZYM-5052 
media (1% N-Z amine, 0.5% yeast extract, 5mM NA2SC>4, 2mM MgS0 4 , 25mM 
(NH4)2C12, 25mM KH2P0 4 , 20mM Na2PC>4, 0.5% glycerol, 0.05% glucose, 0.2% 
lactose, 50nM FeCE, 20nM CaCl2, lOnM MnCl2, lOnM ZnS0 4 , 2nM CoCl2, 2nM 
CuCl2, 2nM NiCl2, 2nM Na2Mo0 4 , 2nM Na2Se0 4 , 2nM H 3 B O 3) supplemented with 
100mg/l ampicillin and left to grow for overnight at 37°C. Soluble protein
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expression was observed on an SDS-page gel. Cells were harvested by 
centrifugation (Beckman Avanti J-25).
Harvested cell pellets was re-suspended in lysis buffer (20mM Hepes pH 7.3, 
500mM NaCl, 0.3mg/ml lysozyme) and stirred on ice for 30 minutes. Cells were 
lysed via sonication (Soniprep 150) and the inclusion bodies removed by high speed 
centrifugation (Beckman Avanti J-25).
Clarified cell lysate was loaded onto a 5ml Hitrap affinity column (GE Healthcare) 
charged with NiSC>4 and equilibrated with 50mM Hepes pH 7.3, 500mM NaCl and 
lOmM imidazole. YopT was eluted as a single peak with 50mM Hepes pH 7.3, 
500mM NaCl and 500mM imidazole. The protein was then applied to a Superdex 
200 gel filtration column (GE Healthcare) equilibrated with 20mM Tris pH 8.5, 
500mM NaCl, lOmM p-mercaptoethanol with a slow flow speed of O.lml/min to 
seperate full length YopT from its 25kDa fragment. The purified YopT and the 
25kDa YopT fragment were concentrated separately in a lOkDa centrifugal 
concentrators (Amicon) to lOmg/ml and stored at 4°C for crystallisation.
Crystallisation of YopT
Crystallisation trials were performed as hanging drops using 1.75pl of protein with 
1.75pl of reservoir solution in the drop, giving a final protein concentration of 
5mg/ml in the crystallisation drops. Structure screens I and II (Hampton Research) 
were used to generate initial crystallisation conditions. Optimisation trials centering 
around lOOmM sodium cacodylate or Hepes pH 6.5, 0.2M magnesium acetate, 15% 
PEG8000 were performed. Plates were incubated at either 16°C or 4°C.
Micro-seeding experiments were performed as follows: A 24 well plate was set-up 
with lOOmM Hepes pH 6.5, 0.2M magnesium acetate, 10-15% PEG8000 with 
lOmg/ml YopT and was left to equilibrate overnight at 16°C. A drop containing 
crystals was resuspended in 800ul of lOOmM Hepes pH 6.5, 0.2M magnesium
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acetate, 12.5% PEG8000 and mixed vigorously for -10  minutes. Then 0.5pl of the 
solution was added to each crystal drop on the equilibrated plate. The plate was then 
incubated for at 16°C until crystals appeared.
Streak-seeding experiments were performed as follows: A 24 well plate set-up with 
lOOmM Hepes pH 6.5, 0.2M magnesium acetate, 10-15% PEG8000 and lOmg/ml 
YopT was left to equilibrate overnight at 16°C. A cat’s whisker was then brushed 
through a drop containing micro-crystals and then brushed across the surface of each 
drop on the equilibrated plate. The plate was then incubated for at 16°C until 
crystals appeared. Additive screens were set-up by the addition of small amounts of 
the additive to the crystallisation reservoir. Additives used were 1-10% MPD, 1- 
20% ethanol, 5-20 % isopropanol and 1-10% 1,6-hexandiol.
Crystallisation of the YopT fragment
Crystallisation trials were performed as hanging drops using 1.75pl of protein with 
1.75pl of reservoir solution in the drop, giving a final protein concentration of 
5mg/ml in the crystallisation drops. Structure screens I and II (Hampton Research) 
were used to generate initial crystallisation conditions. The initial condition from the 
structure screen consisted of lOOmM Tris pH 8.5, 50% MPD and 0.1M (N H ^SO ^ 
Optimisation screens were performed varying: pH of the Tris buffer, percentage of 




The expression and purification of YopT posed several problems during 
optimisation. The initial choice to use the pET22b vector (Novagen) was based on 
the work by Zhu and colleagues (Zhu et al, 2004) in purifying the AvrpPhB cysteine 
protease from P. syringae. AvrpPhb was identified as a member of the same family 
of 30-40kDa type III effectors as YopT (Shao et al, 2002). Initial cloning into 
pET22b was straight forward and was confirmed with sequencing, double digestion 
using Ndel and Sail restriction enzymes (Promega) and colony PCR. Expression 
was more difficult however. Standard trials using ImM IPTG to induce expression 
at 37°C failed to produce soluble YopT. The protocol used by Zhu and colleagues 
using M9 minimal media but with expression overnight at 20°C induced with 
0.4mM IPTG was also unsuccessful at producing soluble YopT (Zhu et al, 2004). 
However, this did lead a successful protocol using low temperature, 20°C, and a low 
IPTG concentration, 0.4mM, in terrific broth. This protocol led to high levels of 
expression as shown below in figure B7A. Later trials with autoinduction media at 
37°C resulted in greatly increased yields from 8mg/ml obtained at 20°C in terrific 
broth to >20mg/ml.
The initial purification of YopT was straightforward. Once soluble YopT had been 
obtained histidine affinity chromatography was an effective and efficient method of 
purifying YopT away from the majority of cell contaminants, although in all cases, a 
second band of ~25kDa was co-purified with full length YopT as can be seen in 
figure B2.3B. This second band was thought be a breakdown product of YopT as 
without addition of lOmM p-mercaptoethanol the YopT degraded rapidly increasing 
the ratio of YopT fragment: full length YopT in the solution. The presence of this 
25kDa fragment made gel filtration chromatography more difficult as both the 
fragment and the full length YopT tended to elute as a series of peaks. Reverse 
phase chromatography was attempted but freeze-dried YopT was unable to return to
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solution. Both histidine affinity chromatography and anion-exchange 
chromatography failed to separate the fragment from the full length protein. The 
presence of this 25kDa fragment was unexpected, as, unlike AvrpPhB YopT is not 
known to be proteolytically cleaved before activation (Zhu et al, 2004) and other 
groups expressing YopT have not mentioned the appearance of this 25kDa fragment. 
The fragment co-purified alongside YopT on a nickel affinity column so is likely 
formed from the C-terminus of YopT as the pET22b vector possesses a C-terminal 
hexahistidine tag.









+0 +3 O/N Sol* Insol* H itrap
YopT
Gel Filtration Ladder 







Figure B7: In 3A is the expression of YopT in terrific broth before induction (+0), 3 hours after 
induction with 0.4mM IPTG at 20°C (+3) and expression after overnight incubation at 20°C directly 
before the cells were harvested (O/N). The component of the cell pellet is divided into the soluble and 
insoluble fractions after lysis by sonication. 3B shows the purity after initial metal affinity 
chromatography (Hitrap) and the component of the 3 peaks witnessed upon gel filtration. The full 
length YopT (~40kDa) and the YopT fragment (~25kDa) can be observed.
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Crystallisation of YopT and the fragment of YopT have led to encouraging initial 
results. Micro-crystals and thin needles like those shown below in figure B8A have 
been grown for the full length YopT. Although none of the needles grown to date 
have been large enough for diffraction studies. Crystals of the YopT fragment, 
shown below in figure B1.8, grew in lOOmM Tris pH 8.5, 50% MPD and 0.1M 
(NH4)2S04 but were too small for diffraction study. Further optimisation of the 
crystallisation conditions is in progress.
Figure B8 Crystals of full length YopT
B
Figure B8: Crystals o f (a) the full length YopT protein and (b) the 25kDa breakdown product o f  
YopT.
Homolgy modelling with AvrpPhB
YopT and AvrpPhB were the cysteine proteases that defined this family (Shao et al, 
2002). Both possessed a conserved catalytic triad (C139/H258/D274 in YopT) along 
with similar predicted secondary structure. In common with most other members of 
this family of cysteine proteases they are also thought to share a conserved core 
domain.
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Using the AvrpPhB structure (PDB code 1UKF) (Zhu et al, 2004) the automated 
modelling program 3d-Jigsaw Server (Bates et al, 2001) was used to build a model 
of the full length YopT protein. The central 50 residues around the active site 
features superimposed well on the AvrpPhB structure with an RMSD of 1.67A and 
is shown below in figure B9. The model has an a/p fold with two lobes formed 
primarily of a-helices stacked above and below a five stranded anti-parallel (3-sheet. 
Two long loop regions (residues 230-244 and 284-301) protrude away from the core 
of the molecule as long coils but are more likely areas where the automated 
modelling program was unable to predict accurate secondary structural elements.
Figure B9 Homolgy model of YopT effector from Yersinia pestis
Figure B9: Homolgy model of YopT prepared by 3d-Jigsaw server (Bates et al, 2001) using the 
related cysteine protease AvrPphB from Pseudomanas syringae as the initial model (PDB code 
1UKF) (Zhu et al, 2004).
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The catalytic triad form the active site just under the (3-sheet with Cl 39 lying at the 
very beginning of a2 helix and H258 and D274 lying |3-strands 3 and 4 respectively. 
A detailed look at active site of reveals many similarities to both papain and 
AvrpPhB structures and is shown in figure BIO. The catalytic triad are conserved 
and in the same conformation as is found in AvrpPhB and the rest of the papain 
family (Jia et al, 1995) suggesting that YopT may share a similar catalytic 
mechanism. This involves the cysteine and histidine forming a thiolate-imadozolium 
pair with the catalytic aspartate stabilising the ion pair and orienting the active site 
correctly. Mutagenesis studies confirm that loss of any of those 3 residues results in 
the loss of YopT activity (Shao etal, 2002).




Figure BIO. A close up of the active site of YopT showing the catalytic triad and the conserved 
hydrophobic residues that stack above each other.
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There are also 3 hydrophobic residues that are conserved throughout the YopT 
family of proteases (Shao et al, 2002) (Zhu et al, 2004). In YopT these are: Phe273, 
Pro275 and Trpl46. Phe273 and Pro275 flank the catalytic aspartate on the p4 
strand and Trp248 lies at the tail end of the a2 helix that the catalytic Cysl39 lies 
on. Phe273, Pro275 and Trpl46 stack above each other with strong van der Waal 
interactions. These interactions hold the superstructure of the active site together and 
hold helix a2 and strand p4 in close proximity so the catalytic aspartate is correctly 
positioned to stabilise the thiolate-imadozolium.
In the AvrpPhB structure the equivalent tryptophan also forms a hydrogen bond 
with a glutamate residue (E279 in YopT) that is 5 residues after the catalytic 
aspartate and on the strand P5 separated from strand p4 by a short turn formed by 
the conserved proline (Zhu et al, 2004). The importance of Trpl48 in YopT was 
highlighted by mutagenic studies that demonstrated a W148A mutant lost all activity 
(Shao et al, 2002). The other important features of the cysteine proteases are the 
oxyanion hole that stabilises the PI residue, the residue directly N-term to the 
cleavage site, and the SI, S2 and S3 sites that interact with the side chains of the PI, 
P2 and P3 residues of the substrate.
The PI, P2 and P3 residues are the three residues directly upstream of the point of 
proteolytic attack. In the case of YopT’s cleavage of RhoA the PI, P2 and P3 
residues are a glycine, serine and lysine respectively as can be seen in figure B2.1. 
In papain and AvrpPhB the oxyanion hole is formed from the amide group of an 
asparagine residue (Zhu et al, 2004) (Schroder et al) (Menard et al, 1991). Although 
YopT lacks an asparagine at this position the loop upon which the equivalent reside, 
Gly 137, lies is shorter than in papain or AvrpPhB resulting in the amide group of 
Glyl37 in YopT lying in a similar position to the amide group of the asparagines in 
papain or AvrpPhB. The SI, S2 and S3 sites in papain and AvrpPhB are involved in 
the substrate specificity, however in YopT the specificity is governed by the prenyl 
group attached to the cysteine and a short polybasic sequence lying further upstream 
of the cleavage site.
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Figure B l l .  The SI, S2 and S3 sites of YopT (Blue) compared with AvrpPhB (red). The catalytic 
triad of YopT is shown. In all cases the AvrpPhB residue is numbered in italics. The difference in the 
loop regions around the oxyanion hole is highlighted.
In AvrpPhB the SI site is centred around Y175 whilst in the equivalent position in 
YopT there is a lysine (K178). S2 in AvrpPhB is formed by arginine 205 whilst in 
YopT the equivalent residue is Leu251. The S3 site is formed by a pocket of several 
residues at the tip of helix a4 and is comprised of leucine, phenylalanie and tyrosine 
in AvrPphB but lysine, isoleucine and aspartate (K178, 1182 and D190) in YopT. 
These are shown in figure B 11. In the related AvrpPhB the nature of S1 -S3 provide 
complimentary binding sites for the PI, P2 and P3 residues (Zhu et al, 2004). In 
YopT the same strong link between residue and binding site is not so obvious, 
especially as can be seen from figure B11 there are differences in the PI, P2 and P3 
residues between the three known substrates of YopT. From our structural model it
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is not immediately obvious how substrate specificity is controlled and where the 
prenyl group or polybasic sequence interact with the YopT molecule.
Conclusions
We have cloned and optimised a purification strategy to isolate pure YopT cysteine 
protease. We have managed to grow small needle-like crystals, though at present 
these are too small to be of use in diffraction experiments. Homology modelling 
with the structure o f the related cysteine protease AvrpPhB from Pseudomonas 
syringae shows conserved features around the active site including the catalytic 
triad, oxyanion hole and a trio of hyrdrophobic residues. As AvrPphB and YopT 
share different substrates and YopT has 3 substrates the manner in which the 
polybasic sequence and prenyl group determine specificity in YopT is still unkown.
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P76 High weight immunoglobulin binding protein from 
Haemophilus somnus
Aims of cloning and purification of the YopT-like domain of P76
H. somnus possesses P76, a large immunoglobulin binding protein on its surface. 
The C-terminal half of this 76kDa protein has been identified as having strong 
sequence identity to the YopT effector from Yersinia pestis. We hope to clone, 
purify and subsequently determine the structure of the YopT-like domain to gain 
insight into its substrate and to investigate if it shares similar structural features to 
the rest of the YopT-like cysteine protease family.
An introduction to Immunoglobulin binding proteins in H. somnus
Haemophilus somnus is a gram negative pleiomorphic bacterium that causes many 
debilitating and serious conditions in cattle and sheep. Symptoms caused by H. 
somnus are serious and include thrombotic meningoencephalitis, septicaemia, 
pneumonia, infertility, abortion, myocarditis and arthritis (Harris & Janzen, 1989; 
Humphrey & Stephens, 1983; Kwiecien & Little, 1991; Miller et al, 1983; Stephens 
et al, 1981). However many cattle carry H. somnus as a commensal on the genital 
mucosa (Corbeil et al, 1997). One of the differences that have been noted between 
the virulent strains and the asymptomatic strains is their resistance to being killed by 
the complement system in bovine serum. This gives rise to invasive, virulent serum 
resistant strains and asymptomatic commensal serum sensitive strains (Corbeil et al, 
1985). In H. somnus resistance to complement mediated killing comes about from 
the lipooligosaccharide composition and the presence of immunoglobulin binding 
proteins on the cell surface (Inzana et al, 1988; Widders et al, 1989). These 
immunoglobulin binding proteins (IgBPs) consist primarily of either high molecular 
weight IgBPs (HMW-IgBPs) that bind to bovine immunoglobulin 2 (IgG2) or a 
41kDa outer membrane protein with a lower affinity for several immunoglobulins 
including IgGl and IgG2 (Yamall et al, 1988). The HMW-IgBPs are a series of 
proteins with molecular weights ranging from 120 to 350kDa and more recently,
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P76 was also shown to be a member o f the HMW-IgBPs as well (Corbeil et al, 
1997). All of the IgBPs, including P76, are coded for by a single, long 12kb insert 
(Corbeil et al, 1988). More recent work has shown that the entire 12kb insert codes 
for a single ORF, IbpA, which encodes all of the HMW-IgBPs and P76 but has 
many translation initiation sites (Tagawa et al, 2005). IbaA is coupled with another 
ORF, IbaB, that is consistent with a 66kDa outermembrane protein and meets the 
requirements for two-partner secretion pathway for transporting large virulence 
exoproteins (Jacob-Dubuisson et al, 2001). This two protein secretion couple is also 
seen for LspAl and A2 from H. ducreyi coupled with LspB (Tagawa et al, 2005).
Within the IbpA sequence there are two regions; one in the centre of the insert, the 
other in the P76 region, that are homologus to Fc binding domains of S. pyogenes 
and play a similar role in inhibition of complement mediated killing. Binding to Fc 
domain of IgG2 in this manner may prevent the immunoglobulin achieving the 
correct conformation to activate the complement cascade (Cole et al, 1993; Johnsson 
et al, 1994; Pack et al, 1996). The IpbA ORF also encodes several adhesion motifs 
that may aid in adhesion to epithelial cells (Tagawa et al, 2005). The role of the 
HMW-IgBPs in H. somnus involves binding to the IgG2 to prevent complement 
mediated killing and also to assist in adhesion to epithelial cells. To this end the 
HMW-IgBPs, including P76, are presented to the extracellular matrix as a series of 
surface fibrils coating the H. somnus bacterium (Corbeil et al, 1997). These surface 
fibrils bear a strong resemblance to the surface virulence factors from other 
pathogens including YadA form Yersinia spp. (Kapperud et al, 1987) filamentous 
hemagglutinin of B. pertussis (Reiman et al, 1989) and a family o f high molecular 
weight proteins (HMW1 and HMW2) from H. influenzae (St Geme et al, 1993). All 
o f these surface fibrils are involved in adhesion to epithelial cells, and in the case o f 
YadA, resistance to complement mediated killing (Pilz et al, 1992).
P76 along with LspAl and LspA2 of H. ducreyi possess the most closely related 
cysteine protease domains to the Yersinia spp. (Shao et al, 2002) though in the case 
o f P76 the function is unknown.
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Methods
Expression of the YopT-like domain of H. somnus P76 gene was attempted through 
three different strategies. These were: cloning into pET22b (Novagen) with a 
hexahistidine tag, cloning into pMalp2x (New England Biolabs) as an MBP fusion 
protein and cloning into the ligation independent vector ysbLIC based on pET28 
(Novagen). Ultimately only the LIC clone was successful.
Expression and purification of the P76-ysbLIC construct
The ysbLIC vector was a gift from Dr. Philip Leonard and was based on pET28 
(Novagen) and possesses an N-terminal hexahistidine tag.
The P76 gene fragment was received as freeze-dried plasmid in the pDR4TOPO 
plasmid provided by Etelechon GmbH. Primers were designed with the appropriate 
ends for insertion in to the ysbLIC vector.
Forward primer (LIC specific ends underlined):
5’ CAC CAC CAC CAC ATG GAA TTT CTC AAA GAA CTT GCT AAA 
A A A G G T A G 3’
Reverse primer (LIC specific ends underlined):
5’ GAG GAG AAG GCG CGT TAG TCG ACT TAG AAT TCG TTA TTT 
TTT TTG TAG TTA A 3’
The PCR was performed using KOD polymerase (Novagen) and the following 
protocol: 94°C 2 minutes, 35 cycles of 94°C 30 seconds, 45°C 30 seconds, 72°C 25 
seconds, followed by a 7 minute hold at 72°C and storage at 4°C. The resulting 
DNA was visualized on a 1% agarose gel and purified using a DNA purification kit 
(Promega).
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For the insertion into the ysbLIC vector 0.2pmol of the purified P76 DNA was 
incubated at 22°C for 30 minutes with T4 DNA polymerase (Novagen) 2.5mM 
dATP and 5mM DTT, the reaction was stopped by heating to 75°C for 20 minutes. 
After treatment with T4 DNA polymerase P76 DNA was incubated with 50ng of the 
ysbLIC vector for 10 minutes at room temperature before addition of EDTA and 
incubation at room temperature for a further 10 minutes. 1.25ul of the annealing 
reaction was transformed into Nova-Blue (Novagen) and subsequently plated out 
onto LB-agar plates supplemented with 30pg/ml kanamycin.
Successful transformants were screened for by PCR using KOD polymerase 
(Novagen) and the following protocol: 95°C 1 minute, 35 cycles of 95°C 30 
seconds, 45°C 30 seconds, 72°C 25 seconds, followed by a 7 minute hold at 72°C 
and storage at 4°C. The resulting DNA visualised on a 1% agarose gel and 
successful colonies were used to inoculate 10ml of luria broth supplemented with 
300p.g/ml kanamycin overnight at 37°C. The plasmid DNA was recovered using the 
Promega wizard miniprep kit and 1.25pl of the purified P76-ysbLIC was then used 
to transform BL21(DE3) expression cells (Novagen Inc., UK). Successful insertion 
of the P76 gene was confirmed with T7 forward and reverse sequencing (MWG 
Biotech).
Single colonies of ysbLIC-P76 were grown overnight at 37°C in 10ml luria broth 
supplemented with 30jng/ml kanamycin. The overnight cultures were then diluted 
1:100 into fresh terrific broth supplemented with 0.5% w/v glycerol and 30mg/l 
kanamycin and left to grow for ~3 hours at 37°C until an OD600 ~0.6 was reached. 
Protein expression was induced with ImM IPTG for 5 hours at 25°C and high levels 
o f soluble expression were observed as a 36kDa band on an SDS-page gel. Cells 
were harvested by centrifugation (Beckman Avanti J-25).
Harvested cell pellets were re-suspended in lysis buffer (20mM BisTris pH 7.0, 
500mM NaCl, 0.3mg/ml lysozyme) and stirred on ice for 30 minutes. Cells were
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lysed via sonication (Soniprep 150) and the inclusion bodies removed by 
centrifugation (Beckman Avanti J-25).
Clarified cell lysate was loaded onto a Hitrap column (GE Healthcare) charged with 
M S O 4  and equilibrated with 50mM Hepes pH 7.3, 500mM NaCl. P76 was eluted as 
a single peak with the addition of 50mM Hepes pH 7.3, 500mM NaCl, 500mM 
imidazole. Fractions containing P76 were further purified using reverse phase 
chromatography (Jupiter C-25 column) and an acetonitrile gradient. P76 was eluted 
as a single band at ~47.5% acetonitrile. The fractions containing P76 were 
lyophilised overnight and re-suspended in distilled water and concentrated to 
lOmg/ml with a lOkDa cut-off concentrator (Amicon) for crystallisation trials.
Crystallisation
Crystallisation trials were performed as hanging drops using 1.75pl of protein with 
1.75pl of reservoir solution in the drop, giving a final protein concentration of 
5mg/ml in the drops. Structure screen I and II (Hampton Research) were used to 
generate initial conditions with two conditions offering possible crystals. The 
conditions were: (1) structure screen II condition 37, lOOmM Tris pH 8.5, 1.0M 
Li2SC>4, lOmM NiCh and (2) structure screen II condition 6, lOOmM sodium acetate 
pH 4.5, 1.0M 1,6-Hexanediol, lOmM C0CI2. Grid screening around these two 




Initial cloning into the pET22b construct was straightforward and gave positive 
results in many of the colonies obtained after transformation. However, correct 
insertion of the P76 gene no expression was observed in either luria broth, terrific 
broth or auto-induction media.
Cloning into the pMal-p2x vector was more successful and it expressed well. 
However efforts to purify the P76-MBP fusion protein using ion-exchange and 
amylose affinity chromatography both failed to purify P76.
Figure B12 Expression and purification of the YopT-like P76 domain 
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F i g u r e  B12. A;The expression o f  the P76-LIC construct with time points before induction (+0), 2 
hours after induction with ImM IPTG(+2) and 5 hours after induction with ImM IPTG (+5). The 
soluble and insoluble contents o f the cell after lysis are also shown and it P76 can be seen clearly in 
the soluble fraction. B; the purity o f  P76 after inckel affinity (Hitrap) and reverse phase 
chromatograpghy (HPLC).
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Cloning into the ysbLIC vector was markedly and a large soluble expression band 
was observed on an SDS-page gel shown above in figure B12A. Purification was 
straightforward with no optimisation of either the metal chelating step or reverse 
phase step and pure P76 was still soluble after freeze-drying. This resulted in a yield 
o f 9mg of P76 per litre of culture that was pure, homogeneous, soluble at high 
concentration and suitable for crystallisation. The purity of P76 can at each stage of 
the process is shown above in figure B12B.
Crystallisation yielded little initial success. However after ~2 months small 
crystallioids were observed in the two conditions mentioned previously. 
Optimisation screens designed around condition 6 and 37 from structure screen II 
(Hampton) have as yet yielded no crystals. For the condition based on structure 
screen II number 6 grid screening was performed around the concentrations of 
C0CI2 and 1,6-hexandiol. For the other condition grid screens were performed with 
varying concentrations of NaCl and Li2S0 4 .
Homolgy modelling of P76 using AvrpPhB
P76 was the YopT homolog identified with the highest sequence similarity to YopT 
and using the plant effector molecule AvrpPhB [PDB code 1UKF] (Zhu et al, 2004), 
a model of the structure was built by the web-based server CPH model (Lund et al, 
2002). The CPH model server identified the sequence of the P76 domain as having 
16.3% identity with AvrpPhB and a homology model was built with an RMSD of 
1.68A around 50 residues of the active site. The model, however, does omit the first 
135 residues of the P76 fragment indicating substantial differences at the N- 
terminus. The P76 model was comprised o f the same secondary structure 
arrangement as YopT and AvrpPhB (Zhu et al, 2004) with a 4 stranded anti-parallel 
P-sheet sandwiched between two lobes comprised of loop regions and a-helices. The 
catalytic of triad of P76 were conserved with C l39, H262 and D277 superimposing 
exactly on all of the homology models examined. The model of P76 also possessed 
the stacked hydrophobic rings F276, P278 and W146 that interact strongly via van
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der Waals interactions and hold helix a-1 and strands (3-2 and (3-3 together in the 
same manner as seen in the YopT model and the structure of AvrpPhB and are 
shown below in figure B3.2. The P76 also possesses a glutamate residue (Glu282) 
on strand [3-4 that is oriented in a manner to form a hydrogen bond to the conserved 
tryptophan residue (Trpl46).












Figure B13. A close up view of the P76 active site highlighting the catalytic triad (Cysl39, His262, 
Asp277), the trio of hydrophobic stacking rings (Phe276, Pro278, Tip 146) and the glutamate 
(Glu282) that interacts with Trp 146. Also highlighted is the amide of Glyl37 that forms the oxyanion 
hole and the proposed SI, S2 and S3 sites.
Other areas of importance around the SI, S2 and S3 sites also strongly resemble the 
features seen in AvrpPhB and the model of YopT. The oxyanion hole amide is 
available for the amino group of Glyl37, similar to the YopT model. However, the
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SI site and S2 sites show marked differences to YopT with the SI site substituting a 
isoleucine (lie 176) for the tyrosine and at the S2 site the change is from a leucine to 
a serine (Ser 254). The large pocket involving the cleft between helices a2 and a3 
forming the S3 site is also different to that seen in YopT as seen below in figure 
B13.
In P76 the cleft is lined with hydrophobic isoleucine and leucine residues (lie 176 
and Leul82), except at the top adjacent to the loop connecting helix a2 and a3, 
where there is a glutamine (Gin 195). These differences in the SI, S2 and S3 binding 
sites may suggest that whilst P76 shows a strong similarity to YopT in overall 
structure it is likely to possess a different substrate.
Conclusions
We have successfully cloned and optimised a purification strategy to isolate the 
YopT-like domain of P76 from H. somnus. Crystallisation experiments are still 
ongoing. Homology modelling with the structure of the related cysteine protease 
AvrpPhB from Pseudomonas syringae shows conserved features around the active 
site including the catalytic triad, oxyanion hole and a trio of hydrophobic residues 
that stack via van der Waals interactions and maintain the structure of the active site. 
A comparison of the substrate binding sites in the P76 model with the YopT model 
highlighted differences that may be related to the as yet unknown target of the 
cysteine protease domain of P76.
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HopPtoC (AvrPpci2) from Pseudomonas syringae pv tomato 
DC3000
Aims of cloning and purifying HopPtoC
Plant pathogens have a broad range of TTSS effectors. Several of these have been 
identified as being cysteine pro teases that are related to YopT from Yersinia spp. 
The structure of one of these, AvrpPhB, has been determined but the others have 
not. We hope to clone, purify and subsequently determine the structure of HopPtoC 
to understand its catalytic mechanism and possibly shed some light on its as yet 
unknown role in plant pathogenicity.
An introduction to type III effectors in Pseudomonas syringae
Pseudomonas syringae is a gram negative bacteria composed of many strains that 
infect different plant species causing a broad range of diseases (Jin et al, 2003). 
However, individual strains of P. syringae tend to be specific to only a few species 
of plants or even a select range within a plant species and this give rise to different 
pathovars (pv.). In P. syringae infection the bacteria enter the apoplast of the plant 
and multiply extracellularly resulting in tissue necrosis. This ability to multiply 
extracellularly and cause disease is mediated by a TTSS and the effector proteins 
that are secreted by it (Alfano & Collmer, 1997).
In P. syringae the TTSS assembly is encoded for by the hypersensitive reaction and 
pathogencity (hrp) genes and secretes avirulence proteins (Avr) and Hrp outer 
proteins (Hops). These names have come about from experiments that describe a 
hypersensitive reaction that occurs when strains of P. syringae are exposed to non­
host plant species or resistant plant species. This hypersensitive response results in a 
rapid physiological response in infected plant tissue that culminates in programmed 
cell death and a cessation of bacterial growth. This cessation o f bacterial growth led 
to avirulence and the effectors that elicited this response being named avirulence
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proteins (Avr) (Shao et al, 2002) (Collmer et al, 2002). In susceptible plants 
however these effectors (both Hops and Avr proteins) have been shown to contribute 
to the pathogenicity of P. syringae (Innes, 2001) and the consensus currently is that 
they contribute to pathogenicity in one of two ways: (1) by evading and/or 
suppressing the plant immune response; and (2) by initiating the release of water and 
nutrients from the host cells into the apoplastic space. This allows the extracellular 
proliferation of bacteria that leads to necrosis and other symptoms of disease.
The complete genomic analysis of the tomato and arabadopsis pathogen 
Pseudomonas syringae pv. tomato DC3000 (Petnicki-Ocwieja et al, 2002) has 
allowed many elements of the TTSS to be identified. The secretion apparatus is 
comprised of 27 hrp genes of which 8 are conserved amongst all bacteria that 
possess a TTSS and the bacterial flagellum assembly genes (Alfano & Collmer, 
1997; He, 1997). This TTSS leads to the secretion of ~36 effector genes (Collmer et 
al, 2002; Guttman et al, 2002; Petnicki-Ocwieja et al, 2002). The vast number of 
which have no known targets and only putative functions.
The HopPtoC gene (AvrPpiC2pt0) was one of the effectors identified by Hrp 
dependant secretion as a type III effector. This led to it being classified as a Hop 
protein and led to it being renamed. It was originally identified as a P. syringae 
tomato homologue of an avirulence protein originally found in P. syringae pisi 
(Vivian & Mansfield, 1993). The HopPtoC gene possesses a putative N-terminal 
sequence export signal pattern that is common to many of the identified Hop 
effectors (Petnicki-Ocwieja et al, 2002). Supporting evidence from micro array 
analysis and RNA blotting confirm that it is a secreted by the Hrp assembly 
(Collmer et al, 2002; Fouts et al, 2002; Zwiesler-Vollick et al, 2002) as a type III 
effector though its substrate and role in pathogenesis is unknown. HopPtoC was 
identified as a cysteine protease through the conserved catalytic triad and other 
conserved hydrophobic residues (Shao et al, 2002) suggesting that it may play a 
similar role to YopT or one of the YopT family of cysteine proteases.
202
Methods
HopPtoC expression and purification was attempted through two different strategies. 
The first was cloning into pET22b (Novagen Inc., UK) and following a similar 
protocol to that employed in the purification and structural determination of the 
related cysteine protease AvrpPhb from P. syringae (Zhu et al, 2004). The second 
strategy was to clone HopPtoC into the solubility enhancing pMalp2x vector (New 
England Biolabs) as an MBP fusion protein thought proved unsuccessful...
Expression and purification of the HopPtoC-pET22b construct
The 817bp HopPtoC gene was received as freeze-dried plasmid in the pDR4TOPO 
plasmid provided by Etelechon GmbH. Primers were designed to introduce a 5’ 
Ndel site and a 3’ Sail site prior to cloning HopPtoC into pET22b (Novagen Inc., 
UK).
Forward primer (Ndel site underlined):
5’ GGG CAT ATG ATG ACG ATT GTT AGT GGT C 3’
Reverse primer (Sail site underlined):
5’ CGC GTC GAC GAA TTC ATC AAT TTT AGA GG 3’
The PCR reaction and subsequent restriction digestion, ligation and transformations 
were performed following the protocol used in creating the YopT-pET22b construct.
HopPtoC-pET22b was expressed in auto-induction media in the same manner as 
YopT.
Purification of the insoluble pET22b-HopPtoC protein was attempted through 3 
different methods; on the column refolding, batch refolding using the protocol 
developed in our laboratory (Holloway et al, 2001) and using an optimised refolding
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condition determined from a home-made refolding screen. The optimised refolding 
was the only method that proved successful.
Inclusion bodies were isolated and solubilised as above. A 24 condition refolding 
screen based on an amalgam of commercially available was performed to obtain 
refolding conditions suitable for HopPtoC. 50pl of solubilised protein was added 
slowly to 1ml of each refolding condition and then left overnight at 4°C. Precipitate 
was removed using centrifugation and the supernatant containing refolded protein 
was visualised on an SDS-page gel.
The remaining solubilised protein was then dripped slowly over ~2 hours into 500ml 
of refolding buffer containing lOmM Tris pH 8.5, 9.6mM NaCl, 0.4mM KC1, 0.5% 
triton X-100 and 5mM p-mercaptoethanol and left without stirring for >24 hours at 
4°C. This was then centrifuged at high speed for 1 hour to remove precipitate and 
other contaminants (Beckman Avanti J-25) and applied to a 5ml Hitrap column (GE 
Healthcare) charged with NiSC>4 and equilibrated with 20mM Tris pH8.0, 0.5M 
NaCl. HopPtoC was eluted as a single peak with 20mM Tris pH8.0, 0.5M NaCl and 
0.5M imidazole. The protein was then applied to a Superdex 200 gel filtration 
column (GE Healthcare) equilibrated with 20mM Tris pH 8.0, 500mM NaCl, 5mM 
p-mercaptoethanol. The purified sample was concentrated in a lOkDa centrifugal 
concentrator (Amicon) to a maximum concentration of 2mg/ml.
Crystallisation of HopPtoC
Crystallisation trials were performed as hanging drops using 1.75pl of protein with
1.75pl of reservoir solution in the drop, giving a final protein concentration of 
1 mg/ml in the crystallisation drops. Structure screens I and II (Hampton Research) 
were used to generate initial crystallisation conditions. At present no optimisation 




The initial cloning of HopPtoC into pET22b proved straightforward and high levels 
of HopPtoC could be observed in the inclusion bodies as seen in figure B14A. 
Attempts were made to obtain soluble HopPtoC using low temperature growth, 
minimal media and heat shocking the cultures directly prior to induction but soluble 
HopPtoC expression was never achieved. Initial purification attempts of HopPtoC 
centred on the GE Healthcare on column refolding protocol (GE Healthcare).
Figure B14 Expression and purification of HopPtoC 
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Figure B14. A: The expression of HopPtoC in terrific broth with time points before induction of 
expression (+0), 3 hours after induction with 0.4mM IPTG at 20°C (+3), and after overnight 
expression at 20°C (O/N). The insoluble (Insol) and soluble (sol’) fractions of the lysed cell pellet are 
also shown and an arrow marking the 30kDa band corresponding to HopPtoC. B: An SDS gel 
illustrating the purity of HopPtoC at various stages of purification. These stages include refolding in 
buffer A6 (lOmM Tris pH 8.5, 9.6mM NaCl, 0.4mM KC1, 0.5% triton X-100 and 5mM 0- 
mercaptoethanol), directly after the Ni+ affinity Hitrap column and after the final step of size 
exclusion chromatography.
205
It involved a slow gradient of urea from 6M to OM whilst the protein was physically 
bound to the column. Although this was successful once and led to very pure protein 
the protein subsequently precipitated out of solution before further purification steps 
could be taken.
The batch refolding protocol involving arginine has worked well for proteins in our 
laboratory in the past (Holloway et al, 2001). The use of arginine in the refolding 
buffer resulted in ion-exchange chromatography being used as the primary 
purification step as arginine can interfere with histidine based tags binding to 
affinity columns. The calculated pi of HopPtoC is 6.63 (Gasteiger et al, 2005) and 
both Q-sepharose chromatography at pH8.0 and SP-sepharose chromatography at 
pH 5.5 failed to bind significant amounts of HopPtoC. Hence purification via 
arginine based refolding was abandoned and attempts to optimise an improved 
refolding condition were begun. The refolding screen was designed based on an 
amalgam of several commercially available refolding screens but was focused on 
avoiding refolding conditions containing arginine. The insistence on arginine free 
conditions was to allow the easy use of the hexahistidine tag on the pET22b vector. 
Initial screening of HopPtoC in the refolding screen gave positive results in four 
different conditions: (1) Condition A5 containing 50mM Tris pH 8.5, 9.6mM NaCl, 
0.4mM KC1, 0.05% PEG3350, 0.5% triton X-100 2mM MgCl2, 2mM CaCl2, 
400mM sucrose and 5mM P-mercaptoethanol; (2) Condition A6 containing; 50mM 
Tris pH 8.5, 9.6mM NaCl, 0.4mM KC1, 0.5% triton X-100 and 5mM P- 
mercaptoethanol; (3) Condition B1 containing lOOmM Tris pH8.5, 240mM NaCl, 
lOmM KC1, 0.05% PEG3350, 5mM P-mercptoethanol; and (4) condition D6 
containing 50mM Borate pH 9.5, 264mM NaCl, 1 ImM KC1, 0.05% PEG3350, 0.5% 
Tween 80, 550mM Guanidine HC1 and 5mM P-Marcaptoethanol. The choice was 
made to focus on condition A6 as it contained the least components and avoided the 
use of 550mM Guanidine HC1 and 440mM sucrose that may have led to 
downstream problems with the selection of compatible chromatography techniques.
I
After successful refolding conditions were obtained purification through Ni 
affinity and size exclusion chromatography in a similar manner to the protocol for
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YopT gave pure homogenous HopPtoC as shown in figure B14B. Concentration of 
HopPtoC was difficult however as at concentrations >2mg/ml the protein began to 
precipitate. The very low concentration of HopPtoC in the crystallisation drops may 
be partly responsible for the lack of any crystals or conditions that may be suitable 
for optimisation.
Homolgy modelling with AvrpPhB
HopPtoC is one of 19 ORF’s identified as possessing strong sequence similarity to 
YopT (Shao et al, 2002). The plant effector molecule AvrpPhB [PDB code 1UKF] 
(Zhu et al, 2004), was used to construct a homology model of HopPtoC the web- 
based geno3d server (Combet et al, 2002). The geno3d model server identified the 
sequence of the HopPtoC as having 20% identity with AvrpPhB and a homology 
model was able to be built with an RMSD of 2.93A when superimposed onto the 
central 50 residues.
The model is however missing the first 57 N-terminal residues. While the core of the 
molecule superimposes over the core structure of AvrpPhB well many of secondary 
structural elements have been lost. Whilst AvrpPhB has a seven stranded anti­
parallel and the models of both YopT and P76 have 5 stranded anti-parallel p-sheets 
the model of HopPtoC has only a 3 stranded anti-parallel p-sheet. Although sections 
o f HopPtoC modelled as loop regions do lie where the missing strands are found. As 
in the other related cysteine proteases there are two lobes composed primarily o f a- 
helices above and plane of the p-sheet, though in the HopPtoC model many of these 
helices are drastically shortened.
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Figure B15 The active site of the homology model of HopPtoC
Figure 15. The active site of the homology model o f HopPtoC illustrating the catalytic triad (Cys 72, 
His 213 and Asp 230), the conserved hydrophobic trio (Pro 231, Phe 229 and Tip 77), the amide of 
Ser 67 that forms the oxyanion hole and the conserved Glu 235 that forms a hydrogen bond with Trp 
72 to stabilise the secondary structure elements around the active site.
There is also a large 25 residue loop between residues 82-107 that is modelled as an 
unstructured loop but is likely to adopt an additional secondary structural element 
not present in the AvpPhB structure. The catalytic triad is still arranged in the same 
spatial organisation as seen in AvrpPhB and the other models although the (3-strand 
containing the catalytic histidine (His 213) has been modelled here as unstructured 
coil and is shown in figure B15. The other conserved features around the active site 
including the 3 stacking hydrophobic rings (Pro 231, Phe 229 and Trp 77) are also 
present and can be seen in figure B4.2 to still directly stack above another one via 
Van der Waals interactions and the bond between the Trp 77 and Glu 235 that lies
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on strand p-3 but is the conserved glutamate residue that is seen in all of the other 
structures.
Conclusion
We have cloned, and using a novel refolding screen, purified the Pseudomonas 
syringae type III effector HopPtoC. Although efforts to crystallise HopPtoC have so 
far been unsuccessful a homology model based on the related P. syringae type III 
effector showed a conserved secondary structure and a strongly conserved core 
active site. This core active site was centred on the catalytic C/H/D triad and a series 
of 3 conserved hydrophobic residues that stack above one another and play a role in 
maintaining the conformation of the active site.
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Toxin B from E.coli 0157:H7
Aims of cloning & purifying the YopT-like domain of toxB
Enteropathogenic E. coli is a major cause of m o r t a l i t y  and morbidity worldwide. Its 
pathogenicity is closely related to its TTSS and a family of putative adhesion 
factors. ToxB has been identified as an adhesion factor that also plays a role in 
regulating the TTSS. ToxB has also been identified as possessing a YopT-like 
cysteine protease domain though its exact role in E. coli pathogenesis is unknown. 
We hope to clone, purify and subsequently determine the structure of the YopT-like 
domain to gain some insight as to what is substrate specificity might be and to 
investigate if it shares similar structural features to the rest of the YopT-like cysteine 
protease family.
An introduction to Enteropathogenic E. coli
Enteropathogenic E. coli (EPEC) and its close relative enterohemorrgahic E. coli 
(EHEC) are major causes of mortality and morbidity worldwide. EPEC is the 
leading cause of infant diarrhoea in the developing world (Donnenberg et al, 1997; 
Hueck, 1998). EHEC strains are more dangerous as they produce shiga-like toxins 
that lead to hemorrhagic colitis and the potentially fatal haemolytic uremic 
syndrome (HUS). E. coli 0157:H7 is the most prevalent strain associated with 
outbreaks of HUS (Griffin & Tauxe, 1991) and is responsible for over 73,000 cases 
and 60 deaths in the US annually, with non-0157 EHEC strains responsible for an 
additional 37,000 cases (Gansheroff & O'Brien, 2000; Mead et al, 1999). The 
pathogenicity of 0157:H7 strains are due to 3 main factors; the ability to produce 
shiga-like toxins, the ability to induce enterohemolytic activity and the ability to 
form attaching and effacing (A/E) lesions (Tatsuno et al, 2001; Tozzoli et al, 2005).
In the course of EHEC infection the bacteria are introduced, most commonly by 
ingestion of contaminated food and water, to the lower intestine where it can adhere
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to epithelial cells. Intimate attachment involves the formation of actin-rich pedestals 
and the effacement of microvilli beneath the bacteria. These pedestals topped by the 
attached bacteria form the A/E lesions. The formation of the A/E lesions is reliant on 
a TTSS that secrets several adherence factors and effectors molecules including 
EspA, EspB, EspD, Tir and intimin. These secreted proteins are all encoded on a 
single pathogenicity island known as the locus for enterocyte effacement (LEE) ( Jia 
et al, 1995; McDaniel & Kaper, 1997; Elliott et al, 1998). Of these effectors only 
one, Tir (translocated intimin receptor), has had its structure determined (Luo et al,
2000). During the formation of the A/E lesions the TTSS tranloscates the effectors, 
apart from intimin, into the host cell cytoplasm. In the cytoplasm instigate a range of 
host cell signalling instigating amongst other things actin nucleation and the 
insertion of Tir into the host membrane where it becomes available to bind to 
intimin and form the A/E lesions (DeVinney et al, 1999; Ebel et al, 1998; Kenny et 
al, 1997).
In 0157 strains of EHEC the presence of an additional 93-104kb plasmid may 
contain additional virulence factors that increase the pathogenicity seen in the 0157 
strains (Karch et al, 1987; Schmidt et al, 1996). This plasmid, dubbed p0157, 
contain several other virulence factors including a catalase peroxidase (katP) 
(Brunder et al, 1996), a serine protease (espP) (Brunder et al, 1997), 
enterohemolysin (ehxA) (Schmidt et al, 1994) and toxin B (toxB) (Burland et al, 
1998; Makino et al, 1998; Tozzoli et al, 2005).
ToxB, a large putative virulence gene, was initially discovered in 4 different strains 
under 4 different names before being defined in the 0157: Sakai strain (Tatsuno et al,
2001). The full length ToxB is a very large protein, 3169 residues (361.9kDa) in 
size, and has been found in a large number of EHEC strains (Stevens et al, 2004; 
Toma et al, 2004; Tozzoli et al, 2005). The sequence indicates a glycosyltrasnferase 
domain in the N-terminal that shows -23%  identity with the large Clostridium 
difficile toxins A and B (Tatsuno et al, 2001) and the C-terminal has a cysteine 
protease domain that shows similarity to YopT of Yersinia pestsis (Shao et al,
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2002). ToxB has also been linked with two other large virulence factors in E. coli 
that it shares 28% identity with EPEC lymphostatin (lifA) and EHEC factor for 
adherence (Efal) (Tatsuno et al, 2001).
The exact function of ToxB is still unclear but is has now been linked to 3 areas of 
activity involved in the adhesion to epithelial tissues and the formation of A/E 
lesions. The main role of ToxB seems to be as an adhesion factor that assists in 
bacterial adherence to epithelial cells. Several experiments have now shown the 
strains lacking ToxB, or possessing ToxB mutants, lose much of their ability to bind 
to host cells. Its function as an adhesion factor is similar to that of Efa-1 and the 
presences of both in some strains of 0157 lead to added redundancy and an 
improved ability to adhere to host cells (Stevens et al, 2004). Its second function 
seems to involve inhibition of lymphocyte activity. In this regard it functions in a 
manner similar to that seen for lifA (Klapproth et al, 2000; Tatsuno et al, 2001; 
Stevens et al, 2004). This anti-lymphocyte ability results in inhibition of interleukin 
-2 and -4 production along with other pro-inflammatory cytokines and inhibition of 
lymphocyte proliferation (Klapproth et al, 2000). The third and possibly most 
important role of ToxB is in the regulation of the TTSS effectors encoded by the 
LEE. ToxB has now been shown to affect the production and secretion of EspA, 
EspB, EspD and Tir (Tatsuno et al, 2001; Stevens et al, 2004; Toma et al, 2004), 
though this regulation of LEE effector secretion is also seen for the closely related 
Efal (Stevens et al, 2004). The mechanism by which this secretion comes about is 
still unclear though it is thought that ToxB may be membrane associated and 
interferes with targeting of the LEE effectors or is involved in sensing extracellular 
signals required for full production and secretion of the LEE effectors (Tatsuno et al, 
2001).
The exact mechanism of ToxB action in EHEC virulence is still unclear though it is 
one of number of large virulence genes that are grouped together as putative 
adhesions and possible targets for therapeutic vaccines preventing intestinal 
colonisation by EHEC (Toma et al, 2004). It has multiple roles in EHEC
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pathogenesis including bacterial adhesion, resistance to lymphocytic activity and 
regulation o f the TTSS effectors involved in the formation of A/E lesions. These 
multiple roles are also confined to well defined domains on the gene including the 
glycosyltransferase domain and the YopT-like cysteine protease domain. The 
cysteine protease domain is shared with Efa-1 (Shao et al, 2002; Stevens et al, 2004) 
and may play a role in either the adhesion to host cells or the regulation of the LEE 
effector secretion or an as yet unknown function.
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Methods
Expression of the YopT-like domain of EHEC toxB gene was attempted through 
two different strategies. These were: cloning into pET22b (Novagen) with a 
hexahistidine tag and cloning into the ligation independent vector ysbLIC based on 
pET28 (Novagen). The LIC clone proved to be the successful strategy.
Expression and purification of the toxB-ysbLIC construct
The ysbLIC vector was a gift from Dr. Phillip Leonard and was based on pET28 
(Novagen) and possesses an N-terminal hexahistidine tag.
The toxB gene fragment was received as freeze-dried plasmid in the pDR4TOPO 
plasmid provided by Etelechon GmbH. Primers were designed with the appropriate 
ends for insertion in to the ysbLIC vector.
Forward primer (LIC specific ends underlined):
5’ CAC CAC CAC CAC ATG TTA AAC CTC GAA GGT CTT ATC AAA 
AAG 3’
Reverse primer (LIC specific ends underlines):
5’ GAG GAG AAG GCG CGT TAG TCG ACT TAG AAT TCG TTA TTT 
AAC GATTCACT 3’
The PCR and subsequent annealing and transformations were performed following 
the protocol used to generat the P76-ysbLIC contruct.
The toxB-ysbLIC construct was expressed in auto-induction media following the 
protocol used for YopT.
Harvested cell were re-suspended in lysis buffer (20mM Tris pH 8.0, 500mM NaCl, 
0.3mg/ml lysozyme) and stirred on ice for 30 minutes. Cells were lysed via
214
sonication (Soniprep 150) and the inclusion bodies isolated by centrifugation 
(Beckman Avanti J-25). After cell lysis the inclusion bodies containing toxB were 
resuspended in 20mM Tris pH 8.0, 0.5M NaCl, 2% triton x-100 and 2M urea and 
centrifuged at high speed (Beckman Avanti J-25) to remove lipids and other soluble 
contaminants. This wash step was repeated twice. The washed inclusion bodies were 
solubilised in 20ml 8M urea, 20mM Tris pH 8.0, 0.5M NaCl, 5mM p- 
mercaptoethanol and stirred at room temperature for 2 hours.
The solubilised protein was then dripped slowly over ~2 hours into 500ml of 
refolding buffer containing lOmM Tris pH 8.5, 240mM NaCl, lOmM KC1, 0.05% 
PEG 3350 and 5mM P-mercaptoethanol and left for >24 hours at 4°C. This was then 
centrifuged at high speed for 1 hour to remove precipitate and other contaminants 
(Beckman Avanti J-25).
Refolded toxB was applied to a 5ml Hitrap column (GE Healthcare) charged with 
MSO4 and equilibrated with 50mM tris pH8.0, 0.5M NaCl. ToxB was eluted as a 
single peak with 20mM tris pH8.0, 0.5M NaCl and 0.5M imidazole. The protein was 
then applied to a Superdex 200 gel filtration column (GE Healthcare) equilibrated 
with 50mM tris pH 8.0, 500mM NaCl. The purified sample was concentrated in a 
lOkDa centrifugal concentrator (Amicon) to lOmg/ml and stored at 4°C for 
crystallisation.
Crystallisation of toxB
Crystallisation trials were performed as hanging drops using 1.75pl of protein with 
1.75pl o f reservoir solution in the drop, giving a final protein concentration of 
5mg/ml in the drops. Structure screen I and II (Hampton Research) were used to 
generate initial conditions with one condition suitable for optimisation; 0.4M 
sodium potassium tartarate. Optimisation screens have as yet failed to yield crystals 




The initial cloning of toxB into pET22b proved difficult. Repeated attempts at 
transformation of the toxB-pET22b plasmid into either cloning or expression strains 
of E. coli failed and several strains and techniques were attempted. This included 
both heat-shock and electroportation to transform cells and a wide range of cell lines 
including DH5a, B121(DE3) (Promega), BL21(DE3)codon+ (Promega), Rosetta 
(Novagen), JM109 (Promega) and NovaBlue (Novagen). After no expression was 
observed in the pET22b construct the decision was made not to clone toxB into 
pMalp2x as it was thought that that might suffer from equally large problems.
The cloning into ysbLIC was straightforward and required no optimisation of the 
LIC cloning protocol. As with HopPtoC toxB was expressed in large amounts but 
was only found in the insoluble fraction of the lysed cell pellets as can be seen in 
figure B16A. The refolding screen was designed based on an amalgam of several 
commercially available refolding screens but was focused on avoiding refolding 
conditions containing arginine. The insistence on arginine free conditions was to 
allow the easy use of the hexahistidine tag on the ysbLIC vector as arginine can 
interfere with binding to a metal chelation column and result in a lack of protein 
binding. Initial screening of toxB in the refolding screen gave positive results in two 
different conditions: (1) Condition B1 containing lOOmM Tris pH8.5, 240mMNaCl, 
lOmM KC1, 0.05% PEG3350, 5mM p-Marcptoethanol and (2) condition Cl 
containing lOmM Mes pH6.5, 264mM NaCl, 1 lmM KC1, 0.05% PEG3350, 550mM 
Guanidine HC1, 2.2mM MgCL, 2.2mM CaCl2, 440mM sucrose. The choice was 
made to focus on condition B1 as it contained less solutions and avoided the use of 
550mM Guanidine HC1 and 440mM sucrose as these can lead to downstream 
problems with the selection of compatible chromatography techniques. Initial 
purification steps using a Ni2+ affinity column yielded little or no success and only 
pg amounts of pure toxB were obtained. To yield large amounts of pure toxB it was
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found that altering the solubilisation buffer from 6M guanidine HC1 to 8M urea 
resulted in a significantly higher amount of toxB being successfully refolded and 
binding to the Ni2+ affinity column as shown in figure B16B. Subsequent 
purification using gel filtration and concentration for crystallisation was 
straightforward. The cause for the dramatic improvement in yield, from pg to ~ 
12mg/l, due to changing from guanidine HC1 to urea is unknown though it may be 
involve differences in the stabilisation of the flexible regions of toxB between 
guanidine HC1 and urea.
Figure B16 Expression and purification of the YopT-like domain of toxB 
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Figure B16. A: Expression of toxB in the initial expression trial in terrific broth with time points 
before induction (+0), 3 hours after induction with 0.4mM IPTG (+3) and 5 hours after induction 
with ImM IPTG (+5). The contents of the soluble and insoluble fractions of the lysed cell samples 
are also shown. B: The purity of toxB after a Ni2+affinity Hitrap column followed by gel filtration.
Crystallisation has so far proved unsuccessful. Structure screen I, condition 40 
(Hampton) gave a network of large branchlike structures in the drop that grew 
rapidly. Attempts to optimise this condition have centred on altering the
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concentration of sodium potassium tartarate as well as varying the concentration of 
the protein drop to slow down growth and produce crystals suitable for structural 
studies.
Sequence similarity with the YopT cysteine protease family
The 239 residue fragment of toxB shows some sequence similarity to YopT and a 
family of cysteine proteases. However unlike the other homolgs of YopT no model 
of the YopT-like toxB fragment has been made. All of the web-based modelling 
programs, including Geno3D (Combet et al, 2002), 3D jigsaw server (Bates et al,
2001) and CPH models (Lund et al, 2002), failed to build a model of toxB though 
both Geno3d and CPH models were able to identify the AvrpPhB structure as a 
similar domain. The inability to build a model of toxB may stem from some subtle 
differences in the identity of the conserved residues found in the YopT family. 
Although a conserved catalytic triad of C/H/D was observed there are some other 
important differences. ToxB, and its closely related E. coli adhesions LifA and Efal, 
lack the conserved tryptophan, phenylalanine and glutamate and so may have a 
slightly different arrangement around their active site. This difference may also 
explain the inability o f the web-based modelling programs to build a plausible 
model of the YopT-like domain of toxB. As this fragment represents only a single 
domain of a 320kDa protein it is possible that the rest of the protein may play a part 
in binding to its still unknown target.
Conclusions
We have successfully cloned and optimised a purification strategy to isolate the 329 
residue YopT-like domain of enterohemorrgahic Escherichia coli putative adhesion 
toxB. In doing so the refolding screen was optimised and alterations to the 
solubilisation buffer had a critical impact on protein refolding. Attempts to 
crystallise this protein have so far proved unsuccessful. Though similar to YopT the 
target, function and nature of toxB is at present still unknown.
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General discussion
The YopT family of cysteine proteases
We have cloned, expressed and purified YopT from Yersinia pestis and 3 other 
cysteine proteases that have been shown to be members of a large family of bacterial 
cysteine proteases (Shao et al, 2002). These proteases all share a conserved catalytic 
triad of C/H/D and several other conserved features around the active site. 
Homology modelling using the structure of AvrpPhB (Zhu et al, 2004) has been 
used to build models of three of these cysteine proteases: YopT, HopPtoC and the 
YopT-like domain from P76 while all of the available web-based servers failed to be 
able to construct a model of the YopT-like domain of toxB.
Superimposition of the 3 models with the structure of AvrpPhB shows a general 
conserved structure centred around the anti-parallel p-sheet with two lobes 
comprised of a-helices and coil regions. While there may be differences in the two 
lobe regions, the active sites are highly conserved and all of the catalytic residues 
can be seen to overlay atop one another in figure B17. Whilst the conserved 
histidine of HopPtoC may appear to be adrift from the others it may be due to the 
poorer quality of the HopPtoC model that failed to identify the p-strand containing 
His-213. All of the models built also possessed a tryptophan, phenylalanine and 
proline that stack above one another and form a stack of strong van der Waal bonds 
that may play a strong role in supporting the active site by keeping the a-helix 
containing the catalytic cysteine and the tryptophan in close proximity to the p-sheet 
and the catalytic histidine and aspartate. The importance o f these interactions is also 
partially supported by data from a YopT W146A mutant that lost all its activity 
(Shao et al, 2002).
The biological activity and importance of many of these YopT-family cysteine 
proteases is still unknown, only two of the 19 ORF’s identified (Shao et al, 2002) 
have had their substrate identified. The GTPase RhoA for YopT (Iriarte & Comelis,
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1998) and RPS5 for AvrpPhB (Simonich & Innes, 1995) though in both cases the 
catalytic triad and proteolytic activity are required for cytoxicity (Shao et al, 2002). 
The importance of the cysteine protease activity in the other ORFs is unknown. 
Particularly for those that possess the cysteine protease domain as a small domain of 
a much larger protein such as for P76 and toxB. In both these cases the need or 
importance of the protease domain is unknown.




Figure B17. A close-up view of the active site of the YopT family of cysteine proteases. The three 
catalytic residues are shown coloured according to their protein with YopT (blue), HopPtoC (green), 
YopT-like domain of P76 (red) and AvrpPhB (yellow). The conserved anti-parallel (3-strand is also 




We have managed to purify all 4 cysteine proteases and crystallisation trials have 
begun with all 4 of these. In the case of YopT and P76 further optimisation trials are 
planned in an attempt to improve the crystal quality and yield crystals suitable for 
diffraction experiments. In the case of toxB and HopPtoC more crystallisation trials 
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